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ABSTRACT 
Somatic cells could be reprogrammed into an ES-like state called induced 
pluripotent stem cells (iPSCs) by expression of four transcriptional factors: Oct4, 
Sox2, Klf4 and cMyc. iPSCs have full potentials to generate cells of all lineages 
and have become a valuable tool to understand human development and 
disease pathogenesis. However, reprogramming process suffers from extremely 
low efficiency and the molecular mechanism remains poorly understood.   
This dissertation is focused on studying the role of small non-coding RNAs 
(microRNAs) and kinases during the reprogramming process in order to 
understand how it is regulated and why only a small percentage of cells could 
achieve fully reprogrammed state. We demonstrate that loss of microRNA 
biogenesis pathway abolished the potential of mouse embryonic fibroblasts 
(MEFs) to be reprogrammed and revealed that several clusters of mES-specific 
microRNAs were highly induced by four factors during early stage of 
reprogramming. Among them, miR-93 and 106b were further confirmed to 
enhance iPSC generation by promoting mesenchymal-to-epithelial transition 
(MET) and targeting key p53 and TGFβ pathway components: p21 and Tgfbr2, 
which are important barrier genes to the process.  
To expand our view of microRNAs function during reprogramming, a 
systematic approach was used to analyze microRNA expression profile in iPSC-
enriched early cell population. From a list of candiate microRNAs, miR-135b was 
vii 
found to be most highly induced and promoted reprogramming. Subsequent 
analysis revealed that it targeted an extracellular matrix network by directly 
modulating key regulator Wisp1. By regulating several downstream ECM genes 
including Tgfbi, Nov, Dkk2 and Igfbp5, Wisp1 coordinated IGF, TGFβ and Wnt 
signaling pathways, all of which were strongly involved in the reprogramming 
process. Therefore, we have identified a microRNA-regulated network that 
modulates somatic cell reprogramming, involving both intracellular and 
extracellular networks. 
In addition to microRNAs, in order to identify new regulators and signaling 
pathways of reprogramming, we utilized small molecule kinase inhibitors. A 
collection of 244 kinase inhibitors were screened for both enhancers and 
inhibitors of the process. We identified that inhibition of several novel kinases 
including p38, IP3K and Aurora kinase could significantly enhance iPSC 
generation, the effects of which were also confirmed by RNAi of specific target 
genes. Further characterization revealed that inhibition of Aurora A kinase 
enhanced phosphorylation and inactivation of GSK3β, a process mediated by Akt 
kinase.  All together, in this dissertation, we have identified novel role of both 
small non-coding RNAs and kinases in regulating the reprogramming of MEFs to 
iPSCs.  
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1.1 Introduction 
Since the discovery in Caenorhabditis elegans (C. elegans) that double-stranded 
(ds) RNA could trigger a potent gene-specific silencing phenomenon, termed 
RNA interference (RNAi) (Fire et al, 1998), considerable effort has been made in 
many biological disciplines to address some of the fundamental questions 
surrounding RNAi. For example, is RNAi a general mechanism for gene 
regulation that is conserved across species? What are the physiological triggers 
of RNAi and how does it play a role in biological processes? Work designed to 
address such questions have led to the recognition that RNAi is a widespread 
natural phenomenon that is conserved across fungi, plants, and animals. 
Long dsRNAs generate potent RNAi and silence target genes by inducing 
cleavage of their mRNA. However, in mammals, long dsRNA activates the innate 
immune response by inducing interferon pathways. Further mechanistic studies 
led to the discovery that mRNA cleavage induced by RNAi was guided by small 
~21 nucleotide (nt) RNA fragments derived from long dsRNAs, which revealed 
that these small interfering RNAs (siRNAs) are the essential triggers for RNAi. 
Since these discoveries were made, great effort has been directed at identifying 
endogenous physiological triggers that have similar properties to siRNAs. 
Several endogenous small RNA species have been identified, including small 
non-coding RNAs (microRNAs), piwi-interacting RNAs (piRNAs), and 
endogenous siRNAs (endo-siRNAs).  
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MicroRNAs (miRNAs) are single-stranded RNAs ~21 nt in length that are 
involved in almost every area of biology, including developmental processes, 
disease pathogenesis, and host-pathogen interactions (Ambros, 2011; Kim et al, 
2009a; Krol et al, 2010). The biogenesis of mature miRNAs relies mainly on 
digestion of the precursor RNA hairpin structure by two members of the RNase III 
family, Drosha and Dicer, while other miRNAs can be generated through splicing 
of miR-coding introns.  MicroRNAs are loaded into a functional ribonucleoprotein 
assembly called the RNA-induced silencing complex (RISC), which serves as the 
catalytic engine for miRNA-mediated post-transcriptional regulation. Although 
some studies have suggested a potential role for miRNAs in translational 
activation, the more common mechanism of miRNA-mediated gene regulation 
involves repression. In general, miRNAs bind imperfectly to the 3‘ UTR of target 
mRNA and block their expression by directly inhibiting the translational steps 
and/or by enhancing mRNA destabilization (Bagga et al, 2005; Fabian et al, 2010; 
Guo et al, 2010).  
Piwi-interacting RNAs, piRNAs, are germ cell-specific and larger than 
miRNAs, spanning ~24–29 nts in length. piRNAs were discovered in Drosophila 
melanogaster development studies and most of these RNAs matched to 
intergenic repetitive element sequences including retrotransposons. Distinct from 
miRNAs, piRNAs directly interact with Piwi proteins and have been shown to 
regulate transposon activities in Drosophila (Klattenhoff & Theurkauf, 2008). 
piRNAs associate with Piwi proteins and their biogenesis does not involve 
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Drosha or Dicer activities. Although not tested, it is possible that Piwi proteins 
provide nuclease function to generate piRNAs. piRNAs are encoded in clusters 
throughout the genome. Since Piwi proteins exhibit RNA cleavage activities, a 
unique amplification loop has been proposed for piRNA biogenesis, in which 
each piRNA-mediated cleavage creates the 5‘ end of a new piRNA (Brennecke 
et al, 2007).  
A third class of small RNAs, the endo-siRNAs, was originally discovered in 
Drosophila (Czech et al, 2008; Ghildiyal et al, 2008) where they were shown to 
be expressed in both gonadal and somatic tissues, and bind mainly to the Ago2 
protein (Czech et al, 2008). Endo-siRNAs can be generated from such distinct 
loci as transposon elements, natural antisense transcripts (NAT), and 
pseudogenes, as well as from other long hairpin mRNAs (Czech et al, 2008; 
Ghildiyal et al, 2008). However, the biogenesis of these small RNAs remains 
unclear and, at least in Drosophila, requires the involvement of the protein 
Loquacious (LOQS) (Czech et al, 2008). Classes of small RNAs in various 
species, and their origin and function are summarized in Table 1.1.  
Although piRNAs and endo-siRNAs exhibit an interesting ability to 
regulate certain genomic loci elements, miRNAs are the most abundant species 
of small RNAs in mammalian cells. Despite their importance in biology and 
medicine, the molecular and cellular mechanisms of miRNA biogenesis and  
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Table 1.1. Small RNAs Involved in gene silencing 
Several species of small RNAs have been identified over the years. In mammals, 
there are three main classes of small RNAs: miRNAs, endo-siRNAs and piRNAs. 
miRNAs and endo-siRNAs have similar lengths (~21 nt) while piRNAs are 
generally larger and are often 24–31 nt in length. Among the small RNAs, 
piRNAs and endo-siRNAs are reported to regulate transposon elements, 
imprinted gene expression, and germline cell development, while miRNAs are 
more broadly involved in many different biological processes, including 
developmental biology and cancer pathogenesis. 
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function are not fully understood. In this review, we focus on our current 
understanding of the structure and function of RNAi triggers and how this 
knowledge contributes to our understanding of miRNA function in mammalian 
cells.   
1.2 The RNAi Triggers 
A variety of RNA molecules are able to induce RNAi, including hairpin RNAs, 
long double-stranded RNAs, RNA viruses, transposon elements, and 
exogenously introduced siRNAs (Rana, 2007). Hairpin RNAs and long dsRNAs 
induce RNAi after processing by the enzyme Dicer, an RNase III family 
endoribonuclease (Figure 1.1.). The products of Dicer activity are small RNAs 
with a 2-nt overhang at the 3‘ end of each strand, and a monophosphate at the 5‘ 
end. Dicer binds to both linear dsRNAs and hairpin RNAs; thus, these molecules 
could be expressed by DNA vectors in target cells to induce efficient gene 
silencing. After cleavage by Dicer, the resulting ~21 nt RNAs are loaded into an 
RNA-protein complex called the RNA-induced silencing complex (RISC). 
Alternatively, exogenous siRNAs of the same length can be directly introduced 
into cells and loaded into RISCs without Dicer processing (Rana, 2007); this has 
become the standard experimental method to induce transient gene silencing in 
mammalian cells. Depending on the original source of the small RNAs, RISCs 
are termed miRISCs or siRISCs. Once loaded into RISCs, the two strands of the 
RNA duplex have distinct fates. The sense (passenger) strand that has the same  
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Figure 1.1. Steps in RISC function 
Double-stranded (ds) or short hairpin (sh) RNAs are first bound and cleaved by 
Dicer into small interfering RNAs (siRNAs; ~21nt) with 2-nt overhangs and 5‘ 
phosphates. These siRNAs are then loaded into protein complexes termed RNA-
induced silencing complex (RISCs). Ago2, a component of RISCs, binds the 
double-stranded siRNAs and cleaves the passenger strand, which induces its 
dissociation from the RISC complex and degradation. The remaining guide 
strand then leads the activated RISCs to find target mRNAs that contain perfectly 
matched complementary sequences to the guide strand. Binding of RISCs to the 
target mRNAs induces conformational changes and results in cleavage of the 
mRNA by Ago2. Cleaved mRNAs are then subject to mRNA decay or 
degradation, thus silencing the target gene expression. 
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sequence as the target mRNA will be cleaved and degraded. In contrast, the 
antisense (guide) strand that has the complementary sequence to the target 
mRNA will remain in the RISC and direct recognition and cleavage of the target 
mRNA (Figure 1.1.). Target gene expression is silenced by cleaving the mRNA 
10–11 nt upstream of the 5' end of the guide strand. This is mediated through the 
activity of Ago2, which is one of the main components of RISCs and contains an 
enzymatically competent RNase H-like domain. Ago2 lies at the heart of RNAi 
pathways and is the catalytic center of RISC function. After the target mRNA is 
cleaved, the RISCs are recycled and proceed through several rounds of 
cleavage events.  
Not all siRNAs are loaded into RISC with the same efficiency. Several 
studies have uncovered some key siRNA features that considerably affect their 
RISC loading efficiency, and thus also affect the downstream potency of RNA 
interference. One important feature is the RNA structure. The ideal RNAi triggers 
adopt an A-form helix, which is different from the typical B-form helix of DNA 
molecules. This helical geometry leads to a more tightly packaged RNAi 
molecule with a narrower and deeper major groove, making it more stable than 
the B-form helix. These observations are supported by the results of experiments 
with mutant siRNAs that contain internal bulge structures (Chiu & Rana, 2002; 
Chiu & Rana, 2003) or residues with chemical modifications on functional groups 
(Amarzguioui et al, 2003). The bulge structures may distort the A-form helix by 
widening the major groove and increasing the accessibility of its functional 
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groups (Neenhold & Rana, 1995). Consistent with this, introducing bulge 
structures into the guide strand was found to completely abolish the RNAi activity 
of mutant siRNAs. These results, together with those using chemical modification 
of siRNA, have established the essential role of A-helical geometry in siRNA-
mediated gene silencing (Rana, 2007). Recent crystal structures of Ago bound to 
a guide strand and its target RNA further highlighted the significance of the A-
form helix in RISC catalysis (Figure 1.2.) (Wang et al, 2009). High-resolution 
crystal structures have been reported of T. thermophilus Ago catalytic mutant 
proteins bound to 5′-phosphorylated 21-nt guide DNA and complementary target 
RNAs of 12, 15, and 19 nt in length (Wang et al, 2009). These structural and 
biochemical studies provide insight into the guide-strand–mediated recognition 
and cleavage of target RNA by Ago, as well as the importance of divalent metal 
ions in catalysis (Wang et al, 2009). Ternary structures have determined that 
both ends of the guide strand are anchored forming one helical turn of the A-form 
helix with the 12-nt target RNA spanning the seed region and cleavage site. 
Analysis of base stacking between RNA and protein showed interesting 
interactions: the base at position 16 of the guide strand stacked on the aromatic 
ring of Tyr43 while the base at 16‘ of the target strand stacked over the Pro44 
ring. Base-pair stacking is disrupted for bases 17, 18, and 19, leading to 
separation of guide and target strands (Figure 2). These interactions 
demonstrate an unexpected role of the N domain in blocking the propagation of 
the guide strand-target RNA duplexes beyond position 16 in the 19-nt target  
10 
 
 
Figure 1.2. Crystal Structure of T. thermophilus Ago (Asn478) bound with 
21-nucleotide guide DNA and 19-nucleotide target RNA 
Two views of the 2.8 A crystal structure of the ternary complex. The structure 
was generated using mutant Ago of T. thermophilus, which is unable to cleave 
the target RNA thus facilitating detailed examination of the cleavage site at 
position 10–11. The guide strand DNA (red) is traced for nucleotides 1–16, which 
are perfectly matched with its target mRNA (blue). Target RNA is traced for 
nucleotides 2‘–16‘. Only the 5‘ end of the guide strand is anchored in this ternary 
complex. The two strands retain the conformation to one turn of A-form helix (12 
nt) upon binding (Chiu & Rana, 2002; Chiu & Rana, 2003), and the cleavage site 
of nt 10–11 stack on each other in a catalytically competent conformation. The N-
domain of Ago seems to block the interaction between the guide strand and 
target mRNA beyond position 16, thus the 3‘ end could be released from the PAZ 
domain. Adapted from Wang et al. (Wang et al, 2009) 
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ternary complexes (Figure 1.2.). A second RNAi feature that influences efficient 
RISC loading and RNAi is the requirement for 5' phosphorylation of the guide 
strand. siRNAs generated from long dsRNAs by Dicer all contain 5' 
monophosphates, while exogenously introduced siRNAs often have 5' hydroxyl 
groups. This suggests that loading of siRNAs into functional RISCs may require 
5' phosphorylation of siRNAs. Indeed, this is supported by the observation that 
RNAi activity can be abolished by chemical modification of the 5' end of siRNAs 
with amino groups and 3-carbon linkers to block phosphorylation (Chiu & Rana, 
2002). This modification could also block the binding of cellular factors that 
recognize the 5' hydroxyl group. Interestingly, unlike the guide strand, 
modifications of the passenger strand, such as chemical modification and 
introduction of bulge structures, are well tolerated. Most passenger strand 
modifications will not negatively affect RNAi activity as long as the A-form helix 
structure of the siRNA duplex is maintained (Rana, 2007). This includes capping 
the 5' hydroxyl of the passenger strand to facilitate loading of the guide strand 
into functional RISCs.  
1.3 Kinetics of the Catalytic Engine Assembly 
The assembly of RISCs requires a series of kinetic processes, and can be 
divided into at least two catalytic steps: (1) RISC loading, and (2) target 
recognition, cleavage, and release. These two events each contain several 
further steps, such as dsRNA binding, target recognition, cleavage, product 
release, and RISC recycling (Figure 1.3.). For simplicity, only two checkpoints  
12 
 
 
Figure 1.3. Kinetics of RISC assembly and function 
The assembly and function of RISCs can be divided into at least two catalytic 
steps; for simplicity only two checkpoints are considered here. The first 
checkpoint is RISC loading. siRNA binding by RISCs is denoted as K1 and 
assembly of functional activated RISCs is denoted as K2. K2 can be affected by 
the thermodynamics of siRNAs. The second checkpoint involves target 
recognition and cleavage. After guide strands of siRNAs are loaded into RISCs, 
the protein complex is activated and led by the guide strand to target mRNAs. 
Target mRNAs are bound by functional RISCs, change their conformation to A-
form helices and are finally cleaved by Ago2 at nt position 10–11 from the 5‘ end 
of the guide strand. The target mRNA recognition by RISCs is denoted as K3 and 
mRNA cleavage is denoted as K4. K3 could be affected by several factors such 
as the secondary structure of target mRNAs.  
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steps are considered here. The overall catalytic efficiency of RISC assembly can 
be represented by Kcat, which is the turnover number or the number of reactions 
that occur at the catalytic site per unit of time. The Kcat for RISC loading is 
designated as K2 while that of the second catalytic step, target recognition and 
cleavage, is designated as K4. Therefore, RISCs with high catalytic potentials 
would have high K2 and K4.  
Several parameters may affect the rates of K2 and K4 and thus result in 
the assembly of RISCs with different performance characteristics. For example, 
the thermodynamics of double-stranded siRNAs could determine which strand 
gets loaded into the RISCs. siRNA duplexes with unstable 5‘ ends in the guide 
strands will enable efficient incorporation of the guide strand into the functional 
RISCs (activated RISCs). During this process, the passenger strand will be 
cleaved by Ago2 and subjected to further destruction. Removal of the passenger 
strand facilitates RISC formation (Matranga et al, 2005). Therefore, siRNAs with 
unstable 5‘ ends in the guide strands will likely have a high K2, which indicates 
that it will be more efficiently incorporated into the functional RISCs. As 
mentioned previously, modification of siRNAs would affect their loading efficiency 
into RISCs, which is another factor that could affect K2. However, K2 is not the 
only factor to consider for achieving efficient downstream target gene silencing. 
In reality, not all of the activated RISCs would have the same target mRNA 
recognition and cleavage, thus the second Kcat, K4, is postulated to be crucial as 
well. At least two parameters could control K4. One is the accessibility of target 
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mRNAs. The local environment of a target mRNA could indeed have a profound 
impact on the silencing efficiency of the same RISCs. Recent studies have 
shown that mRNA regions with strong secondary structures, such as hairpin and 
stem loops, are resistant to targeting by RISCs (Brown et al, 2005; Overhoff et al, 
2005; Schubert et al, 2005). In this case then, high K4 represents high 
accessibility of mRNAs for activated RISCs. Another factor that could affect K4 is 
the structural flexibility of the RISC complex. Various studies have shown that 
RISCs formed in vivo (holo-RISCs) by delivery of exogenous siRNAs into the cell 
have lower Kcat (K4) than RISCs formed in cell lysates (minimal RISCs), or 
recombinant RISCs (Brown et al, 2005). This could be due to binding of 
additional cellular factors to the RISCs, thus restricting the structural flexibility of 
the assembled protein complex. It should be noted that RISCs with high K4 might 
not be advantageous since the high structural flexibility could increase the risk of 
non-specific mRNA destruction in cells.  
There are two specific steps of RISC assembly that are rate-limiting 
(Figure 1.3.). The first is the binding and loading of siRNAs into RISCs, and the 
second is the target recognition process. Two mechanisms have been 
envisioned by which activated RISCs could recognize target mRNAs. One is a 
mechanism similar to that used by ribosomes to locate the translation initiation 
site by scanning across the target mRNA and stopping at the first suitable site. 
Alternatively, RISCs could recognize the target mRNAs by a diffusion-controlled 
―hit-and-run‖ mechanism. To test the scanning model, 2‘-O-methyl 
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oligonucleotides were used to create blocks near the target site on the mRNAs. If 
the model is correct, RISCs will be arrested at these blocks due to high-affinity 
binding of the oligos on the mRNAs, which will prevent RISCs from further 
scanning. However, the 2‘-O-methyl oligonucleotides were found to enhance 
cleavage of target mRNAs by RISC due to the removal of nearby secondary 
structures and increased accessibility of the targets (Brown et al, 2005). Thus, 
target recognition of RISCs follows the diffusion-controlled model, where 
antisense strand-guided RISCs are continuously binding to different target 
mRNAs. Once a perfectly matched mRNA is bound, the complementary strands 
form an A-form helix and induce conformation changes in the RISCs, resulting in 
target mRNA cleavage. Interestingly, RISC is about three fold more active in the 
absence of translation and blocking scanning from both the 5‘ and 3‘ ends of an 
mRNA does not interfere with RISC function (Gu & Rossi, 2005).  
1.4 The Origin of Natural Triggers 
Currently, at least two pathways have been identified for miRNA biogenesis 
(Figure 1.4.). The canonical miRNA biogenesis pathway starts with the 
transcription of independent miRNA-encoding transcripts. These primary miRNA 
transcripts (pri-miRNAs) fold into hairpin structures and are processed in the 
nucleus by Drosha and its associated protein complex. Drosha is a member of 
the RNase III family of enzymes and, together with its cofactor DGCR8, cuts the 
pri-miRNA hairpins to generate ~70 nt miRNA precursors (pre-miRNAs). By  
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Figure 1.4. Canonical and non-canonical microRNA biogenesis pathways 
Depending on the origin of miRNAs, two pathways have been proposed for 
miRNA biogenesis in vivo. (a) Canonical miRNA biogenesis. In this pathway, 
miRNA-encoding genes are first transcribed, usually through the Pol II promoter, 
into primary-miRNA–containing mRNAs. Hairpin structures within these mRNAs 
are then detected and bound by the Drosha-DGCR8 protein complex. Drosha 
cleaves the hairpin and generates ~70 nt long miRNA precursors, called pre-
microRNAs. Pre-miRNAs are then transported from the nucleus into the 
cytoplasm through exportin 5, and are further processed by the Dicer complex. 
Processing by Dicer generates ~21 nt mature miRNAs which are then loaded by 
Ago2 to form functional RISCs and carry out downstream functions. (b) Non-
canonical microRNA biogenesis. In this pathway, miRNAs are usually encoded in 
the intron regions of protein-coding genes, called mirtrons. After transcription, 
primary mRNAs are bound and processed by spliceosome protein complexes, 
which give rise to mature protein coding mRNAs and ~70-nt pre-miRNAs after 
debranching. Pre-miRNAs generated in this way then join the ones from the 
canonical pathway for transportation and Dicer processing.  
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contrast, the non-canonical miRNA biogenesis pathway is Drosha-independent. 
Instead, miRNAs generated through this pathway are usually encoded in the 
intron regions of protein-coding genes which are often referred to as mirtrons. 
Mirtron-containing primary transcripts are processed by spliceosomes to 
generate pre-miRNAs. Pre-miRNAs from both canonical and non-canonical 
biogenesis pathways are then exported into the cytoplasm by the exportin 5 
complex and are further processed by Dicer to generate mature miRNAs. Finally, 
the miRNAs are loaded into Ago-containing RISC complexes (miRISCs) to carry 
out their downstream functions.  
     The regulation of miRNA biogenesis mainly relies on transcriptional 
regulation of miRNA-encoding genes. However, recent progress provides 
evidence that other steps in miRNA biogenesis are also tightly regulated (Fabian 
et al, 2010; Krol et al, 2010). In the canonical pathway, Drosha and DGCR8 can 
cross-regulate each other‘s expression. Binding of DGCR8 to Drosha's middle 
domain has a stabilizing effect, but excessive amounts of DGCR8 significantly 
compromise the processing activity of Drosha in vitro. It is likely that maintaining 
the correct ratio of Drosha to DGCR8 is crucial for optimal processing activity of 
the complex and for miRNA biogenesis. In addition to Drosha and DGCR8, Dicer 
is also regulated by its binding partner TRBP, as a decrease in TRBP levels 
results in destabilization of Dicer and defects in pre-miRNA processing. This is 
particularly important in certain diseases such as human carcinomas, where 
TRBP expression is diminished and causes impaired Dicer function. Since many 
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miRNAs act as potent tumor suppressors, impaired miRNA biogenesis could 
contribute to the progression of these carcinomas. Collectively, these findings 
point to a sophisticated network that tightly regulates miRNA biogenesis. 
1.5 MicroRNA-mediated Post-transcriptional Gene Regulation 
Once formed, pre-miRNAs are exported into the cytoplasm where they are 
further processed by Dicer and loaded into functional miRISCs (Figure 1.5.). The 
unique features of miRNAs results in miRISCs having different functions than 
siRISCs. While siRISCs induce gene silencing by cutting target mRNAs with 
perfectly complementary sequences to the guide strand, miRNAs induce gene 
silencing without cleaving the target mRNA, although cleavage activity is retained 
when a perfectly matched target is present. The seed region of miRNAs, 2–7 nt 
at the 5‘ end of mature miRNAs, plays a key role in determining which target 
mRNAs are regulated by a given miRNA (Lewis et al, 2005). The first translation 
repression mechanism by an miRNA was shown when miRNA Lin-4 in C. 
elegans inhibited Lin-14 expression without causing a reduction in Lin-14 mRNA 
levels (Lee et al, 1993; Olsen & Ambros, 1999; Wightman et al, 1993). Based on 
recent developments in understanding miRNA biology and mechanisms, at least 
three main models can be proposed by which miRNAs could modulate gene 
expression post-transcriptionally: (1) inhibition of translation initiation, (2) post-
initiation inhibition of translation, and (3) mRNA destabilization (Figure 5).  
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Figure 1.5 microRNA function 
After loading with Ago proteins to form functional RISCs, miRNA-guided RISCs 
bind to the target mRNAs and inhibit target gene expression. Currently, there are 
at least three mechanisms that have been linked to miRNA-mediated gene 
silencing. (1) Repression of translation initiation. In this case, miRISCs inhibit 
initiation of translation by affecting the eIF4F-cap recognition, 40S small 
ribosomal subunit recruitment, and/or by inhibiting incorporation of the 60S 
subunit and formation of the 80S ribosomal complex. Some of the target mRNAs 
bound by miRISC is transported into P-bodies for storage and may re-enter the 
translation phase when induced. (2) Post-initiation translational repression. 
miRISCs could interfere after translation has been initiated by inhibiting 
elongation of ribosomes, causing ribosome drop-off from mRNAs, and/or by 
facilitating degradation of newly-synthesized nascent peptides. (3) Destabilization 
of target mRNAs. miRISCs could cause destabilization of target mRNAs by 
directly interacting with CCR4-containing deadenylation complexes and 
facilitating the deadenylation of poly A tails of target mRNAs. Following 
deadenylation, the 5‘ end capping structures of target mRNAs are also removed 
by the DCP1-DCP2 complex. 
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Inhibition of translation initiation: MicroRNA-mediated translation repression was 
observed in HeLa cells in which reporter expression was regulated by let-7 
miRNA (Pillai et al, 2005), and no decrease of reporter mRNAs was detected. In 
addition, reporter mRNAs containing let-7 target sites shifted to a lighter fraction 
of polysomal gradients, suggesting that repression could be modulating 
translation initiation (Pillai et al, 2005). There are some observations suggesting 
that this inhibition of translation initiation could be cap-dependent as mRNAs with 
non-traditional cap structures (ApppG) were less repressed by Cxcr4 miRNA 
mimics in HeLa cells (Krol et al, 2010). This was further supported by in vitro 
experiments using cell-free extracts (Krol et al, 2010). miR-2–mediated 
repression was shown to be linked with inhibition of 40S ribosomal subunit 
recruitment and formation of 80S initiation complexes in fly embryo extracts. 
Additional evidence came from experiments where target mRNA with modified 5‘ 
caps exhibited increased repression by miRNAs. Similarly, supplementing the 
protein extracts with eIF4F complexes, which directly recognize cap structures of 
mRNAs, also increased let-7–mediated translational repression of reporter 
mRNAs. Finally, there is additional evidence demonstrating that joining of 60S 
ribosomal subunits could also be inhibited by miRNAs (Fabian et al, 2010). 
Together, these results show that miRNA-mediated repression of target mRNA is 
cap-dependent and results from multiple inhibitory effects on translation initiation.  
Post-initiation Inhibition: Several studies provide evidence that inhibition of target 
gene expression by miRNAs can occur at post-initiation steps (Fabian et al, 
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2010). Despite the observation that certain miRNAs and Ago proteins can be 
detected in polysomal fractions, IRES-containing target mRNAs have been 
reported to be repressed by miRNAs as well (Lytle et al, 2007; Petersen et al, 
2006). Some IRES-bearing mRNAs even showed cap-independent translation 
while still being efficiently repressed by miRNAs (Petersen et al, 2006). One 
model proposed for post-initiation inhibition is ribosomal run-off, in which 
ribosomes fall off the mRNA prematurely. Although no direct evidence exists, this 
model is supported by observations in vitro that inhibition of translation initiation 
causes a more rapid loss of ribosomes on mRNAs targeted by miRNAs 
(Petersen et al, 2006). Premature termination is the simplest explanation for such 
observations.  
mRNA destabilization and decay: mRNA degradation by miRNA was reported in 
C. elegans where partial base pairing of let-7 miRNA resulted in degradation of 
its lin-41 target mRNA (Bagga et al, 2005). This report raised the possibility that 
mRNAs containing partial miRNA complementary sites can be targeted for 
degradation in vivo. Destabilization of target mRNA by miRISCs in mammalian 
cells has recently been proposed as the main mechanism of miRNA gene 
regulation in mammalian cells (Guo et al, 2010). This destabilization is likely due 
to deadenylation of target mRNAs.  
How do miRNAs cause deadenylation of target mRNAs? Recent studies 
have revealed the molecular mechanism of miRNA-mediated mRNA 
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deadenylation, in which one key protein, GW182, is centrally involved (Fabian et 
al, 2010; Krol et al, 2010). GW182 directly interacts with all members of the Ago 
protein family and is localized within P-bodies in the cytoplasm of mammalian 
cells (Fabian et al, 2010). Another P-body protein, RCK/p54, a DEAD box 
helicase, has been shown to interact with the argonaute proteins, Ago1 and Ago2, 
and modulate miRNA function (Chu & Rana, 2006). RCK/p54 facilitates formation 
of P-bodies and is a general repressor of translation, suggesting that miRNAs are 
transferred to P-bodies for further decay or storage (Chu & Rana, 2006). GW182 
binds Ago proteins through GW repeats, and tethering of GW182 to the target 
mRNA promotes mRNA deadenylation (Behm-Ansmant et al, 2006; Eulalio et al, 
2008) through GW182-dependent recruitment of the CCR4-containing 
deadenylation complex (Behm-Ansmant et al, 2006). In addition, GW182 also 
interacts with poly(A) binding proteins (PABP) through its C terminal domain 
(Fabian et al, 2009). PABP has previously been reported to be involved in 
translation initiation by interacting with eIF4G; thus, interactions between GW182 
and PABP may interfere with this process and have multiple effects on target 
gene expression. It is worth noting that mRNA de-capping complexes such as 
DCP1-DCP2 may also be involved in miRNA-mediated gene silencing, as 
knockdown of DCP-1 and DCP-2 stabilizes deadenylated mRNAs and thus 
compromises miRNA-mediated inhibition of expression (Behm-Ansmant et al, 
2006; Fabian et al, 2010).  
1.6 Therapeutic applications 
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Catalytic silencing of specific genes by RNA provided the rationale for RNAi-
based therapeutic agents because siRNAs could be designed to treat diseases 
by lowering concentrations of disease-causing gene products. Similarly, disease-
related miRNA dysregulation can be treated either by expressing miRNA mimics 
to enhance miRNA levels or by inhibiting high levels of disease-related miRNAs 
in cells. Development of such RNA-based therapies requires chemically 
stabilized RNA and vehicles for targeted delivery in vivo. Recent advances in 
understanding the rules for chemically modifying siRNA and miRNA sequences 
without compromising their gene-silencing efficiency have allowed the design 
and synthesis of therapeutically effective RNA molecules that can silence target 
genes in vivo (Burnett et al, 2011). The second remaining challenge to deliver 
RNA-based drugs to diseased organs is being addressed by rapid developments 
in bioengineering and nanotechnologies to design RNA cargo vehicles that can 
efficiently deliver and release RNA compounds at their target sites (Burnett et al, 
2011). Based on this rapid progress in understanding RNA structure and function 
in gene silencing and their applications in disease models, it is likely that RNA-
based therapeutics will become a reality in the very near future. It is remarkable 
to witness that in the short period of time since the discovery of RNAi, a myriad of 
biotechnology and drug discovery companies using RNAi have been formed, and 
a number of RNA therapeutics are being tested in clinical trials.  
1.7 Future Perspectives 
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Given the fundamental roles of miRNAs in regulating a variety of processes, our 
current understanding of the biogenesis, regulation, and function of miRNAs will 
no doubt expand considerably in the coming years. One area of particular 
interest is miRNA editing and modification. Several emerging lines of evidence 
suggest that modifications on miRNA termini could have a broad impact on their 
stability, downstream processing, and protein recruitment.  In addition, variations 
have been observed in mature miRNA sequences from the same pre-miRNA, 
and addition of nucleotides to the miRNA 5‘ end could have dramatic effects on 
its function since the 5‘-end seed region determines the target mRNA population. 
Another potentially interesting area is the emerging role of long noncoding RNAs 
(lncRNAs) and possible crosstalk between lncRNAs and miRNAs. The lncRNAs 
could be the natural sponges for miRNAs, and the available miRISCs may be 
regulated by expression and binding of their corresponding lncRNAs. Additionally, 
different Ago proteins may regulate each other‘s function by competing for the 
available miRNAs. 
Studying these small noncoding RNAs and their potential relationship with 
protein-coding genes or lncRNAs should shed light on the complexity of gene 
regulation and lead to the development of new technologies and therapeutics. 
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CHAPTER II: SMALL RNA-MEDIATED REGULATION OF IPSC 
GENERATION 
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2.1. Abstract 
Somatic cells can be reprogrammed to an ES-like state to create induced 
pluripotent stem cells (iPSCs) by ectopic expression of four transcription factors, 
Oct4, Sox2, Klf4 and cMyc. Here we show that cellular microRNAs regulate iPSC 
generation. Knock-down of key microRNA pathway proteins resulted in 
significant decreases in reprogramming efficiency. Three microRNA clusters, 
miR-17~92, 106b~25 and 106a~363, were shown to be highly induced during 
early reprogramming stages. Several microRNAs, including miR-93 and 106b, 
which have very similar seed regions, greatly enhanced iPSC induction and 
modulated mesenchymal-to-epithelial transition step in the initiation stage of 
reprogramming, and inhibiting these microRNAs significantly decreased 
reprogramming efficiency. Moreover, miR-iPSC clones reached the fully 
reprogrammed state. Further analysis revealed that Tgfbr2 and p21 are directly 
targeted by these microRNAs and that siRNA knock-down of both genes indeed 
enhanced iPSC induction. Here, for the first time, we demonstrate that miR-93 
and its family members directly target TGF-β receptor II to enhance iPSC 
reprogramming. Overall, we demonstrate that microRNAs function in the 
reprogramming process and that iPSC induction efficiency can be greatly 
enhanced by modulating microRNA levels in cells.  
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2.2. Introduction 
Induced pluripotent stem cells (iPSCs), which exhibit properties similar to 
embryonic stem (ES) cells, were originally generated by ectopic expression of 
four transcription factors, Oct4, Sox2, Klf4, and cMyc, in mouse somatic cells 
(Takahashi & Yamanaka, 2006). In human and mouse somatic cells, besides 
these factors (Lowry et al, 2008; Park et al, 2008a; Takahashi et al, 2007), iPSCs 
can be generated with an alternative set of four factors, namely, Oct4, Nanog, 
Lin28, and Sox2 (Yu et al, 2007). Although cell types from several different 
tissues are confirmed to be reprogrammable (Aoi et al, 2008; Eminli et al, 2008; 
Giorgetti et al, 2009; Hanna et al, 2008; Meissner et al, 2007), a major bottleneck 
in iPSC derivation and therapeutic use is low reprogramming efficiency, typically 
from 0.01% to 0.2% (Aoi et al, 2008; Meissner et al, 2007; Nakagawa et al, 2008; 
Takahashi & Yamanaka, 2006). Although tremendous effort has been focused on 
screening for small molecules to enhance reprogramming efficiency and on 
developing new methods for iPSC derivation (Ichida et al, 2009; Li et al, 2009b; 
Lyssiotis et al, 2009; Maherali & Hochedlinger, 2009; Shi et al, 2008a; Shi et al, 
2008b), mechanisms underlying reprogramming of primary fibroblasts to an ES 
cell-like state are still largely unknown. 
Several elegant approaches have been employed to improve 
reprogramming efficiency. Small molecule-based methods have been developed 
based on observation that treatment of cells with DNA methyltransferase 1 
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(Dnmt1) inhibitors accelerates reprogramming (Mikkelsen et al, 2008). TGFβ 
inhibition also enables more efficient iPSC induction, as does omission of Sox2 
and cMyc (Ichida et al, 2009; Maherali & Hochedlinger, 2009). In addition, array 
analysis shows that partially reprogrammed iPS cells can be created and then 
pushed to become fully reprogrammed following treatment with factors such as 
methyl transferase inhibitors (Mikkelsen et al, 2008). Genome-wide analysis of 
promoter binding and induction of gene expression by the four reprogramming 
factors demonstrates that they bind to similar targets in iPS and mES cells and 
likely regulate similar sets of genes, and also that targeting of reprogramming 
factors is altered in partial iPS cells (Sridharan et al, 2009). More recently, 
several groups showed that p53-mediated tumor suppressor pathways may 
antagonize iPSC induction (Banito et al, 2009; Hong et al, 2009; Kawamura et al, 
2009; Li et al, 2009a; Utikal et al, 2009). Both p53 and its downstream effector 
p21 are induced during reprogramming, and minimizing expression of both 
enhances iPSC colony formation. Since these proteins are up-regulated in most 
cells expressing the four reprogramming factors, and cMyc reportedly blocks p21 
expression (Gartel et al, 2001; Seoane et al, 2002), it is unclear how ectopic 
expression of these four factors overcomes the cellular responses to 
oncogenes/transgenes overexpression and why only a very small population of 
cells becomes fully reprogrammed.  
microRNAs are 18-24 nucleotide single-stranded RNAs associated with a 
protein complex called the RNA-induced silencing complex (RISC). Small RNAs 
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are usually generated from noncoding regions of gene transcripts and function to 
suppress gene expression by translational repression (Ambros, 2004; Bartel, 
2004; Kim et al, 2009a; Rana, 2007). In recent years, microRNAs have been 
found to function in many important processes, such as expression of self-
renewal genes in human ES cells (Xu et al, 2009), cell cycle control of ES cells 
(Wang et al, 2008), alternative splicing (Makeyev et al, 2007) and heart 
development (Latronico & Condorelli, 2009). Furthermore, it was recently 
reported that ES cell-specific microRNAs enhanced mouse iPSC derivation and 
replaced the function of cMyc during reprogramming (Judson et al, 2009) and 
hES-specific miR-302 could alleviate the senescence response due to four factor 
expression in human fibroblast (Banito et al, 2009). However, since these 
microRNAs are not highly expressed until very late stages of reprogramming, 
whether microRNAs mediating regulation of gene expression play an important 
role in iPSC induction remains unknown.  
Here we show that microRNAs function directly in iPSC induction and that 
interference with the microRNA biogenesis machinery significantly decreases 
reprogramming efficiency. We also identified three clusters of microRNAs, miR-
17~92, miR-106b~25 and miR-106a~363, which are highly induced during early 
stages of reprogramming. Functional analysis demonstrated that introducing 
these microRNAs into MEFs enhanced Oct4-GFP+ iPSC colony formation. We 
also found that Tgfbr2 and p21, both of which inhibit reprogramming, are directly 
targeted by these microRNAs and that blocking their activity significantly 
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decreased reprogramming efficiency. Overall, we propose that miR-93 and 106b 
are key regulators of reprogramming activity.  
 
2.3. Results 
2.3.1. Post-transcriptional regulation functions in reprogramming of MEFs 
to iPS cells 
To investigate the role of post-transcriptional gene regulation in iPSC induction, 
we used lentiviral shRNA vectors targeting mouse Ago2 as well as Dicer and 
Drosha to stably knock-down these factors in primary Oct4-GFP MEFs. Knock-
down efficiency of shRNA constructs was verified both by Western analysis and 
RT-qPCR (Figure 2.1.A, Figure 2.S1.A,B). For each shRNA, we routinely 
observed ~70%-80% mRNA level knock-down, as well as significant decreases 
in protein levels. We then transduced MEFs with each of these shRNAs 
separately along with viruses expressing the four OSKM (Oct4, Sox2, Klf4 and 
cMyc) factors at a volume ratio of 1:1:1:1:1. After 14 days, colonies were fixed 
and stained for alkaline phosphatase (AP) activity, a widely used ES cell marker. 
We found that knock-down of either Dicer, Drosha or Ago2 resulted in a dramatic 
decrease in the number of AP+ colonies compared with pLKO and pGIPZ 
controls (Figure 2.1.B, Figure 2.S1.C). We also observed similar results by using  
 
 
31 
 
 
Figure 2.1. The RNAi machinery functions in mouse iPSC induction. 
(A) Knock-down of mouse RNAi machinery gene Ago2 by shRNAs. MEFs were 
transduced with lentiviral shRNAs plus 4ug/ul polybrene, and total RNAs or 
proteins were harvested at day 3 post-transduction. mRNA and protein levels of 
targeted genes were analyzed by RT-qPCR and Western blotting, respectively. 
pLKO is the empty vector control for the shRNA lentiviral vectors. pGIPZ is a 
lentiviral vector expressing a non-targeting shRNA. (B) Knock-down of Ago2 
dramatically decreases iPS induction by 4F. Primary MEFs were transduced with 
the four reprogramming factors (OSKM (4F)) plus shRNA Ago2. Colonies were 
stained at day14 post transduction for alkaline phosphatase, which is a marker 
for mES/iPS cells. pLKO and pGIPZ vectors served as negative controls. (C) 
Knock-down of Ago2 decreases iPS induction by OSK. Colonies were stained 
and quantified for AP at day21 post transduction. Error bar represent standard 
deviation from duplicate wells. (D) GFP+ colony quantification of iPSC with 
shAgo2. GFP+ colonies were quantified at day21 post transduction. Error bar 
represent standard deviation from duplicate wells. 
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OSK (3F) transduction. Both GFP+ and AP+ colony quantification verified that 
knocking down Ago2 dramatically decrease reprogramming efficiency while 
proliferation of transduced fibroblasts were not affected (Figure 2.1.C,D, Suppl. 
Figure 2.S2.).  
Despite the decrease in reprogramming efficiency upon Ago2 knockdown, 
we observed some GFP+ colonies in shAgo2 infected MEFs and further 
characterization determined that these colonies were positive for shRNA 
integration and shRNAs were actively expressed (Figure 2.S3.A, B). These cells 
also expressed all the tested ES-specific markers and had turned on the 
endogenous Oct4 locus as well as low expression of p21 and Tgfbr2 (Figure 
2.S3.C, D, E). However, they seemed to have compromised differentiation 
tendency as they were not as responsive to retinoid acid treatment as mouse ES 
cells (Figure 2.S3.F). Understanding the detailed mechanism of GFP+ colony 
formation in shAgo2 infected MEFs needs further investigation.  Taken together, 
these data strongly suggest that post-transcriptional regulation, particularly that 
mediated by microRNAs, functions in the reprogramming process.  
 
2.3.2. miR-17, 25, 106a and 302b clusters are induced during the early stage 
of reprogramming 
Expression of the four reprogramming factors induces numerous changes 
in gene expression during iPS induction (Mikkelsen et al, 2008; Sridharan et al, 
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2009). We hypothesized that some ES cell-specific microRNAs might be induced 
by these factors to facilitate reprogramming. Based on previously published 
results (Houbaviy et al, 2003; Landgraf et al, 2007), we analyzed nine microRNA 
clusters highly expressed in mouse ES cells. Two representative microRNAs 
from each cluster were evaluated using a miR qPCR-based method to quantify 
expression changes at different reprogramming stages—namely days 0, 4, 8 and 
12—following transduction of the OSKM factors. Many ES cell-specific 
microRNAs, such as the miR-290 and miR-293 clusters, were not induced until 
day 8 (Figure 2.S4.), at which stage GFP+ colonies were already detectable. 
Interestingly, we found that several other clusters, including miR-17~92, 106b~25, 
106a~363 and 302b~367, were expressed to varying extents by day 4 of 
induction (Figure 2.2.A). Among these four clusters, the level of miR-302b~367 in 
MEFs was the lowest (data not shown). It is noteworthy that of the three clusters 
highly induced at reprogramming day 4, many shared very similar seed regions 
(Figure 2.2.B). In general, seed region of a microRNA decides the target 
specificity, however, recent reports suggest other mechanisms could also play 
roles in microRNA targeting (Lal et al, 2009; Tay et al, 2008; Wang et al, 2010). 
Together, our findings suggest that these microRNAs function in reprogramming 
and could target similar sets of genes. 
We next asked which of the four reprogramming factor(s) induced these  
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Figure 2.2. miR-17, 25, 106a and 302b clusters are induced during early 
stages of reprogramming. 
(A) Induction of 10 microRNA clusters in the early stages after transduction with 
the four reprogramming factors. miR RT-qPCR was used to quantify expression 
levels of representative microRNAs from clusters highly expressed in ES cells. 
Total RNAs from day 0 MEFs and from MEFs transduced with reprogramming 
factors at day 4 post-infection were analyzed. Blue bars: day 4 MEFs; white bars: 
day 0 MEFs. Asterisks indicate induced microRNAs. (B) Seed region comparison 
of different miR clusters induced at day 4 post-reprogramming factor transduction. 
Red indicates similar seed regions. (C) Representative microRNAs can be 
induced with different combinations of reprogramming factors. microRNA 
expression was quantified at 4 days post transduction.  
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microRNAs by transducing MEFs with different combinations of OSKM factors at 
the same dose and undertaking miR qPCR analysis at day 4 post infection 
(Figure 2.2.C). This analysis confirmed that cMyc alone could induce miR-17~92, 
miR-106b~25, and miR-106a~363 cluster expression, as reported previously 
(Mendell, 2008). However, in each case, a combination of all four reprogramming 
factors induced the most abundant expression of microRNA clusters, and that 
robust expression was correlated with the highest reprogramming efficiency 
(Figure 2.2.C).  
 
2.3.3. miR-93 and miR-106b enhance iPSC induction and mesenchymal-to-
epithelial transition (MET) step of reprogramming 
Since the four identified microRNA clusters contain several microRNAs with 
similar seed regions, we chose the miR-106b~25 cluster for further analysis 
because it contains only three microRNAs: miR-25, miR-93 and miR-106b. miR-
93 and 106b have the identical seed regions, and both were highly induced by 
the four reprogramming factors (Figure 2.2.A). Thus we reasoned that we might 
observe more efficient iPSC induction if we ectopically expressed these 
microRNAs during reprogramming. Besides, microRNAs mimics could be 
transfected into MEFs with high efficiency and have a half-life of 4 days (Figure 
2.S7., Figure 2.S9.B). To test this hypothesis we directly transfected microRNA 
mimics into MEFs harboring Oct4-GFP at days 0 and 5 with vectors expressing 
either all four factors (4F, OSKM) or only Oct4, Sox2, and Klf4 (OSK) and 
36 
 
 
assayed reprogramming based on GFP expression (Figure 2.3.A). GFP+ 
colonies were counted on day 11 to evaluate reprogramming efficiency (Figure 
2.3.B). Transfection of miR-93 and 106b mimics promoted a 4~6 fold increase in 
the number of GFP+ colonies both in 4F and OSK transduction (Figure 2.3.C,D; 
Figure S22), confirming that these microRNAs, which are induced during iPSC 
induction, facilitate MEF reprogramming. Dose/response analysis showed that 
enhanced reprogramming efficiency occurred at as low as the 5-15nM range of 
miRs (Figure 2.S5.). To confirm that the enhancement by these microRNAs was 
from induction of bonafide iPS colonies, we further analyzed the expression of 
another marker Nanog in miR-106b transfected cells. In both 4F and OSK 
infected samples, miR-106b transfection consistently increased the relative 
Nanog expression (Figure 2.S6.A,B). Immunostaining and followed by Nanog+ 
colonies quantification further proved that almost every Oct4-GFP+ colony is also 
Nanog+ at that stage (Figure 2.S6.C) and miR-106b can enhance formation of 
both colonies (Figure 2.S6.D,E). Alkaline phosphatase staining showed no 
obvious increase in the number of AP+ colonies in miR mimic transfections 
(Figure 2.S8.A), suggesting that miR-93 and 106b facilitate maturation of iPS 
colonies. This idea was supported by our observation of the OSK system, in 
which many GFP+ colonies were apparent at day 15 post-OSK transduction in 
miR mimic-transfected cells, while control wells did not exhibit any mature iPS 
colonies at this stage (data not shown). To confirm that these microRNAs play an 
important role in iPSC induction, we used miR inhibitors (Hutvagner et al, 2004;  
37 
 
 
Figure 2.3. miR-93 and 106b greatly enhance iPS induction. 
(A) Reprogramming assay timeline. MicroRNA mimics or inhibitors (or inhibitors) 
were transfected at a final concentration of 50nM on day 0 and day 5 of 
reprogramming. GFP+ colonies were quantified at day 11 for 4F induction and 
days 15-20 for OSK induction. (B) Representative images of GFP+ colonies from 
reprogrammed Oct4-GFP MEFs transfected with microRNA mimics. Arrows 
indicate GFP+ colonies. (C) miR-93 and 106b mimics enhance iPS induction with 
4F induction. Oct4-GFP MEFs were transfected with 50nM of the indicated 
microRNAs at days 0 and 5 of reprogramming. GFP+ colonies were quantified at 
day 11 post-transduction. Fold-induction and error bars were calculated from 
three independent experiments using triplicate wells. *** p<0.0001. (D) The 
enhancing effect of miR-93 and 106b is observed using the OSK system. 
microRNA mimics were transfected as in 4F experiments. GFP+ colonies were 
quantified on days 15-20. Error bars represent standard deviation from three 
independent experiments in triplicate wells. *** p<0.0001.  (E) miR-93 and 106b 
inhibitors dramatically decrease reprogramming efficiency. microRNA inhibitors 
were transfected at a final concentration of 50 nM. The experimental timeline was 
the same as in miR mimic transfections. Error bars represent standard deviation 
from three independent experiments in triplicate wells. *** p<0.0001. (F) miR-106 
promotes the MET transition during 4F mediated reprogramming. miR-106b 
mimic was transfected into MEFs and cells were harvested at different time point 
to analyze E-Cadherin expression. Fold induction of ECad was normalized to 
day4 samples after 4F infection. Error bar represents standard deviation of three 
independent experiments. * p<0.001. (G) miR-106b promotes the MET transition 
in OSK infected cells. The experimental procedures were the same as in (f). Fold 
induction of ECad was normalized to day4 samples after OSK infection. Error bar 
represents standard deviation of three independent experiments. * p<0.001. (H) 
Inhibition of miR-106b decreases induction of MET process. The experimental 
procedures were the same as in (f), except anti-miR oligos were transfected 
instead of miR mimics. Fold induction of ECad was normalized to day4 samples 
after 4F infection. Error bar represents standard deviation of three independent 
experiments. * p<0.001.  
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Figure 2.3. miR-93 and 106b greatly enhance iPS induction. 
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Meister et al, 2004; Vermeulen et al, 2007) to knock down targeted microRNAs 
during the reprogramming process. All of the miR inhibitors could efficiently 
decrease target miR expression and their transfection did not affect proliferation 
(Figure 2.S9.A,C).  Consistent with miR mimic experiments, miR-93 and 106b 
knock-down promoted a dramatic decrease in the number of GFP+ colonies 
(Figure 2.3.E). It is also noteworthy that although the miR-25 mimic did not 
enhance MEF iPS induction, knocking down this microRNA decreased 
reprogramming efficiency by ~40% (Figure 2.3.E). These results suggest that 
miR-25 could also function during reprogramming.  
Recent reports have identified that during the initial stage of 
reprogramming, a mesenchymal-to-epithelial transition (MET) is required (Li et al, 
2010; Samavarchi-Tehrani et al, 2010). E-Cadherin is one of the most important 
genes for MET process and we used it as the marker to determine whether miR-
106b could facilitate this step of iPSC generation. We detected a significant 
increase of E-Cadherin expression in both 4F and OSK infected samples (Figure 
2.3.F,G). In addition, knocking down of miR-106b also dramatically decreased 
the induction of E-Cadherin expression (Figure 2.3.H). Overall, these data 
indicate that miR-93 and 106 promote reprogramming of MEFs to iPSCs and 
modulate MET transition in the initiation step of reprogramming. 
2.3.4. MicroRNA-derived clones are fully pluripotent  
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Next we asked whether induced cells reach a fully pluripotent state. To 
answer this question, several iPS clones for each microRNA as well as miR 
controls were derived and analyzed for expression of pluripotency markers. All 
clones were GFP+ indicative of reactivated Oct4 expression (Figure 2.4.A). 
Immunostaining confirmed that Nanog and SSEA1 were also activated in all 
clones (Figure 2.4.B). RT-qPCR for other mES markers such as Eras, ECat I and 
endogeneous Oct4 showed similar results (Figure 2.4.C). Whole genome mRNA 
expression profiling also indicated that derived clones exhibited a gene 
expression pattern more similar to mouse ES cells than MEFs (Figure 2.S10.A). 
Promoter methylation of endogenous Nanog loci was also analyzed, and all 
tested clones showed de-methylated promoters, as is observed in mouse ES 
cells (Blelloch et al, 2006) (Figure 2.10.B).  
To investigate whether derived clones exhibit the full differentiation 
capacity of mES cells, we evaluated embryoid body (EB) formation. All derived 
clones showed efficient EB formation, and EBs showed positive staining for 
lineage markers such as such as β-tubulin III (ectoderm), AFP (endoderm) and 
α-actinin (mesoderm) (Figure 2.4.D). Beating EBs were also derived from these 
cells (Suppl. Video 1), indicating that functional cardiomyocytes can be derived 
from these miR-iPSC clones.  When these miR-iPSCs were injected into 
athymus nude mice, teratomas were readily derived in 3-4 weeks (Figure 2.4.E). 
Finally, as a more stringent test, we injected miR-derived iPSC clones into 
albino/black B6 blastocysts and generated chimera mice (Figure 2.4.F).  
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Figure 2.4. Characterization of iPS clones derived from miR mimic 
experiments. 
(A) Derived clones activate endogenous Oct4-GFP expression. Colonies were 
picked starting at day 12 post-OSKM transduction with microRNA mimics and 
maintained on irradiated MEF feeder plates. Green fluorescence is GFP signal 
from the endogenous pou5f1 locus. (B) Clones shown in (a) are positive for 
alkaline phosphatase staining and immunostaining of ES-specific markers based 
on Nanog and SSEA1 staining. Hoechst 33342 was used for nuclear staining. (C) 
RT-PCR of endogenous ES markers. Total RNAs were isolated from iPS cell 
lines at day 3 post-passage. ES cell-specific markers such as Eras, ECat I, 
Nanog, and endogenous Oct4 expression were analyzed by RT-PCR. (D) Cells 
from all three germ layers can be obtained in embryoid body (EB) assays using 
derived iPS clones. iPS cells were cultured for EB formation at ~4000 cells/20ul 
drop for 3 days, and EBs were then reseeded onto gelatin coated plates for 
further culture until day 12-14, when beating cardiomyocytes were observed 
(Supplementary Video 1). Cells were immunostained with different lineage 
markers. β-tubulin III: ectoderm marker; AFP: endoderm marker; α-Actinin: 
mesoderm marker. (E) Teratomas form from injected iPS cells. 1.5 million cells 
were injected into each mouse, and tumors were harvested 3~4 weeks after 
injection for paraffin embedding and H&E staining. Structures representing 
different lineages are labeled. Representative pictures are from miR-106b clone 
1#. (F) Derived clones can be used to generate chimeric mice.  iPS cells were 
injected into blastocysts from albino or black C57B6 mice (NCI) and the 
contribution of iPSCs can be seen with agouti or black coat color.  
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Figure 2.4. Characterization of iPS clones derived from miR mimic 
experiments. 
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Furthermore, these cells could contribute to the genital ridge of derived E13.5 
embryos (Figure 2.S11). Taken together, these results indicate that the 
enhancing effects of miR-93 and 106b on reprogramming do not alter 
differentiation capacity of induced pluripotent cells and that those derived clones 
can differentiate into all three germ lines.  
2.3.5. miR-93 and 106b target Tgfbr2 and p21 
To further understand the mechanism underlying miR-93 and 106b enhancement 
of reprogramming efficiency, we investigated cellular targets of these microRNAs. 
We chose miR-93 for analysis since it shares the same seed region as miR-106b. 
miR-93 mimics were transfected into MEFs, and total RNAs were harvested at 
day2 for mRNA expression profile analysis. That analysis identified potential 
functional targets of miR-93 that we compared with published expression profiles 
of MEFs and iPSCs (Sridharan et al, 2009). We found that genes significantly 
decreased upon miR-93 transfection showed a threefold enrichment of genes 
which are lowly expressed in iPSCs (Figure 2.S13.A), while genes which were 
increased upon miR-93 transfection did not show such enrichment. In addition, 
we undertook pathway ontology analysis of the expression profile of miR-93 
transfected MEFs (data not shown). Interestingly, two important pathways for iPS 
induction were regulated by miR-93: TGF-β signaling and G1/S transition 
pathways.  
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     For TGF-β signaling, Tgfbr2 is among one of the most significantly 
decreased genes upon miR-93 transfection. Tgfbr2 is a constitutively active 
receptor kinase that plays a critical role in TGF-β signaling, and recent small 
molecule screens indicate that inhibitors of its heterodimeric partner Tgfbr1 
enhance iPSC induction (Ichida et al, 2009; Maherali & Hochedlinger, 2009).  
MicroRNA target site prediction suggested that there were two conserved 
targeting site for miR-93 and its family microRNAs in its 3‘UTR. Therefore we 
choose it as the candidate target for further investigation.  
     Regarding the G1/S transition, we choose p21 as the potential target 
because recent results in human solid tumor samples (breast, colon, kidney, 
gastric, and lung) and gastric cancer cell lines indicate that the miR-106b~25 
cluster can target cell cycle regulators, such as the CDK inhibitors p21 and p57 
(Ivanovska et al, 2008; Kim et al, 2009b) and that human and mouse p21 share a 
conserved miR-93/106b target site in the 3‘UTR.  Furthermore, mouse ES cell-
specific microRNA clusters, such as miR-290 and 293, reportedly target negative 
regulators of the G1-S transition, including p21 (Wang et al, 2008). miR-290 and 
293 cluster microRNAs also share very similar seed regions with miR-93 and 
106b (unpublished observations). p21 is also greatly induced by OSKM factors 
during early stages of iPSC induction, (Kawamura et al, 2009) an up-regulation 
that we confirmed in MEFs (Figure 2.S12.A). Detailed analysis revealed that p21 
induction is primarily due to Klf4 and cMyc misexpression, as a combination of 
Oct4 and Sox2 only did not significantly alter p21 protein levels (Figure 2.S12.A).  
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To determine whether mouse Tgfbr2 and p21 are targeted by miR-93 and 
106b, miR mimics were transfected into MEFs, and total cell lysates were 
analyzed by Western blotting 48 hours later. Indeed, miR-93 and 106b 
expression efficiently decreased both Tgfbr2 and p21 protein levels (Figure 
2.5.A,D) and p21 mRNA levels were decreased by ~25-30% while Tgfbr2 was 
decreased by ~60-70% (Figure 2.S14.A,B). These levels of suppression were 
further confirmed in 4F and OSK infected MEFs (Figure 2.S15&S16).  To 
determine whether p21 is a direct target of miR-93 and 106b, we constructed a 
luciferase reporter with p21 3‘UTR sequence inserted downstream of the firefly 
luciferase coding sequence. We observed consistent ~40% repression of 
luciferase activity following transfection of miR-93 and 106b mimics into co-
transfected Hela cells, a repression lost when mutations were introduced into the 
seed region of conserved p21 3‘UTR target sites (Figure 2.S17.A,B). For Tgfbr2, 
luciferase assay also showed ~50% decrease of GL activity while miR-93 mutant 
did not have such effect (Figure 2.S18.A,B). 
     Cell cycle arrest promoted by p21 may inhibit epigenetic modifications 
required for reprogramming, since those modifications occur more readily in 
proliferating cells. To determine whether p21 expression compromises iPS, HA-
tagged p21 cDNA was cloned into the pMX retroviral backbone and 
overexpressed in MEF cells. When HA-p21 virus was introduced into MEFs 
together with the four OSKM factors, an almost complete inhibition of iPS 
induction was observed, based on both alkaline phosphatase staining and Oct4-  
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 Figure 2.5. miR-93 and 106b directly target mouse p21 and Tgfbr2. 
(A) miR-93 and 106b transfection decreases p21 protein levels. Oct4-GFP MEFs 
were transfected with 50nM miR mimics and harvested 48hr after transfection for 
Western analysis. Actin was used as the loading control. (B) p21 is knocked 
down efficiently by siRNA. P21 siRNA- and control-transfected MEFs were 
harvested at 48hr and RT-qPCR, and western blotting was undertaken to verify 
p21 expression. p21 mRNAs were normalized to GAPDH. (C) Knock-down of 
p21 by siRNA enhances iPSC induction. MEFs were infected with 4F virus, and 
siRNAs were transfected following the same timeline as microRNAs mimic 
transfection. GFP+ colonies were quantified at day 11. Error bars represent three 
independent experiments using triplicate wells. (D) miR-93 and 106b transfection 
decreases TGFBR2 expression. Transfected cells were harvested at 48hr for 
western blotting. (E) Tgfbr2 is knocked down by siRNAs. Relative Tgfbr2 mRNA 
levels were normalized to those of Gapdh. (F) Knock-down of Tgfbr2 by siRNAs 
enhances iPSC induction. Error bars represent four independent experiments in 
triplicate wells.  
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GFP-positive colony formation (Figure 2.S19.A). Similar results were obtained 
when the three OSK factors were used for reprogramming (Figure 2.S19.B). 
Since our analysis indicated that miR-93 and 106b efficiently repress both 
Tgfbr2 and p21 expression, we asked whether Tgfbr2 and p21 activity 
antagonizes reprogramming. To do so, we transfected Tgfbr2 or p21 siRNAs into 
MEFs using the same experimental time line employed with microRNA mimics.  
Western blotting and RT-qPCR confirmed that both protein and mRNA levels, 
respectively, were efficiently knocked down by siRNAs without virus transduction 
(Figure 2.5.B, E). MEF reprogramming was then initiated by OSKM transduction, 
and Oct4-GFP+ colonies were quantified at day 11 post-transduction. We 
observed a ~2-fold induction in colony number for each gene (Figure 2.5.C, F). 
TGFBR2 was also overexpressed in MEFs and iPS enhancement by miR-106b 
was compromised under such condition (Figure 2.S20). All together, our data 
identify that Tgfbr2 and p21 are the direct target of miR-93 and 106b and down 
regulation of these genes can enhance the reprogramming process.  
2.3.6. Additional upregulated microRNAs enhance iPSC induction 
As noted, we identified three microRNA clusters induced by reprogramming 
factors, and several microRNAs within these clusters have the same seed 
regions, suggesting that they target similar mRNAs (Figure 2.2.). To investigate 
whether other microRNAs that share the same seed region with miR-93 and 
106b also enhance iPSC induction, microRNA mimics of miR-17 and 106a were 
48 
 
 
tested using an experimental procedure similar to that described above for miR-
93 mimic treatment and iPSC induction. These microRNAs enhanced 
reprogramming in a manner similar to that seen with the miR-106b~25 clusters 
(Figure 2.6.A), and transfection of these miRs resulted in decreased TGFBR2 
and p21 protein levels (Figure 2.6.B,C) as well as Tgfbr2 mRNA (Figure 2.S21.). 
Together, this evidence suggests that induction of miR-17~92, miR-106b~25 and 
miR-106a~363 clusters is important for proper reprogramming and that 
upregulation of these microRNAs lowers reprogramming barriers to the iPSC 
generation process (Figure 2.6.D).  
 2.4. Discussion 
Since the discovery that MEFs can be reprogrammed to iPS cells, much effort 
has been directed toward understanding fundamental mechanisms underlying 
this process. Our results show for the first time that post-transcriptional gene 
regulation occurs during reprogramming and that interference with the RNAi 
machinery can significantly alter reprogramming efficiency. We identified three 
microRNAs clusters significantly up-regulated by the four factors used to induce 
iPS cells and found that microRNAs in those clusters likely target two important 
reprogramming pathways: TGF-β signaling and cell cycle control. While these 
experiments were in progress, several investigators also reported that the p53 
pathway, which includes downstream tumor suppressors such as p21, is a major  
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Figure 2.6. Reprogramming is enhanced by other family microRNAs 
(A) miR-17 and miR-106a can also enhance reprogramming efficiency. miR-17 
and 106a mimics were transfected into MEFs at a final concentration of 50nM. 
GFP+ colonies were quantified at day 11 post-transduction. Error bars represent 
three independent experiments in triplicate wells. (B) miR-17 and 106a also 
target p21. p21 Western blotting was performed 2 days after transfection of 
microRNA mimics into MEFs. (C) miR-17 and 106a target TGFBR2 expression. 
microRNA mimics were transfected into MEFs at 50nM final concentration. 
Western blotting was performed 2 days post transfection. (D) Model for the role 
for microRNAs during iPS induction. Several microRNAs, including miR-17, 25 
and 106a clusters, are induced during early stages of reprogramming. These 
microRNAs facilitate full reprogramming by targeting factors that antagonize the 
process, such as p21 and other unidentified proteins. Up and down represent the 
potential different stages and barriers during reprogramming process and dashed 
line indicates that barriers for reprogramming which are lowered upon 
microRNAs induction in reprogrammed cells.  
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barrier to iPSC induction (Banito et al, 2009; Hong et al, 2009; Kawamura et al, 
2009; Li et al, 2009a; Utikal et al, 2009). Much evidence indicates that ectopic 
expression of the four factors (OSKM) readily up-regulates p53 and initiates 
cellular ―def nse programs,‖ such as cell cycle arrest, apoptosis or DNA damage 
responses. These responses likely underlie low reprogramming efficiency, which 
we observe to be ~0.1%. However, these data do not explain how successfully 
reprogrammed cells overcome these barriers to become iPS cells. Our data 
suggest that cells do so in part by inducing expression of microRNAs that target 
pathways that antagonize successful reprogramming. By modulating microRNA 
levels in primary fibroblasts, we were able to achieve a significant increase in 
reprogramming efficiency.  
     TGF-β signaling is an important pathway that functions in processes as 
diverse as gastrulation, organ-specific morphogenesis and tissue homeostasis 
(Moustakas & Heldin, 2009). The current model of canonical TGF-β transduction 
indicates that TGF-β ligand binds the TGF-β receptor II (TGFBR2), which then 
heterodimerizes with TGFBR1 to transduce signals through receptor-associated 
Smads (Kahlem & Newfeld, 2009). TGF-β signaling reportedly functions in both 
human and mouse ES cell self-renewal, and FGF2, a widely used growth factor 
for ES cell culture, induces TGF-β ligand expression and suppresses BMP-like 
activities (Greber et al, 2007; Ogawa et al, 2007). Blocking TGF-β receptor I 
family kinases by chemical inhibitors compromises ES cell self-renewal (Ogawa 
et al, 2007). These findings are particularly significant for iPSC induction, 
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because those inhibitors seem to have completely different roles during 
reprogramming. Recent chemical screening has shown that small molecules 
inhibitors of the  TGF-β receptor I (TGFBR1) actually enhance iPSC induction 
and can replace the requirement for Sox2 by inducing Nanog expression (Ichida 
et al, 2009). Moreover, treating reprogramming cells with TGF-β ligands has a 
negative effect on iPSC induction (Maherali & Hochedlinger, 2009). Therefore, 
although TGF-β signaling is important for ES cell self-renewal, it is a barrier for 
reprogramming. Our results determined that, in addition to TGFBR1, activity of 
the constitutively active kinase TGFBR2 also antagonizes reprogramming. Here, 
for the first time, we demonstrate that miR-93 and its family members directly 
target TGFBR2 to modulate it‘s signaling and reprogramming.  
     p21, a protein of only 165 amino acids, functions as a tumor suppressor 
by mediating p53-dependent G1 growth arrest and promoting differentiation and 
cellular senescence (Abbas & Dutta, 2009). Our data (Suppl. Fig. 11) and that of 
others (Kawamura et al, 2009) demonstrate that p21 expression is up-regulated 
when the four factors (OSKM) are introduced into MEFs and that this up-
regulation antagonizes reprogramming, since p21 overexpression almost 
completely blocked iPSC induction (Figure 2.S16.). p21 induction in 
reprogramming cells could be dependent or independent of p53, as the Klf4 
reprogramming factor reportedly binds to the p21 promoter and increases p21 
transcription (Abbas & Dutta, 2009). This finding raises an interesting question 
regarding the function of the four reprogramming factors, since the same 
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transcription factor can both promote and antagonize iPSC induction. In fact, we 
cannot currently rule out the possibility that a certain level of p21 induction 
benefits the reprogramming process. Besides its well-known role in p53-
dependent cell cycle arrest, p21 also reportedly has an oncogenic activity by 
protecting cells from apoptosis, a function unrelated to its usual role in cell cycle 
control (Abbas & Dutta, 2009). A potential benefit for p21 in reprogramming may 
depend on its ability to regulate gene expression through protein-protein 
interactions (Abbas & Dutta, 2009). For example, p21 directly binds to several 
proteins regulating apoptosis, such as caspases 8 and 10 and procaspase 3. It 
also suppresses pro-apoptotic activity of Myc by associating with the Myc N-
terminus to block Myc-Max heterodimerization (Abbas & Dutta, 2009). Indeed, 
when Myc itself is overexpressed in MEFs, a significant increase in cell death is 
observed in cell culture, while in four-factor transduced cells, cell death is 
minimal compared to myc-only samples (data not shown). Therefore, p21 
induction may not only serve as a barrier to reprogramming but may maintain 
levels of p21 necessary to reduce apoptosis and thus increase reprogramming 
efficiency. Our data serves as partial evidence to support this hypothesis, since 
miR-93 and 106b treatment had greater enhancing effects on reprogramming 
than did p21 siRNA transfection (Figure 2.3.C, Figure 2.5.A, C). It is also possible 
that this effect is due to targeting of multiple proteins such as TGFBR2 in addition 
to p21 by these microRNAs.  
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     Finally, since the miR clusters identified here, such as miR-17~92, miR-
106b~25 and miR-106a~363, are induced during iPS induction and are 
conserved between mouse and humans, the enhancing effects of miR-93 and 
106b may apply to human reprogramming. Further studies should focus on the 
activity of these microRNAs in human cells and in various disease models.  
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Materials and Methods 
Cell culture, vectors and virus transduction 
Oct4-GFP MEFs were derived from mice carrying an IRES-EGFP fusion cassette 
downstream of the stop codon of pou5f1 (Jackson lab, Stock#008214) at E13.5.  
MEFs were cultured in DMEM (Invitrogen, 11995-065) with 10% FBS (Invitrogen) 
plus glutamine and NEAA. Only MEFs at passage of 0 to 4 were used for iPS 
induction.  pMX-Oct4, Sox2, Klf4 and cMyc were purchased from Addgene. pMX-
HA-p21 was generated by inserting N-terminally tagged-p21 into the pMX EcoRI 
site. pLKO-shRNA clones were purchased from Open Biosystems. To generate 
retrovirus, PLAT-E cells were seeded in 10cm plates, and 9ug of each factor 
were transfected the next day using Lipofectamine (Invitrogen, 18324-012) and 
PLUS (Invitrogen, 11514-015). Viruses were harvested and combined 2 days 
later. For iPS induction, MEFs were seeded in 12-well plates and transduced with 
―four factor‖ virus the next day with 4ug/ml Polybrene. One day later, the medium 
was changed to fresh MEF medium, and 3 days later it was changed to mES 
culture medium supplemented with LIF (Millipore, ESG1107). GFP+ colonies 
were picked at day 14 post-transduction, and expanded clones were cultured in 
DMEM with 15%FBS (Hyclone) plus LIF, thioglycerol, glutamine and NEAA. 
Irradiated CF1 MEFs served as feeder layers to culture mES cells and derived 
iPS clones. To generate shRNA lentivirus, shRNA lentiviral vectors were 
cotransfected into 293FT cells together with the pPACK-H1 packaging system 
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(SBI, LV500A-1). Lentiviruses were harvested at day 2 after transfection and 
centrifuged at 4000 rpm for 5min at room temp. shRNA virus was added together 
with 4 factor virus at a volume ratio of 1:1:1:1:1. 
MicroRNA and siRNA transfection of MEFs  
MicroRNA mimics and inhibitory siRNAs were purchased from Dharmacon. To 
transfect MEFs, microRNA mimics or inhibitors were diluted in Opti-MEM 
(Invitrogen, 11058-021) to the desired final concentration. Lipofectamine 2000 
(Invitrogen, 11668-019) was added to the mix at 2ul/well in 12 well plates, which 
were incubated 20 min at RT. For 12-well transfections, 80ul of the miR mixture 
was added to each well with 320ul of Opti-MEM. Three hrs later, 0.8ml of the 
virus mixture (for iPS) or fresh medium was added to each well and the medium 
was changed to fresh MEF medium the next day.  
Western blotting 
Total cell lysates were prepared by incubating cells in MPER buffer (PIERCE, 
78503) on ice for 20 min, and then cleared by centrifugation at 13,000 rpm for 10 
min. An equal volume of lysates was loaded onto 10%SDS-PAGE gels, and 
proteins were transferred to PVDF membranes (Bio-Rad, 1620177) using the 
semi-dry system (Bio-Rad). Membranes were blocked with 5% milk in TBST for 
at least 1hr at room temp or overnight at 4°C.  Antibodies used include: anti-p21 
(BD, 556430), anti-mNanog (R&D, AF2729), anti-h/mSSEA1 (R&D, MAB2156), 
anti-HA (Roche, 11867423001), anti-mAgo2 (Wako, 01422023), anti-Dicer 
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(Abcam, ab13502), anti-Drosha (Abcam, ab12286), anti-Actin (Thermo, 
MS1295P0), anti-AFP (Abcam, ab7751), anti-Beta III tubulin (R&D systems, 
MAB1368), anti-TGBR2 (Cell signaling, 3713s) and anti-alpha actinin (Sigma, 
A7811). 
mRNA and microRNA quantitative PCR 
Total RNAs were extracted using Trizol (Invitrogen). After extraction, 1ug total 
RNA was used for RT using Superscript II (Invitrogen). Quantitative PCR was 
performed using a Roche LightCycler480 II and the Sybr green mixture from 
Abgene (Ab-4166). Mouse Ago2, Dicer, Drosha, Gapdh and p21 primers are 
listed in Supplementary Table 2. Other primers were previously described 
(Takahashi & Yamanaka, 2006). For microRNA quantitative analysis, total RNA 
was extracted using the method above. After extraction, 1.5~3ug of total RNA 
was used for microRNA reverse transcription using QuantiMir kit following the 
manufacturer‘s protocol (SBI, RA420A-1). RT products then were used for 
quantitative PCR using the mature microRNA sequence as a forward primer 
together with the universal primer provided with the kit.  
Immunostaining 
Cells were washed twice with PBS and fixed with 4% paraformaldehyde at room 
temperature for 20min. Fixed cells were permeabilized with 0.1% Triton X-100 for 
5min. Cells were then blocked in 5% BSA in PBS containing 0.1% Triton X-100 
for 1hr at room temperature. Primary antibody was diluted from 1:100 to 1:400 in 
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2.5% BSA PBS containing 0.1% Triton X-100, according to the manufacturer‘s 
suggestion. Cells were stained with primary antibody for 1hr and then washed 
three times with PBS. Secondary antibody was diluted 1:400 and cells were 
stained for 45min at room temperature.  
EB formation and differentiation assay 
iPS cells were trypsinized into a single cell suspension and the hanging drop 
method was used to generate embryoid bodies. For each drop, 4000 iPS cells in 
20ul EB differentiation medium were used. EBs were cultured in hanging drops 
for 3 days before being reseeded onto gelatin-coated plates. After reseeding, 
cells were further cultured until day 14 when beating areas could be identified.  
Promoter methylation analysis 
CpG methylation of the Nanog and Pou5f1 promoters was analyzed following 
procedures described elsewhere (Takahashi & Yamanaka, 2006). Briefly, 
genomic DNA of derived clones was extracted using a Qiagen kit. 1ug DNA was 
then used for genome modification analysis following the manufacturer‘s protocol 
(EZ DNA Methylation –Direct Kit, Zymo Research, D5020). After modification, 
PCR of selected regions was performed, and products were cloned into pCR2.1-
TOPO (Invitrogen). Ten clones were sequenced for each gene. 
Teratoma formation and chimera generation 
58 
 
 
To generate teratomas, iPS cells were trypsinized and resuspended at a 
concentration of 1x107 cells/ml. Athymus nude mice were first anesthetized with 
Avertin, and then approximately 150 ul of the cell suspension was injected into 
each mouse. Mice were checked for tumors every week for 3~4 weeks. Tumors 
were harvested and fixed in zinc formalin solution for 24hrs at room temp before 
paraffin embedding and H&E staining. To test the capacity of derived iPSC 
clones to contribute to chimeras, iPS cells were injected into C57BL/6J-Tyr(C-2J)/J 
(albino) blastocysts. Generally, each blastocyst received 12-18 iPS cells. ICR 
recipient females were used for embryo transfer. The donor iPSC cells are either 
in agouti or black color.   
mRNA microarray analysis 
miR-93 and siControl were transfected into MEFs and total RNAs were harvested 
at 48hrs post transfection. mRNA microarray was carried out by Microarray 
facility in Sanford-Burnham institute. Gene lists for both potential functional 
targets (fold change >2, p<0.05) and total targets (fold change >25%, p<0.05) 
were generated by filtering through volcano maps. Gene lists were then used for 
ontology analysis using GeneGo software following guidelines from the company. 
Dual luciferase assay 
3‘UTR of both p21 and Tgfbr2 were cloned into XbaI site of pGL3 control vectors. 
For each well of 12-well plates, 200ng of resulted vectors and 50ng of pRL-TK 
(renilla luciferase) were transfected into 1x105 Hela cells which were seeded one 
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day before the transfection. 50nM of microRNAs were used for each treatment 
and cell lysates were harvested at day 2 post transfection. 20ul of lysates were 
then used for dual luciferase assay following manufacturer‘s protocol (Dual-
Luciferase® Reporter Assay System Promega, E1910) 
Cell proliferation assay 
3000 MEFs were seeded in each well in 96-well plates and transduced with 4F 
virus and shRNA lentivirus (or transfected with microRNA inhibitors). Starting 
from day 1 post transduction/transfection, every two days, cells were incubated 
with mES medium containing Celltiter 96 Aqueous one solution (Promega, 
G3580) for 1hr in tissue culture incubator. Absorbance at 490nm was then 
measured for each well using plate reader and collected data was used to 
generate relative proliferation curve using signal from day 1 post 
transduction/transfection as the reference. 
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Figure 2.S1. Knock-down of Dicer and Drosha decrease iPS induction 
(A) Drosha can be efficiently knocked down by shRNAs. MEFs were transduced 
with lentiviral shRNAs plus 4ug/ul polybrene, and total RNAs or proteins were 
harvested at day 3 post-transduction. mRNA and protein levels of targeted genes 
were analyzed by RT-qPCR and Western blotting, respectively. (B) Dicer can be 
efficiently knocked down by shRNAs. The procedure is the same as Ago2 and 
Drosha shRNA experiments. (C) Knock-down of Dicer and Drosha decrease iPS 
colony formation. Alkaline phosphatase staining was performed at day14 post 
transduction. 
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Figure 2.S2. Proliferation curve of MEFs with 4F and shRNAs 
MEFs were seeded in 96-well plates and incubated with Celltiter 96 Aqueous 
One solution for 1hr at 37°C before absorbance reading at 490nm. Signal from 
day1 samples was used as the reference to calculate relative proliferation curve. 
Error bar represents standard deviation of 6 wells for each treatment. Drosha and 
Dicer knock-down by shRNAs resulted in a gradual loss of transduced cells while 
shAgo2 transduced ones had similar proliferation rate as control non-targeting 
samples. 
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Figure 2.S3. Characterization of shAgo2 iPSC clones 
(A) Picked shAgo2 clones were positive for shRNA integration in the genome. 
Genomic DNAs from shAgo2 iPSCs were extracted and analyzed by PCR for 
integration of puromycin, which is the drug resistant gene contained in the 
shRNA virus. Primers for endogenous PGK locus were used as the loading 
control. (B) shAgo2 iPSCs were actively expressing shRNAs. Northern blotting 
was used to detect the expression of shAgo2 shRNAs. rRNA was used as the 
loading control. (C) shAgo2 iPSCs were expressing all the tested mES markers. 
Nanog, Oct4, Eras and ECatI expression were analyzed in picked clones and 
they were all positive for those tested markers. (D) shAgo2 iPSCs have activated 
the endogenous Oct4 locus and are positive for immunostaining of Nanog. (E) 
shAgo2 iPSCs have similar expression level of Tgfbr2 and p21 as mES cells. (F) 
shAgo2 iPSCs have compromised tendency to differentiation. mES cells and 
shAgo2 iPS clones were treated with RA for two days to analyze their 
differentiation tendency. Nanog was used as the self renewal marker. Mouse 
embryonic stem cell line CCE was used as control. Error bar represents data 
from duplicate samples.  
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Figure 2.S4. miR expression profile at different reprogramming stages 
MEFs were transduced with 4F and harvested at different time points (days 0, 4, 
8 and 12). Total RNAs were extracted using Trizol and microRNA RT-qPCR was 
used to evaluate expression changes of different miRs. Data was normalized to 
U6 expression, and expression data at day 12 was used as the reference (100%). 
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Figure 2.S5. Dose/response analysis of the effect of miR-93 and 106b on 
mouse iPS induction 
Oct4-GFP MEFs were transfected with different concentrations (5, 15 and 50nM) 
of indicated microRNAs. Nontargeting siRNA was used as the control. GFP+ 
colonies were quantified at day 11 post-transduction. Data represents triplicate 
wells of 12-well plates. 
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Figure 2.S6. miR-106b enhances reprogramming of MEFs to iPSCs 
(A) miR-106b transfection increased endogenous Nanog expression in 4F 
transduced cells. Cells were harvested at day12 post transduction for RT-qPCR 
analysis of Nanog gene. Data was normalized to Gapdh expression. Error bar 
represents standard deviation of three separate wells. (B) miR-106b increased 
Nanog expression in OSK transduced cells. Cells were harvested at day15 for 
RT-qPCR analysis of Nanog. Error bar represents standard deviation of three 
separate wells. (C) Oct4-GFP+ colonies were also positive for Nanog staining. 
GFP+ colonies from 4F (day12) and OSK (day15) infected cells were fixed and 
stained with Nanog antibody to detect activation of Nanog expression. (D,E) 
Quantification of both Oct4-GFP+ and Nanog+ colonies generated by 3 factors 
OSK (d) or 4 factors OSKM confirmed that miR-106b could enhance the 
reprogramming of MEFs to bonafide iPSCs. Error bar represents standard 
deviation of three separate wells. 
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Figure 2.S7. miR mimic level in transfected MEFs 
(A) miR-93 level in transfected MEFs. MEFs were transfected with different 
concentration of miR-93 and the level of miR mimics were analyzed at day 3 post 
transfection by RT-qPCR. (B) microRNAs can be efficiently delivered to MEFs. 
Fluorescence labeled siRNAs were tranfected into MEFs and transfection 
efficiency was monitored at day1 post transfection. Almost all the cells were 
positive for Cy3 signal. (C) Decay of transfected microRNA mimics in MEFs. 
miR-17 was transfected into MEFs and cells were harvested at different time 
points and qPCR was used to quantify the relative level of miR-17 in these cells. 
microRNA mimics showed a half life of ~4 days in MEF cells. 
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Figure 2.S8. microRNA mimics do not seem to alter overall AP+ colony 
formation, while microRNA inhibitors do 
(A, B) Reprogrammed cells at day 12 were stained using alkaline phosphatase 
substrates. Transfection with miR mimics did not significantly alter the number of 
AP+ colonies; however, miR-93 and 106b knock-down resulted in significant loss 
of AP+ and GFP+ colonies. Non-targeting siRNA served as control for miR mimic 
experiments, and non-targeting hairpin inhibitors were used as controls for the 
inhibitor experiments (labeled as inh-Control).  
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Figure 2.S9. Efficacy of microRNA inhibitors in transfected MEFs 
(A) microRNAs can be efficiently knocked by hairpin inhibitors. miR inhibitors 
were transfected into MEFs at 50nM and total RNAs were harvested at day4 post 
transfection for miR expression analysis by RT-qPCR. (B) microRNAs could be 
transfected into MEFs efficiently. miR mimics were transfected into MEFs at 
50nM and total RNAs were harvested at day2 post transfection for miR 
quantification. Error bar represents duplicate samples. (C) Transfection of miR 
inhibitors did not change the proliferation of MEFs. MEFs were seeded in 96-well 
plates and transfected with 50nM inhibitors. Starting from day1, cells were 
incubate with Celltiter 96 aqueous one solution for 1hr at 37°C before 
absorbance reading at 490nm. All signals were normalized using day1 signal as 
the reference. Error bar represents standard deviation of 6 wells for each 
treatment. 
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Figure 2.S10. Characterization of derived iPS clones 
(A) Global mRNA comparison of derived iPS clones versus a mouse CCE ES cell 
line confirmed that all derived iPS lines were clustered with mES rather than 
starting MEFs. Total RNAs were isolated from iPS cell lines at day 3 post-
passage and analyzed for global mRNA expression profiling using Illumina 
mRNA array chips. (B) The promoter of the ES cell marker gene Nanog is 
demethylated in derived iPS clones. Genomic DNAs from starting MEFs and iPS 
lines were isolated and then treated with bisulfite reagent using the Zymo DNA 
Methylation Direct kit. Modified DNAs were analyzed by PCR and subcloned into 
the pTOPO vector for sequencing.  
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Figure 2.S11. miR-iPSCs contribute to the germline of derived embryos 
Embryos were collected at E13.5 and fixed in 4% paraformaldehyde for O.N. and 
genital ridges were dissected out for fluorescence analysis. Oct4-GFP wild type 
embryos were used as the positive control. 
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Figure 2.S12. p21 expression is induced during iPS induction 
(A) p21 expression is induced by Klf4 and cMyc. MEFs infected with 4F, OSK, 
OS, Klf4 and cMyc were harvested at day 5 post-transduction for Western 
analysis. (B) Confirmation of transgene expression in MEFs. Total RNAs were 
isolated from transduced MEFs and analyzed by RT-qPCR for transgene 
expression. 
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Figure 2.S13. Gene expression pattern analysis of miR-93-transfected MEFs 
(A) mRNA microarray analysis identified genes showing significant mRNA level 
changes upon miR-93 transfection.  A Volcano map was generated with a 2-fold 
expression change and p value <0.05. Red dots indicate the genes which are 
significantly changed in such settings (altered by more than two fold). (B) Genes 
significantly altered were divided into two groups (increased or decreased 
expression upon miR-93 introduction) and compared with published iPS/MEF 
expression profiles (Sridharan et al., 2009). ―Correlated‖ indicates genes with 
expression changes similar to published iPS/MEF expression profile (Sridharan 
et al., 2009) (i.e,genes exhibiting decreased expression in miR-transfected MEFs 
show decreased expression in iPS cells vs MEFs). 
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Figure 2.S14. Tgfbr2 and p21 mRNAs decrease upon miR transfection 
(A) Global mRNA expression analysis indicates that Tgfbr2 mRNA levels 
decrease ~60%-70% upon miR-93 transfection, a finding confirmed by RT-qPCR. 
Error bars represent two independent experiments in duplicate wells. (B) p21 
mRNA level is decreased ~25-30% by miR-93 and 106b. Total RNAs of 
transfected cells were harvested at 48hrs post-transfection. While miR-93 and 
106b decreased the mRNA level of p21, miR-25 did not have any effect. Error 
bars represent three independent experiments using duplicate wells. 
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Figure 2.S15. p21 and Tgfbr2 expression is regulated by miR-106b in 4F 
transduced MEFs 
(A) p21 mRNA level decreased upon miR-106b transfection. miR-106b was 
transfected into 4F transduced MEFs at day0 and day5 and cells were harvested 
at indicated time points. RT-qPCR was used to analyze the expression of p21 
and data was normalized to Gapdh. Error bar represents standard deviation of 
three independent experiments. * p<0.001. (B) p21 mRNA increased upon miR-
106b inhibition. miR-106b inhibitor was transfected the same way as miR mimics. 
Error bar represents standard deviation of three independent experiment. * 
p<0.001. (C) Tgfbr2 mRNA level decreased upon miR-106b transfection. The 
experimental procedures were the same as for p21 experiment. Error bar 
represents standard deviation of three independent experiments. * p<0.001. (D) 
Tgfbr2 mRNA increased upon miR-106b inhibition. The experimental procedures 
were the same as for p21 experiment. Error bar represents standard deviation of 
three independent experiments.  *p<0.001. (E) P21 and TGFBR2 were regulated 
by miR-106b in 4F transduced MEFs. Both miR mimic and inhibitor were 
transfected into 4F infected MEFs. Cells were harvested at indicated time points 
for immunoblotting and analysis of P21 and TGFBR2 levels. 
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Figure 2.S16. p21 and Tgfbr2 expression is regulated by miR-106b in OSK 
infected MEFs 
(A) p21 mRNA level decreased upon miR-106b transfection. The procedures 
were the same as 4F experiments. Error bar represents standard deviation of 
three independent experiments. *p<0.001. (B) p21 mRNA level decreased upon 
miR-106b transfection. Error bar represents standard deviation of three 
independent experiments. *p<0.001. (C) P21 and TGFBR2 proteins decreased 
upon miR-106b transfection. 
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Figure 2.S17. p21 expression is directly regulated by the miR-106b~25 
cluster 
(A) (upper) Two potential miR-93 and 106b binding sites were found in the p21 
mRNA 3‘UTR. Blue box stands for the coding region of p21 mRNA.  (lower) 
Mutations were introduced into the first conserved site to disrupt binding. (B) 
Quantification of pGL3-p21 luciferase reporter expression in Hela cells. Cells 
were transfected with the luciferase reporter pGL3-p21 and the renilla luciferase 
control vector (pRL-TK), as well as microRNAs for 48hrs before harvesting. 
Results were normalized to pRL-TK levels in transfected cells.  
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Figure 2.S18. TGFBR2 expression is directly regulated by the miR-106b~25 
cluster 
(A) Two potential miR-93 and 106b binding sites were found in the Tgfbr2 mRNA 
3‘UTR. Blue box stands for the coding region of Tgfbr2 mRNA. (B) Quantification 
of pGL3-Tgfbr2 luciferase reporter expression in Hela cells. Cells were 
transfected and harvested the same as p21 dual luciferase assay. 
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Figure 2.S19. Ectopic expression of p21 inhibits reprogramming 
 (A) p21 ectopic expression dramatically decreases the number of both GFP+ 
and AP+ colonies using a 4F transduction protocol. (left) AP+ and GFP+ colony 
quantification. (right) AP staining at day11 and western blotting for p21 
overexpression. p21 virus was introduced at the same time with 4F, and induced 
cells were stained for alkaline phosphatase activity at day 11. (B) p21 ectopic 
expression dramatically decreases the number of both GFP+ and AP+ colonies 
following OSK transduction. (left) AP+ and GFP+ colony quantification. (right) AP 
staining of samples with OSK and p21 overexpression. p21 virus was introduced 
at the same time with OSK, and induced cells were stained for alkaline 
phosphatase activity at day 20. 
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Figure 2.S20. Ectopic expression of Tgfbr2 inhibits reprogramming and 
compromises the enhancement of miR-106b transfection 
 (A) TGFBR2 was overexpressed in MEFs by pMX retroviral vector. MEFs were 
transduced with 4F and pMX-TGFBR2 and harvested for western blotting 
analysis of TGFBR2. (B) Overexpression of TGFBR2 decreased reprogramming 
efficiency and compromised miR-106b enhancing effect. Both 4F and 
4F+TGFBR2 transduced MEFs were transfected with miR-106b and Oct4-GFP+ 
colonies were quantified at day12. miR-106b can enhance reprogramming by 
three fold in 4F only cells while only increases colony number by ~1.5 fold in 
TGFBR2 overexpressing cells. Error bar represents standard deviation of three 
separate wells.  
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Figure 2.S21. Tgfbr2 is targeted by miR-93 and its family microRNAs 
miR mimics were transfected into MEFs and total RNAs were extracted at day2 
post transfection. RT-qPCR was used to quantify the relative mRNA level of 
Tgfbr2 in samples treated with different microRNAs. Only miR-93 and its family 
microRNAs showed efficient decrease of Tgfbr2 mRNA while other unrelated 
miRs did not have any effect.  
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Figure 2.S22. Absolute Oct4-GFP+Colony Quantification 
(A) Three representative experiments for Figure 3c. (B) Three representative 
experiments for Figure 3d. (C) Three representative experiments for Figure 3e. 
(D) Three representative experiments for Figure 6a. (E) Three representative 
experiments for Figure 5c. (F) Three representative experiments for Figure 5f. 
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CHAPTER III: MicroRNA-mediated Regulation of Extracellular 
Matrix Formation Modulates Somatic Cell Reprogramming 
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3.1. Abstract 
Somatic cells can be reprogrammed to reach an embryonic stem cell-like state 
by overexpression of defined factors (Takahashi et al, 2007; Takahashi & 
Yamanaka, 2006; Wernig et al, 2007; Yu et al, 2007). The current 
reprogramming process is extremely inefficient, suggesting the need for a better 
understanding of the underlying mechanisms to develop new reprogramming 
methods and to understand the transition to a pluripotent state. MicroRNAs 
(miRs) are small non-coding RNAs that primarily regulate target gene expression 
post-transcriptionally. Here we present a systematic and comprehensive study of 
microRNAs in mouse embryonic fibroblasts (MEFs) during the early stage of cell 
fate decisions and reprogramming to a pluripotent state. One microRNA found to 
be highly induced during reprogramming, miR-135b, targeted the expression of 
extracellular matrix (ECM) genes including Wisp1 and Igfbp5. Wisp1 was shown 
to be a key regulator of additional ECM genes that serve as barriers to 
reprogramming. Regulation of Wisp 1 is likely mediated through biglycan, a 
glycoprotein highly expressed in MEFs that is silenced in reprogrammed cells. 
Collectively, this is the first report, to the best of our knowledge, revealing a novel 
link between microRNA-mediated regulation of ECM formation and somatic cell 
reprogramming, and demonstrate that microRNAs are powerful tools to dissect 
the molecular mechanisms of reprogramming.  
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3.2. Introduction 
Since the first report that mouse fibroblasts can be reprogrammed into a 
pluripotent state reminiscent of embryonic stem cells (termed induced pluripotent 
stem cells, iPSC)(Takahashi & Yamanaka, 2006), this phenomenon has been 
confirmed using many different mouse and human cell types (Lowry et al, 2008; 
Nakagawa et al, 2008; Park et al, 2008b; Takahashi et al, 2007; Wernig et al, 
2007; Yu et al, 2007). Currently, the main obstacle for reprogramming to iPSCs is 
its extremely low efficiency; typically only 0.01%–0.2% of starting cells are 
successfully reprogrammed into iPSCs (Aoi et al, 2008; Meissner et al, 2007; 
Nakagawa et al, 2008; Takahashi & Yamanaka, 2006). Great effort has been 
made to identify small molecules that enhance the reprogramming process or 
that replace one or more of the four transgenes (Oct3/4, Sox2, Klf4, and c-Myc; 
OSKM, 4F) commonly used in the reprogramming protocol(Esteban et al, 2010; 
Ichida et al, 2009; Li et al, 2009b; Lyssiotis et al, 2009; Maherali & Hochedlinger, 
2009; Shi et al, 2008a; Shi et al, 2008b). However, the molecular mechanisms by 
which the four factors are able to reprogram somatic cells remain largely 
unknown. 
     Mounting evidences from recent researches have suggested that somatic 
reprogramming could be a complicate process involving many different 
processes. Systematic analysis of the promoters targeted by overexpression of 
the four reprogramming factors has demonstrated that expression of the factor 
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target genes is similar in iPSCs and mouse embryonic stem (mES) cells, and is 
altered in some partially reprogrammed cells (Sridharan et al, 2009). p53 
pathway is also identified as one primary barrier to reprogramming (Banito et al, 
2009; Hong et al, 2009; Kawamura et al, 2009; Li et al, 2009a; Utikal et al, 2009). 
Chemical screening has also discovered that inhibition of TGFβ signaling 
significantly enhances reprogramming(Ichida et al, 2009) and that some 
inhibitors of this pathway can replace the Sox2 transgene in inducing expression 
of Nanog, a transcription factor crucial for ESC pluripotency(Maherali & 
Hochedlinger, 2009). In addition, it was also suggested that a mesenchymal-to-
epithelial transition (MET) is a key step that takes place at an early stage of 
reprogramming(Li et al, 2010; Samavarchi-Tehrani et al, 2010). During 
reprogramming, expression of markers on the initial somatic cell, such as mouse 
embryonic fibroblasts (MEFs), are downregulated and characteristic mES 
markers, such as alkaline phosphatase, SSEA1, Nanog, and endogenous Oct4 
become expressed(Brambrink et al, 2008; Stadtfeld et al, 2008). Interestingly, the 
cellular origin of the iPSCs apparently influences their ability to retain an 
epigenetic ―memory‖ of the originating cell, a property that is gradually lost 
through continuous passaging of iPSCs(Polo et al, 2010).  However, iPSCs do 
not seem to have a generic epigenetic state that could clearly define fully 
reprogrammed state(Carey et al, 2011). Despite these progresses, there remains 
only limited information on the mechanisms by which the four transgenes and 
other cellular factors reprogram MEFs to an undifferentiated or ES-like state. 
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     Extracellular matrix (ECM) is a multifunctional system that is involved in 
many stages of mammalian developments (Adams & Watt, 1993; Rozario & 
DeSimone, 2010; Sanes, 1989) and human disease progressions, including 
tumor formation (Bissell & Hines, 2011; Kessenbrock et al, 2010). ECM encodes 
a variety of proteins which could be divided into two groups: proteins with 
structural role, such as fibrous proteins and glycosaminoglycans, and proteins 
with regulatory role, including different growth factors (TGFβ, IGFs etc), 
matricellular proteins (CCN family proteins, IGFBPs, decorin, biglycan etc), 
enzymes (metalloproteinases etc) and receptors (integrins etc). ECM plays a 
crucial role in regulating various cellular behaviors and maintaining the identity 
and normal function of those cells(Bissell & Hines, 2011; Kessenbrock et al, 
2010). For embryonic stem cells, recent discoveries have found that ECM 
components are essential for establishing the proper niche for long term ES cell 
survival and self-renewal(Bendall et al, 2007; Peerani et al, 2007). Therefore, it is 
possible that ECM is also involved in regulating somatic reprogramming process. 
In fact, given the dramatic changes of both cellular morphology and functional 
characteristics during course of reprogramming, potential iPSCs would need to 
establish their own niche for supporting their growth and colony formation. 
Meanwhile, iPSCs also need to exclude the effects brought by secreted ECM 
proteins from surrounding unreprogrammed cells. However, despite that iPSCs 
expressed a different set of ECM proteins from starting fibroblasts cells (ref), little 
is known about the dynamic remodeling of ECMs during reprogramming and 
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studying it could yield considerate novel information regarding the molecular 
mechanism of this process.  
     MicroRNAs are 18–24 nucleotide long, single-stranded RNAs associated 
with a protein complex termed the RNA-induced silencing complex (RISC). Small 
RNAs are usually generated from non-coding regions of gene transcripts and 
function to suppress gene expression by translational repression and mRNA 
destabilization (Ambros, 2004; Bartel, 2004; Guo et al, 2010; Kim et al, 2009a; 
Rana, 2007). Individual microRNAs target a relatively limited set of genes, 
suggesting they could be used as tools to modulate expression of distinct 
subsets of genes and determine their involvement in the molecular mechanism of 
reprogramming. Recent work indicates that ES-specific microRNAs can enhance 
iPSC induction(Judson et al, 2009) and, specifically, that the hES miR-302 can 
antagonize the senescence response induced by four-factor expression in 
human fibroblasts (Banito et al, 2009). In addition, our recent findings suggest 
that the microRNA biogenesis machinery may be required for efficient 
reprogramming (Li et al, 2011), and microRNAs induced by OSKM are known to 
regulate several key pathways affecting reprogramming efficiency, including cell 
cycle control, the p53 pathway, TGFβ signaling, and MET (Choi et al, 2011; Li et 
al, 2011; Liao et al, 2011; Subramanyam et al, 2011; Yang et al, 2011). 
Importantly, expression of microRNAs alone can fully reprogram fibroblasts to 
iPSCs (Anokye-Danso et al, 2011; Miyoshi et al, 2011). These findings clearly 
suggest that microRNAs play crucial roles during the reprogramming process by 
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targeting key barrier signaling networks. However, most studies to date have 
focused on intracellular signaling networks regulated by microRNAs, and the 
ability of microRNAs to influence critical cellular interactions with the 
microenvironmental niche during reprogramming has not yet been investigated.   
     Here, we performed a systematic analysis of expression of microRNAs 
and their potential target genes at an early stage of reprogramming, and 
identified a novel link between ECM formation and reprogramming of MEFs. In 
particular, we found that microRNA-135b is induced to a very high level and 
modulating its expression significantly affected the reprogramming process. 
Using genome-wide mRNA array analysis, we show that miR-135b controls 
expression of Tgfbr2, Igfbp5, and Wisp1, the latter two genes encoding 
components of the MEF ECM. Wisp1 was found to regulate the secretion of 
several ECM proteins including TGFBI (TGF-beta induced), IGFBP5 (insulin-like 
growth factor binding proteins-5), NOV (nephroblastoma overexpressed gene), 
and DKK2 (dickkopf homolog 2) proteins. Interestingly, the effects of Wisp 1 are 
mediated through biglycan, a glycoprotein that is highly expressed in MEFs and 
is incompletely silenced in reprogramming cells. Notably, knockdown or 
overexpression of biglycan enhanced or suppressed MEF reprogramming, 
respectively. Collectively, our results have identified a novel role for microRNA-
mediated regulation of ECM formation in iPSC generation, and further, 
demonstrate that microRNAs can be powerful tools to dissect and understand the 
molecular mechanisms of somatic reprogramming.  
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3.3. Results 
3.3.1. Systematic identification of highly regulated microRNAs during the 
early stages of reprogramming  
We hypothesized that at different reprogramming stages, potential iPSCs may 
express unique ‗marker signatures‘ of microRNAs that regulate how the cells 
reach a fully reprogrammed stage. Previous findings indicate that reprogramming 
of MEFs is accompanied by sequential modulation of somatic cell and stem cell 
markers at different reprogramming stages (Brambrink et al, 2008; Stadtfeld et al, 
2008), which can be used to track the process. These markers include the cell 
surface antigen Thy1, the mES markers alkaline phosphatase (AP) and SSEA1, 
and the self-renewal genes Nanog and Oct4. Thy1 is highly expressed in MEFs 
but its expression is repressed at the initiation of reprogramming. Conversely, AP 
and SSEA1 expression is upregulated, followed by upregulation of Nanog and 
endogenous Oct4. Thus, MEFs expressing GFP under control of Oct4 are often 
used as the starting somatic cells because GFP expression then identifies cells 
that have been fully reprogrammed to the iPSC stage. To identify key microRNAs 
in reprogramming, we focused on the early reprogramming stage in the first 5 
days after transduction of MEFs with the four factors (4F; OSKM). To determine 
whether the fate of 4F-transduced cells is set at that stage, Oct4-GFP MEFs 
were infected with 4F virus and then harvested five days later for cell sorting 
(Figure 3.1.A). PE-conjugated Thy1 antibody was used to isolate pure Thy1+ and 
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Figure 3.1. Identification of highly regulated microRNAs during the early 
reprogramming stage 
(A) Scheme of experimental design. MEFs were infected with 4F virus for 5 days, 
and sorted based on expression of the Thy1 surface antigen. Both Thy1- and 
Thy1+ cells were collected for microRNA expression profile analysis. (B) 
Representative gating for day 5 4F-infected MEF sorting. PE-conjugated Thy1 
antibody was used to detect Thy1- and Thy1+ populations. (C) iPSCs were 
enriched in the Thy1- population of 4F-infected MEFs at day 5. Equal numbers of 
cells (10,000 cells) sorted from 4F-infected MEFs were replated into feeder 
plates and cultured for 14 days, then GFP+ colonies were counted. (D) AP 
staining confirmed that iPSCs generated in (C) were enriched in the Thy1- 
population. Cells were harvested for AP staining at day 14 post-infection. (E) 
Representative image of AP+ colonies from replated Thy1- and Thy1+ cells. (F) 
Induced or repressed microRNAs were identified in Thy1- cells. Both Thy1- and 
Thy1+ cells were harvested for microRNA expression profiling. Data from the 
Thy1– population was compared with the original MEFs and microRNAs showing 
a 2-fold change and p<0.05 were identified using a volcano map. Hits are labeled 
as red dots. (G) Set of significantly induced microRNAs. MicroRNAs induced by 
at least 2-fold are shown. (H) Set of significantly repressed microRNAs. 
MicroRNAs repressed by at least 2-fold are shown. 
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Figure 3.1. Identification of highly regulated microRNAs during the early 
reprogramming stage 
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Thy1- populations, with gates set to exclude cells expressing intermediate Thy1 
levels (Figure 3.1.B). Equal numbers (10,000 cells) of Thy1+ and Thy1- cells 
were reseeded in 12-well plates on CF1-MEF feeders and their potential for iPSC 
induction was evaluated based on GFP and marker expression. Potential iPSCs 
were enriched mainly in the Thy1- population, as determined by counting of 
colonies expressing GFP or AP (Figure 3.1.C, D). We detected no GFP+ colonies 
and only a few AP+ colonies in the Thy1+ population at day14 post 4F infection 
(Figure 3.1.C, E). These results suggest that the fate of 4F-infected MEFs is 
determined before day 5 post-infection and that potential iPSCs are enriched in 
the Thy1- population. We therefore collected total RNA from sorted Thy1- cells at 
day 5 post-transduction to analyze overall microRNA expression changes by 
microarray. To identify microRNAs whose expression is significantly altered 
relative to that seen in starting MEFs, we filtered the data by setting a gate of at 
least a 2-fold change in expression with p<0.05 (Figure 3.1.F). We identified a set 
of microRNAs in the Thy1- – population that were significantly induced by 4F 
transduction (Figure 3.1.G). Among them, miR-135b was the most highly induced 
and showed a statistically significant change in expression (Table 3.2.), and was 
thus selected for further analysis of its role, and that of its direct gene targets, in 
the reprogramming process. We observed that other microRNAs, such as miR-
93 which belongs to miR-25~106b cluster, miR-92a which belongs to miR-17~92 
cluster, and miR-302b which belongs miR-302 cluster, were also highly induced 
at the early stage of reprogramming, confirming previous findings(Li et al, 2011; 
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Liao et al, 2011; Subramanyam et al, 2011). Our analysis also revealed a set of 
microRNAs that were significantly repressed (Figure 3.1.H), suggesting that they 
may serve as reprogramming barriers. Of these, we chose to evaluate the 
potential barrier function of miR-223 and miR-495, because they are highly 
expressed in MEFs. 
3.3.2. Reprogramming is enhanced by miR-135b and inhibited by miR-223 
and miR-495  
To determine how miR-135b affects reprogramming, miR-135b microRNA mimic 
was transfected into Oct4-GFP MEFs infected with 4F virus, and GFP+ colonies 
were counted at day 11–12 post-transduction. Transfection of the miR-135b 
mimic increased the number of Oct4-GFP+ colonies by ~ 2-fold, as did 
transfection with miR-93, which was previously characterized as an enhancer of 
reprogramming (Anokye-Danso et al, 2011) (Figure 3.2.A). In similar experiments, 
cells were transfected with miR-223 or miR-495 mimics, which had minor 
inhibitory effects on reprogramming (Figure 3.2.A). This observation is potentially 
due to the saturation effect of endogenous miRs as these miRs already have 
high expression in MEFs. We then analyzed the percentage of GFP+ cells in the 
miR-transfected reprogrammed cells and found that although both miR-93 and 
miR-135b increased GFP+ colony formation, only miR-135b increased the overall 
percentage of GFP+ cells by ~2 fold (Figure 3.2.B, Figure 3.S1.). In the same 
assay, miR-223 transfection significantly decreased the GFP+ population (Figure  
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Figure 3.2. miR-135b enhances reprogramming of MEFs to iPSCs 
(A) miR-135b enhances Oct4-GFP+ colony formation. The indicated microRNA 
mimics were transfected at a final concentration of 50 nM into MEFs on day 0 
and again on day 5 after 4F transduction. GFP+ colonies were counted at 
day 11-12. Data represents two independent experiments with triplicate wells. 
Let-7a was used as a control. *p<0.05. (B) miR-135b increases the percentage of 
Oct4-GFP+ cells. Cells from the indicated treatments were harvested at day 14 
post-infection with 4F and paraformaldehyde-fixed prior to FACS analysis to 
determine the percentage of GFP+ cells. Data represents two independent 
experiments with triplicate wells. *p<0.05. (C) Blocking of miR-135b compromises 
reprogramming. MicroRNA inhibitors were transfected into MEFs on days 0 and 
5 post-infection with 4F. GFP+ colonies were counted at day 11-12 post-infection. 
Data represents two independent experiments with triplicate wells. *p<0.05. (D) 
miR-135b iPSCs reach a fully reprogrammed state. miR-135b–transfected iPSCs 
were fixed with paraformaldehyde and stained for alkaline phosphatase, Nanog, 
and SSEA1 expression. Endogenous Oct4 expression was monitored by GFP 
expression. (E) Teratoma formation confirms the pluripotency of miR-135b iPSCs. 
1x106 iPSCs were injected into athymic nude mice and tumors were harvested 
for H&E staining 3–4 weeks later. (F) miR-135b iPSCs show expression profiles 
similar to mES cells. Total RNA from miR-135b iPSCs was used for mRNA 
expression profile analysis and compared with original MEFs and with mES cells. 
The three tested miR-135b iPSC clones (clones 1, 3, and N1) showed similar 
expression patterns to mES cells, which were quite different from the expression 
profile of the original starting MEFs. (G) Chimeric mouse from miR-135b iPSC 
clone 4. (H) miR-135b iPSC could contribute to the germline of recipient embryos 
(miR-135b iPSC clone 4) 
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Figure 3.2. miR-135b enhances reprogramming of MEFs to iPSCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
 
3.2.B), supporting the possibility that it serves as a reprogramming barrier. To 
confirm our findings, we used microRNA inhibitors. As expected, blocking miR-
135b compromised reprogramming efficiency, while inhibiting miR-223 resulted 
in a significant increase in the number of Oct4-GFP+ colonies (Figure 3.2.C). 
Overall, these data demonstrate that miR-135b enhances reprogramming, 
consistent with its high induction by the 4F factors, while miR-223, which our 
analysis showed to be the most highly repressed microRNA, serves as a barrier.  
     Because GFP expression by putative iPSC could result from inappropriate 
reactivation of the Oct4 locus, we asked whether miR-135b–transfected iPSCs 
reached a fully reprogrammed state, both phenotypically and functionally. 
Analysis of miR-135b–transfected iPSCs indicated that they expressed 
appropriate markers, including AP, SSEA1, Nanog, and endogenous Oct4 
(Figure 3.2.D). Moreover, these cells had the full capacity to differentiate into 
three germ layers as indicated by marker analysis (Figure 3.S2.), and to form 
heterogeneous teratomas when injected into athymic nude mice (Figure 3.2.E). 
Genome-wide mRNA profiling also confirmed that gene expression in miR-135b–
transfected iPSCs resembled mES cells and differed significantly from MEFs 
(Figure 3.2.F), and these cells contributed to chimeric mice and showed germline 
transmission (Figure 3.2.G, H) which clearly indicated that a fully reprogrammed 
state has been achieved in these cells. These data demonstrated that miR-135b 
transfection in iPSCs did not adversely affect their pluripotency. 
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3.3.3. Identification of miR-135b–regulated genes 
We next sought to identify genes that are directly regulated by miR-135b. Initially, 
microRNAs were thought to simply repress mRNA translation. However, recent 
findings suggest that microRNA-mediated destabilization of mRNA is a major 
mechanism of repression(Guo et al, 2010). Thus, we performed a genome-wide 
mRNA expression analysis to detect potential miR-135b targets. miR-135b or 
control siRNA were transfected into Oct4-GFP MEFs, and total RNAs were 
harvested 48 hr later for array analysis. The raw data was filtered to detect at 
least 2-fold changes in gene expression, (either increased or decreased) with 
p<0.05 (Figure 3.3.A). Candidate genes were then compared with published 
mESC, iPSC, and MEF expression profiles (Sridharan et al, 2009) and 
segregated into genes induced (group 1) or repressed (group 2) after miR-135b 
transfection, the latter being considered more likely to contain direct targets. 
Notably, we found that over 80% of the genes repressed by miR-135b 
transfection (group 2) were genes that are silenced as MEFs are reprogrammed 
to iPS/mES cells (correlated) (Figure 3.3.B). This was not observed in genes that 
were induced by miR-135b transfection (group 1), of which approximately half 
are normally suppressed during reprogramming (uncorrelated), and the other half 
are increased (correlated). This data suggests that miR-135b targets a subset of 
genes that are normally repressed during reprogramming.  
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Figure 3.3. Genome-wide identification of potential miR-135b target genes 
(A) Volcano maps from miR-135b–transfected MEFs. MEFs were transfected 
with siControl and miR-135b for two days and analyzed by mRNA expression 
array. Hits (red dots) were gated for at least 2-fold expression change and 
p<0.05. (B) miR-135b–repressed genes are enriched for genes suppressed in 
ES/iPS cells. miR-135b–regulated genes were separated into two groups 
(induced or repressed) and then compared with existing iPS/ES/MEF expression 
profiles. ―Correlated genes‖ indicates that genes changed upon miR-135b 
transfection showed similar changes from MEFs to iPS/mES cells. ―Uncorrelated 
genes‖ indicates a group of genes that were changed upon miR-135b 
transfection but had a different (reversed) change in expression pattern from 
MEFs to iPS/mES cells. (C) List of correlated miR-135b–repressed genes. (D) 
Representative miR-135b–regulated genes from microarray. (E) Expression of 
miR-135b–regulated genes was confirmed by RT-qPCR. MEFs were transfected 
with microRNA mimics for two days before harvesting for RT-qPCR analysis. 
Error bar represents two independent experiments with duplicate samples. (F) 
TGFBR2 protein expression is suppressed by miR-93 and miR-135b. Total 
proteins were harvested for western blotting analysis at day 2 post-transfection 
with miR mimic. (G) IGFBP5 protein expression is suppressed by miR-135b. A 
miR-93-transfected sample was included as a negative control.  
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Figure 3.3. Genome-wide identification of potential miR-135b target genes. 
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     To identify the targets of miR-135b, the ―correlated‖ genes in group 1 
(Figure 3.3.C) were analyzed using both miRanda (Enright et al, 2003) and 
Targetscan (Lewis et al, 2005). Potential target sites were identified based on 
seed region matches and overall predicted binding energy. Of 27 genes 
repressed by miR-135b by at least 2-fold, 14 contained at least one predicted 
miR-135b target site (Figure 3.S3.A and Table 3.1). Among them, Wisp1, Tgfbr2, 
and Igfbp5 showed high expression intensity detected by microarray and 
appeared to have direct miR-135b target sites. Therefore, they were chosen for 
further validation. 
    To confirm our mRNA microarray analysis, total RNAs were harvested 
from miR-135b–transfected Oct4-GFP MEFs in an independent experiment, and 
RT-qPCR was used to quantify the representative mRNAs. Indeed, we detected 
decreases in mRNA levels upon miR-135b transfection that were in good 
agreement with the mRNA array data (Figure 3.3.D, E). Tgfbr2 and Igfbp5 mRNA 
levels were decreased ~70% upon miR-135b transfection, and western analysis 
confirmed that this was accompanied by a dramatic decrease in Tgfbr2 and 
Igfbp5 protein expression (Figure 3.3.F, G). Although expression of Wisp1 mRNA 
was also markedly reduced by miR-315b expression (Figure 3.3.D, E), no Wisp1 
antibodies are currently available, which prevented us from analyzing Wisp1 
protein expression. We cloned the 3‘UTR of these potential targets into the pGL3 
luciferase reporter vector and co-transfected the reporters plus the pRL-TK 
plasmid into HeLa cells. Indeed, miR-135b decreased luciferase activity of Tgfbr2 
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and Wisp1 reporters by ~80%, and the Igfbp5 reporter by ~30% (Figure 3.S3.B). 
These data strongly suggest that Tgfbr2, Wisp1, and Igfbp5 are direct targets of 
miR-135b, of which the latter two are key component of extracellular matrix 
proteins.  
3.3.4. Wisp1 has dual roles during reprogramming and is a key regulator of 
ECM proteins 
We next asked whether the potential miR-135b targets Tgfbr2, Wisp1, and Igfbp5 
function as reprogramming barriers. Tgfbr2 was previously reported to be a 
reprogramming barrier and a potential target of miR-93 and its family of 
microRNAs (Li et al, 2011). In addition to Tgfbr2, Wisp1, and Igfbp5, we chose to 
investigate several other genes that might be indirectly regulated by miR-135b, 
such as Eif4ebp1 and Cxcl14 as they do not have predicted miR-135b target 
sites. Before using siRNAs for these experiments, we confirmed by RT-qPCR 
that each mRNA was efficiently knocked down by at least 60% by its cognate 
siRNA (Figure 3.4.A).  
To determine whether knock-down of the candidate barrier genes 
increased reprogramming efficiency, we transfected siRNAs into Oct4-MEFs on 
the same day as 4F transduction (day 0), then again on day 5 post-infection, and 
counted GFP+ iPSC colonies on day 11–12. We detected a significant increase in 
the number of GFP+ colonies after transfection of siRNA targeting Igfbp5 and  
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Figure 3.4. Wisp1 plays a dual role during reprogramming, while Tgfbr2 and 
Igfbp5 knockdown enhances reprogramming 
(A) Potential target genes are efficiently knocked down by siRNAs. Smartpool 
siRNAs at a final concentration of 50 nM were used to transfect MEFs. Total 
RNAs were harvested at day 2 for RT-qPCR to evaluate knockdown efficiency of 
each siRNA. (B) Knockdown of Tgfbr2 or Igfbp5 enhances Oct4-GFP+ colony 
formation, while knockdown of Eif4ebp1 and Cxcl14 had no effect. MEFs were 
transfected with siRNAs on days 0 and 5 at the same time as 4F infection. GFP+ 
colonies were counted at day 11-12 post-infection. Error bars represent three 
independent experiments with triplicate wells. The p value was calculated using 
Student‘s t-test. **p<0.01. (C) Knockdown of Wisp1 shows stage-specific effects 
on reprogramming. Knockdown of Wisp1 on the same days as 4F transduction 
(day 0) decreased the reprogramming efficiency by ~70% percent, while 
knockdown on day 5 enhanced reprogramming by ~3 fold. Error bars represent 
three independent experiments with triplicate wells. **p<0.01. (D) Wisp1 is 
efficiently knocked down by siRNAs during both procedures. siWisp1 was 
transfected at a final concentration of 50 nM on day 0 or day 5. Total RNAs were 
harvested at day 2 post-transfection for RT-qPCR analysis of Wisp1 expression. 
(E) Knockdown of Wisp1 at day 0 inhibits mesenchymal-to-epithelial transition 
(MET). MEFs were infected with 4F and transfected with siRNA on the same day 
(day 0). Total RNAs were harvested 2 days later. Expression of several MET 
markers was evaluated. (F) Knockdown of Wisp1 at day 5 does not affect MET. 
MEFs were transduced with 4F at day 0 and transfected with siRNA at day 5 
post-4F infection. Total RNAs were harvested 2 days after transfection and 
expression of the MET markers was evaluated.  
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Figure 3.4. Wisp1 plays a dual role during reprogramming, while Tgfbr2 and 
Igfbp5 knockdown enhances reprogramming 
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Tgfbr2, consistent with their possible function as barrier genes (Figure 3.4.B). 
Interestingly, a dramatic decrease in reprogramming efficiency was observed in 
cells transfected with siWisp1 on days 0 and 5 post-4F infection. However, if 
siWisp1 was transfected on day 5 only, there was a 3-fold increase in the number 
of GFP+ colonies (Figure 3.4.C), suggesting that Wisp1 can play temporally 
distinct roles during reprogramming. This effect was not due to a difference in 
siRNA transfection efficiency, because Wisp1 mRNA knockdown was equivalent 
under both protocols (Figure 3.4.D). To probe this observation further, we next 
analyzed the effect of Wisp1 siRNA transfection on markers of MET, which is 
believed to be the initial step of the reprogramming process (Li et al, 2010; 
Samavarchi-Tehrani et al, 2010). Remarkably, knockdown of Wisp1 on day 0 
dramatically decreased mRNA expression of each of the MET markers tested, 
suggesting a significant delay or suppression of MET by siWisp1 (Figure 3.4.E). 
In contrast, Wisp1 knockdown on day 5 had little effect on MET marker mRNA 
levels, except a small and insignificant decrease in Epcam expression (Figure 
3.4.F). Thus, these data suggest that Wisp1 may play dual roles during 
reprogramming.  
     To probe the mechanism by which Wisp1 affects reprogramming, we next 
investigated the downstream targets of Wisp1. Wisp1 is a member of CCN family 
proteins, the function of which usually includes two aspects: (1) binding of 
scaffold of extracellular matrix proteins; (2) binding receptors and transcriptionally 
regulating signaling events mediated by biological active molecules such as 
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growth factors and cytokines(Jun & Lau, 2011). We reasoned that since somatic 
reprogramming is an in vitro process, it is more likely that Wisp1 functions 
through transcriptional regulation of downstream genes. To identify the 
downstream targets of Wisp1, we utilized mRNA microarrays to search for genes 
significantly changed upon Wisp1 knockdown in control, non-infected and 4F-
transduced MEFs (Table 3.4). The microarray experiments identified a panel of 
ECM genes, including Dkk2, Igfbp5, Nov, and Tgfbi, that showed profoundly 
decreased expression upon Wisp1 knockdown, which was confirmed by RT-
qPCR (Figure 3.5.A). Moreover, expression of Dkk2, Igfbp5, Nov, and Tgfbi was 
suppressed by 4F transduction. In addition, Wisp1 knockdown increased 
expression of Ccl20 (Figure 3.5.A), which was also induced in MEFs by 4F 
transduction alone. To rule out the possibility of off-target effects of the Wisp1 
siRNA, two additional shRNAs were tested. These shRNAs efficiently 
suppressed Wisp1 expression, and had the same inhibitory effects on expression 
of Wisp1 target genes. (Figure 3.S4.). To confirm that the miR-135b effects on 
MEFs was at least partially mediated through Wisp1, we transfected MEFs with 
an miR-135b mimic, and found decreased expression of Dkk2, Igfbp5, Nov, and 
Tgfbi (Figure 3.S5.). Thus, Wisp1 may serve as a key regulator of ECM genes in 
MEFs. 
To determine if expression of Wisp1-regulated ECM genes could affect 
reprogramming, Oct4-GFP MEFs were infected with 4F and on day 5 were 
transfected with siRNAs targeting Dkk2, Igfbp5, Nov, and Tgfbi. Indeed,  
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Figure 3.5. Wisp1 is a key regulator of extracellular matrix genes 
(A) Wisp1 regulates expression of several ECM genes. Expression of Tgfbi, 
Igfbp5, Dkk2 , Nov, and Ccl20 were dramatically changed upon Wisp1 
knockdown. Uninfected and 4F-infected MEFs were transfected with siWisp1 for 
2 days and total RNAs were harvested for RT-qPCR analysis of different ECM 
genes. Error bars represent two independent experiments with duplicate wells. (B) 
Knockdown of Nov, Dkk2, and Tgfbi significantly enhances iPSC generation. 
MEFs were transduced with 4F at day 0 and transfected with siRNAs at day 5 
post-infection. GFP+ colonies were quantified at around day 11-13. Error bars 
represent three independent experiments with triplicate wells. **p<0.01. (C) 
Overexpression of Wisp1-regulated ECM genes compromises reprogramming. 
The indicated ECM genes were cloned into pMX retroviral vectors. MEFs were 
transduced with 4F plus the indicated ECM genes and GFP+ colonies were 
quantified at around day 11-13. Data was normalized to pMX-RFP–transduced 
cells. Error bars represent three independent experiments with triplicate wells. 
**p<0.01. (D) Addition of recombinant ECM proteins compromises 
reprogramming. Purified recombinant TGFBI, DKK2, NOV, and CCL20 were 
added at a final concentration of 100 ng/ml to cultures of 4F-MEFs undergoing 
reprogramming. GFP+ colonies were quantified at day 11-13. Error bars 
represent two independent experiments with triplicate wells. *p<0.05.  
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knockdown of each of these genes significantly increased reprogramming 
efficiency (Figure 3.4.B, Figure 3.5.B). We also detected an increase in mES 
marker gene expression in the siRNA-transfected cells (Figure 3.S6.). 
Conversely, overexpression of these genes in MEFs strongly reduced GFP+ 
colony formation, particularly with Igfbp5, which reduced reprogramming by ~70% 
(Figure 3.5.C). Interestingly, addition of recombinant DKK2, TGFBI, and NOV 
proteins to the 4F-transfected MEF cultures from day5 post infection had similar 
effects on the cells as overexpression of the genes (Figure 3.5.D), demonstrating 
that the effects of Wisp1 were mediated by secretion of the protein products of its 
target genes, and confirming that the Wisp1-regulated ECM genes do indeed act 
as barriers to the reprogramming process.  
Based on the results described above, we propose a model of how Wisp1 
may display dual roles in MEF reprogramming (Figure 3.6.A). Wisp1 is highly and 
specifically expressed in MEFs compared with iPSCs (Sridharan et al, 2009), and 
through its effects on the downstream ECM genes, plays a crucial role in 
maintaining normal MEF growth. This is supported by our finding that persistent 
knockdown of Wisp1 in MEFs compromises their proliferation (Figure 3.S7.). 
Upon 4F transduction and reprogramming, infected MEFs would have two 
regulatory networks, one established by the four reprogramming factors, and the 
other being endogenous. The ability of a cell to become fully reprogrammed 
would depend on whether the 4F-induced network could silence the existing MEF 
regulatory network. In these cells, although MEF-specific genes such as Wisp1  
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Figure 3.6. Target gene regulation by Wisp1 through biglycan 
(A) Proposed model for Wisp1 dual role during reprogramming. In wild type 
MEFs (fibroblast state), normal proliferation and function of the cells are 
dependent on a MEF-specific regulation network, where Wisp1 is one of the most 
important ECM components and regulates the expression of several other ECM 
genes. In 4F-transduced MEFs (intermediate state), two systems co-exist; one 
from the MEF-specific network and the other from the four transcription factors. 
ECM signals from the MEF-specific network interfere with the cells becoming 
fully reprogrammed. In fully reprogrammed cells (ES cell state), ECM receptors 
are no longer expressed, and the cells are thus resistant to interfering signals 
from surrounding MEFs. (B) Biglycan and decorin are specifically expressed in 
MEFs. Expression of biglycan and decorin was analyzed by RT-qPCR in sorted 
cells. (C) Biglycan and decorin are efficiently knocked down by siRNAs. MEFs 
were transfected with siRNAs for 2 days and total RNAs were harvested for RT-
qPCR analysis. (D) Knockdown of biglycan decreases expression of Wisp1-
regulated ECM genes. Expression of Wisp1-regulated ECM genes was analyzed 
in MEFs subjected to knockdown of biglycan or decorin. Error bars represent two 
independent experiments with duplicate wells. **p<0.01. (E) Overexpression of 
biglycan inhibits reprogramming. Flag-tagged biglycan was cloned into pMX 
vector and transduced into MEFs together with 4F. GFP+ colonies were 
quantified at day 11-13. Error bar represents two independent experiments with 
triplicate wells. *p<0.05. (F) Knockdown of biglycan enhances reprogramming. 
Biglycan siRNAs were transfected into MEFs at day 5 post-4F transduction. 
GFP+ colonies were quantified at day 11-13. Error bar represents two 
independent experiments with triplicate wells. *p<0.05.  
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Figure 3.6. Target gene regulation by Wisp1 through biglycan 
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and its potential receptors are being down-regulated, the remaining receptors 
could still be stimulated by signals secreted by surrounding unreprogrammed 
cells. This constant stimulation of original MEF network would compete with 4F-
mediated ES regulatory network and resulted in a low efficiency for cells to 
become fully reprogrammed. Thus, knocking down Wisp1 in these cells could 
reduce the MEF signaling stimulation, significantly break the balance and push 
them toward fully reprogrammed state. Once the cells become mES-like cells, 
MEF ECM genes and receptors are completely shut down and they become 
resistant to the signals from nearby feeder cells.  
3.3.5. Wisp1 may regulate ECM genes through biglycan 
To test our model (Figure 3.6.A), we searched the literature for known factors 
that could interact with Wisp1. If our model is correct, we predict we will see high 
expression of these genes in the starting population of MEFs, whereas cells 
undergoing reprogramming will downregulate but not extinguish their expression, 
and expression will be silenced in fully reprogrammed iPSCs/mES cells. 
Interestingly, Wisp1 has been reported to bind the proteoglycans decorin and 
biglycan on the surface of human skin fibroblasts(Desnoyers et al, 2001) and 
both are highly expressed in MEFs(Sridharan et al, 2009). To determine if 
decorin and biglycan might be involved in Wisp1 regulation in MEFs, we first 
examined their gene expression in the starting MEFs, the sorted Thy1+/– cells, 
and in mES populations. The two genes were highly expressed in MEFs but 
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undetectable in mES cells (Figure 3.6.B). They were highly expressed in Thy1+ 
cells and showed strongly reduced but detectable expression in Thy1- cells 
(Figure 3.6.B), which are enriched in potential iPSCs (Figure 3.1.C-E). We then 
transfected MEFs with siRNAs targeting these two genes and confirmed the 
knock-down efficiency by RT-qPCR (Figure 3.6.C). Of interest, knockdown of 
biglycan also decreased decorin expression, suggesting possible cross 
regulation of the two genes. Knockdown of biglycan also decreased the 
expression of the Wisp1 target genes Dkk2, Igfbp5, Nov, and Tgfbi, to a similar 
level to that seen with Wisp1 knockdown (Figure 3.6.D). Consistent with these 
observations, overexpression of biglycan strongly suppressed reprogramming, 
and conversely, knockdown significantly enhanced reprogramming (Figure 3.6.E, 
F). Therefore, we conclude that biglycan may be an intermediate for Wisp1-
mediated regulation of its target ECM genes.  
3.4. Discussion 
Since the discovery that MEFS can be directly reprogrammed to iPSCs, 
considerable effort has been made to understand how the four reprogramming 
transcription factors extinguish endogenous MEF gene expression and gradually 
re-establish mES-like regulatory networks. Because the process is extremely 
inefficient, understanding the critical barriers to reprogramming is essential to 
allow development of novel technologies and compounds to improve the 
efficiency. Here, we show that microRNAs can be used as a powerful tool to 
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dissect the molecular mechanisms that elicit successful reprogramming. We 
analyzed a Thy1– cell population enriched in potential iPSCs to identify its 
microRNA expression profile during the early stages of reprogramming. From 
these experiments, we identified sets of microRNAs that were induced or 
repressed during the process, and showed that manipulating their expression 
with miR mimics or inhibitors dramatically altered the efficiency of iPSC induction. 
Among the microRNAs analyzed, miR-135b was the most highly induced by the 
four factors, and was shown to enhance iPSC generation. Moreover, by mining 
genome-wide mRNA expression data for potential miR-315b target genes, we 
showed that Wisp1 and its downstream ECM genes could compromise the 
efficiency of the reprogramming process. Therefore, our approach has not only 
identified a novel ECM network that is involved in modulating the reprogramming 
process, but we have also shown that using microRNAs as probes could be an 
efficient method to study the molecular mechanisms of reprogramming. 
     Wisp1 was first described as a Wnt1-inducible protein (Pennica et al, 
1998). It belongs to the CCN gene family that encodes six 30–40 KDa secreted 
proteins (Berschneider & Konigshoff, 2011; Chen & Lau, 2009). CCN proteins 
have four conserved structural domains with sequences homologous to insulin-
like growth factor binding proteins (IGFBPs), von Willebrand factor type C repeat 
(VWC), thrombospondin type I repeat (TSP), and carboxyl-terminal (CT) domain 
(See the marked sentence). These domains determine the function of CCN 
member proteins during development and in human diseases. Although Wisp1 
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has been linked to oncogenic transformation (Pennica et al, 1998; Xu et al, 2000), 
proliferation and cell survival (Venkatachalam et al, 2009; Venkatesan et al, 
2010), and epithelial-to-mesenchymal transition (Konigshoff et al, 2009), little is 
known about its downstream genes or how it regulates their expression. In this 
study, we identified several ECM components that were regulated by Wisp1, 
likely through its interaction with biglycan. These include Tgfbi, Dkk2, Igfbp5, and 
Nov. These findings provide some new insights into Wisp1 function. For example, 
TGFBI is a known downstream gene induced by TGFβ signaling and has 
profound tumor suppressive effects (Ahmed et al, 2007; Zhang et al, 2009). The 
TGFβ signaling pathway has itself been identified as a barrier for somatic 
reprogramming (Ichida et al, 2009; Maherali & Hochedlinger, 2009). Our finding 
thus indicates there may be crosstalk between Wisp1 and TGFβ signaling in 
regulating expression of the ECM protein TGFBI. Knockdown of Wisp1 
decreases Tgfbi expression, which might compromise TGFβ signaling and allow 
cells to become fully reprogrammed. Two other Wisp1 target genes we identified 
are DKK2 and IGFBP5. DKK2 is known as a Wnt signaling antagonist (Kawano & 
Kypta, 2003) and IGFBP5 could regulate IGF signaling by binding to IGF-1/2 
(Beattie et al, 2006). We found that knockdown of Wisp1 decreased expression 
of Dkk2 and Igfbp5, which would derepress Wnt and IGF signaling. Consistent 
with this, previous studies have indicated that Wnt signaling could promote 
somatic reprogramming (Marson et al, 2008). It was recently shown that IGFBP5 
overexpression induces cell senescence in a p53-dependent manner (Kim et al, 
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2007). This protein is highly expressed in fibroblasts, and its expression is further 
increased upon senescence (Yoon et al, 2004). Thus, decreased expression of 
IGFBP5 and DKK2 is likely to be beneficial to iPSC generation.  
     Over the past few years much progress has been made in understanding 
the molecular mechanisms of somatic reprogramming and several important 
barrier pathways have been discovered. However, these efforts have mainly 
focused on intracellular signaling networks, and the effect of the extracellular 
environment on reprogramming has not been fully explored. Interestingly, recent 
work has indicated that more than 92% of the monoclonal pre-B cells could reach 
a fully reprogrammed state when cultured as monoclonal for extended 
periods(Hanna et al, 2009), which could be only less than 0.1% with mixed 
starting population and total number of iPSC colonies usually reached plateau at 
later time points post 4F(Sridharan et al, 2009). This clearly suggests that 
secreted ECM components could affect the ability of neighboring cells to become 
fully reprogrammed. In our study, biglycan, a surface glycoprotein that binds 
Wisp1, is expressed in MEFs but decreases in reprogramming cells, as shown in 
Thy1- cells that are enriched with potential iPSCs. These cells will still be 
stimulated by Wisp1 and presumably other ECM proteins secreted by 
surrounding feeder MEF cells or unreprogrammed cells, as they still express the 
receptors such as biglycan, although at much lower level compared with original 
MEFs. These stimulations would prevent the cells from shutting down MEF-
specific regulation network and compete with four factors-mediated regulatory 
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network to determine the fate of target cells. Meanwhile, our discovery that 
microRNAs induced by the four factors can regulate ECM genes reveals some 
new insights into how the four factors manage to reprogram a small percentage 
of cells. Down-regulation of MEF-specific ECM proteins seems to be part of the 
entire reprogramming process and is mediated at least in part by 4F-mediated 
induction of microRNAs such as miR-135b. Together with previous findings, it is 
clear that microRNAs are important regulators of reprogramming, both through 
intracellular and extracellular mechanisms (Figure 3.7.).  
     In summary, we have identified a novel microRNA-mediated pathway of 
ECM gene regulation that is involved in iPSC generation. Our results indicate 
that 4F-induced miR-135b expression in turn regulates expression of Wisp1 and 
Igfbp5. Wisp1 is a key regulator of several ECM proteins, which may be 
mediated through Wisp1 interaction with biglycan. Our findings not only identify a 
novel role for ECM components in somatic reprogramming, but also demonstrate 
that microRNAs can be powerful tools to dissect the molecular mechanisms of 
iPSC generation.  
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Figure 3.7. Model for roles of microRNAs during the reprogramming 
process 
MicroRNAs induced by the four factors could have both intracellular and 
extracellular roles. Intracellularly, some microRNAs may target signaling 
pathways that are barriers for iPSC generation, such as TGFβ signaling, the p53-
p21 pathway, and cell cycle control. Meanwhile, some microRNAs may regulate 
expression of ECM genes to establish a growth environment that promotes the 
fully reprogrammed state. Both groups of microRNAs work collaboratively to help 
4F to reprogram MEFs to iPSCs.  
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Materials and Methods 
 
Cell culture, vectors, and virus transduction 
Oct4-GFP MEFs were derived from mouse embryos harboring an IRES-EGFP 
fusion cassette downstream of the stop codon of pou5f1 (Jackson lab, 
Stock#008214) at E13.5. MEFs were cultured in DMEM (Invitrogen, 11995-065) 
with 10% FBS (Invitrogen) plus glutamine and nonessential amino acids (NEAA). 
Only MEFs at passage 0 to 4 were used for iPSC induction. pMXs-Oct4, Sox2, 
Klf4, and cMyc were purchased from Addgene. Tgfbi, Dkk2, Igfbp5, Nov, and 
biglycan overexpression vectors were constructed by inserting cDNA coding 
sequences into the pMX vector. To generate retrovirus, PLAT-E cells were 
seeded in 10 cm plates. The next day, the cells were transfected with 9 μg of 
each vector using Lipofectamine (Invitrogen, 18324-012) and PLUS (Invitrogen, 
11514-015). Viruses were harvested and combined 2 days later. For iPSC 
induction, MEFs were seeded in 12-well plates and the next day were transduced 
with ―four factor‖ (4F) virus with 4 μg/ml Polybrene. One day later, the medium 
was changed to fresh MEF medium, and 3 days later it was changed to mES 
culture medium supplemented with LIF (Millipore, ESG1107). GFP+ colonies 
were picked at day 14 post-transduction, and expanded clones were cultured in 
DMEM with 15% FBS (Hyclone) plus LIF, thioglycerol, glutamine, and NEAA. 
Irradiated CF1 MEFs served as feeder cells to culture mES and derived iPSC 
clones. 
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Recombinant proteins were obtained from commercial sources as follows: mouse 
Dkk2 (R&D systems, 2435DK/CF), human NOV/CCN3 (R&D systems, 1640NV), 
human TGFBI (Prospec, #PRO-568), CCL20 (R&D systems, 760-M3). 
 
MicroRNAs, siRNAs, and MEF transfection 
microRNA mimics and inhibitory siRNAs were purchased from Dharmacon. To 
transfect MEFs, microRNA mimics were diluted in Opti-MEM (Invitrogen, 11058-
021) to the desired final concentration. Lipofectamine 2000 (Invitrogen, 11668-
019) (2 μl/well) was added and the mixture was incubated for 20 min at RT. For 
12-well plate transfections, 80 μl of the miR mixture was added to each well with 
320 μl of Opti-MEM. Three hours later, 0.8 ml of the virus mixture (for iPSC) or 
fresh medium was added to each well, and the medium was changed to fresh 
MEF medium the next day.  
 
Western blotting 
Total cell lysates were prepared using M-PER buffer (PIERCE, 78503), 
incubated on ice for 20 min, and cleared by centrifuging at 13,000 rpm for 10 min. 
Equal amounts of lysate were loaded onto 10% SDS-PAGE gels. Proteins were 
transferred to PVDF membranes (Bio-Rad, 1620177) using the semi-dry system 
(Bio-Rad) and then blocked with 5% milk in Tris-buffered saline–Tween 20 
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(TBST: 50mM Tris, 150mM NaCl, 0.05% Tween20) for at least 1 hr at room temp 
or overnight at 4°C. The following antibodies were used: anti-mNanog (R&D 
Systems, AF2729), anti-h/mSSEA1 (R&D Systems, MAB2156), anti-TGFBR2 
(Cell Signaling, #3713), anti-IGFBP5 (R&D Systems, AF578), anti-actin (Thermo, 
MS1295P0), anti-AFP (Abcam, ab7751), anti-beta III tubulin (R&D Systems, 
MAB1368), and anti-alpha actinin (Sigma, A7811). 
 
mRNA and microRNA RT and quantitative PCR 
Total RNAs were extracted using Trizol (Invitrogen), and then 1 μg total RNA was 
used for RT using Superscript II (Invitrogen). Quantitative PCR was performed 
using a Roche LightCycler480 II and the SYBR Green mixture from Abgene (Ab-
4166). Mouse Ago2, Dicer, Drosha, Gapdh, and p21 primers are defined in 
Supplemental Table 2. Other primers were described previously (Takahashi & 
Yamanaka, 2006). For microRNA quantitative analysis, total RNA was extracted 
using the method described above. Between ~1.5 and 3 μg of total RNA was 
used for microRNA reverse transcription using QuantiMir kit following the 
manufacturer‘s protocol (System BioSciences, RA420A-1). RT products were 
then used for quantitative PCR using the mature microRNA sequence as a 
forward primer and the universal primer provided with the kit.  
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Immunostaining 
Cells were washed twice with PBS and fixed with 4% paraformaldehyde at room 
temperature for 20 min. Fixed cells were permeabilized with 0.1% Triton X-100 
for 5 min, and then blocked in 5% BSA in PBS containing 0.1% Triton X-100 for 
1 hr at room temperature. Primary antibody was diluted at 1:100 to 1:400 in 2.5% 
BSA PBS containing 0.1% Triton X-100, according to the manufacturer‘s protocol. 
Cells were stained with primary antibody for 1 hr and then washed three times 
with PBS. Secondary antibody was diluted 1:400 and cells were stained for 
45 min at room temperature.  
 
Embryoid body formation and differentiation assay 
iPSCs were trypsinized to a single cell suspension, and the hanging drop method 
was used to generate embryoid bodies (EB). For each drop, 4000 iPSCs in 20 μl 
EB differentiation medium were used. EBs were cultured in hanging drops for 3 
days before being reseeded onto gelatin-coated plates. After reseeding, cells 
were cultured until day 14, when apparent beating areas could be identified.  
 
Teratoma formation 
To generate teratomas, iPSCs were trypsinized and resuspended at a 
concentration of 1x107 cells/ml. Athymic nude mice were anesthetized with 
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Avertin, and 150 μl of iPSCs were injected into each mouse. Tumors were 
monitored every week for ~3–4 weeks. Tumors were then harvested and fixed in 
Z-Fix solution for 24 hrs at room temperature, before paraffin embedding, 
sectioning, and H&E staining. To further evaluate pluripotency of derived iPSC 
clones, iPSCs were injected into C57BL/6J-Tyr(C-2J)/J (albino) blastocysts. 
Generally, each blastocyst received 12–18 iPSCs. ICR recipient females were 
used for embryo transfer. 
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Figure 3.S1. miR-135b enhances the overall percentage of Oct4-GFP+ cells 
during reprogramming 
MEFs were transfected with the indicated microRNA mimics 3 hrs before 
infection with 4F, and cells were trypsinized on day 14 for FACS analysis. Single 
cells were collected by filtering through a cell strainer. Non-transduced MEFs 
served as negative controls.  
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Figure 3.S2. miR-135b iPSCs show full differentiation capacity 
Lineage markers are expressed in differentiated EBs from miR-135b–induced 
iPSCs. EBs were formed using the hanging drop method for two days and 
replated onto gelatin-coated plates until day 12-14. Cells were then fixed and 
stained for AFP (endoderm), tubulin III (ectoderm), and α-actin (mesoderm) 
expression. DAPI was used for nuclear staining.  
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Figure 3.S3. Tgfbr2, Wisp1, and Igfbp5 are directly regulated by miR-135b 
 (A) List of predicted miR-135b target sites identified by both miRanda software 
and Targetscan in Tgfbr2, Wisp1, and Igfbp5 3‘UTRs. (B) Dual luciferase assay 
supported direct regulation by miR-135b. The full length Tgfbr2 3‘UTR, a Wisp1 
fragment, and the Igfbp5 3‘UTR were cloned into pGL3 luciferase reporters and 
transfected into HeLa cells together with pRL-TK. Relative luciferase activity was 
calculated by the GL/RL signal and normalized to siControl-transfected cells. p 
values were calculated using Student‘s t-test from at least two independent 
experiments with duplicate wells.  
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Figure 3.S4. Wisp1 regulates expression of several ECM genes 
Wisp1 was knocked down in MEFs by two shRNAs. Expression of representative 
ECM genes was examined 4 days post-infection. Expression of Tgfbi, Nov, and 
Dkk2 were strongly decreased upon Wisp1 knockdown, similar to results from 
siRNAs transfection (Figure 3.5.A) 
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Figure 3.S5. Wisp1 ECM target genes are regulated by miR-135b in MEFs 
MEFs were transfected with miR-135b mimic at a final concentration of 50 nM for 
4 days. Total RNAs were harvested for RT-qPCR analysis of the indicated 
Wisp1-regulated ECM genes. Error bar represents experiment with duplicate 
wells.  
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Figure 3.S6. Knockdown of Wisp1 target genes enhances iPSC marker 
expression 
Nov, Dkk2, and Tgfbi were knocked down in 4F-transduced MEFs at day 5 post-
transduction. Cells from each well were harvested at around day 14 and total 
RNAs were extracted for RT-qPCR analysis of the representative mES markers, 
E-Ras, Nanog, and Tet1.  
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Figure 3.S7. Knockdown of Wisp1 compromises proliferation of normal 
MEFs 
(A) Wisp1 was efficiently knocked down by shRNAs. Two shRNAs targeting 
mouse Wisp1 were transduced into MEFs. Knockdown efficiency was evaluated 
at day 4 post-transduction. (B) Consistent knockdown of Wisp1 compromised 
proliferation of MEFs. MEFs were transduced with shRNAs and then reseeded 
into 96-well plates. Proliferation of MEFs was measured every four days using 
Celltiter 96 One Solution assay (Promega, G3582).  
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Table 3.1. miR-135b target site analysis 
Genes showing significantly repressed expression upon miR-135b transfection 
were analyzed with miRanda and TargetScan to identify potential miR-135b 
target sites in their 3‘UTR regions. Sites with good seed match and significant 
predicted energy are listed. 
Gene 
Names 
No. Of 
Predicted 
Sites 
Represetative Sites Predicted 
Energy 
Mmp13 2/0 
 
-20.3kcal/mol 
Gpc1 1/1 
 
-20.8kcal/mol 
Mmp10 0/0 N/A N/A 
Ece1 1/1 
 
-18.79kcal/mol 
1190002H
23Rik 1/na  
-16.7kcal/mol 
Rgs16 2/2 
 
-19.2kcal/mol 
Entpd4 1/1 
 
-17.2kcal/mol 
Sema7a 0/0 N/A N/A 
Inhba 0/1 
 
N/A 
Adra2a 0/1 
 
N/A 
Creld1 0/0 N/A N/A 
Sprr2k 0/na N/A N/A 
Cxcl14 0/0 N/A N/A 
Tgfbr2 0/1 
 
N/A 
Wisp1 3/1 
 
-24.7kcal/mol 
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Ccl12 0/na N/A N/A 
2310001A
20Rik 1/na  
-28.6kcal/mol 
Ogfr 0/0 N/A N/A 
Aqp5 1/na 
 
-18.7kcal/mol 
Dusp4 0/0 N/A N/A 
Grem1 0/0 N/A N/A 
Trib3 0/0 N/A N/A 
Ifit3 0/0 N/A N/A 
St3gal3 1/0 
 
-20.3kcal/mol 
Mthfd2 0/0 N/A N/A 
Igfbp5 1/0/1* 
 
-16.8kcal/mol 
Nbl1 0/0 N/A N/A 
 
Target sites are shown as ―miRanda predicted/ Targetscan predicted‖. * RNAhybrid 
identified another  seed-match site. 
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Table 3.2. Original microRNA expression profile data 
List of microRNAs significantly (2-fold, p<0.05) altered at reprogramming day 5 in 
Thy1- cells. 
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Table 3.3. mRNA expression profile upon miR-135b transfection 
Significantly altered mRNAs upon miR-135b mimic transfection are listed. 
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Table 3.4. mRNA microarray data upon Wisp1 knockdown 
Significantly altered mRNAs upon siWisp1 transfection are listed.  
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CHAPTER IV: A KINASE INHIBITOR SCREEN IDENTIFIES SMALL 
MOLECULE ENHANCERS OF REPROGRAMMING AND IPSC 
GENERATION 
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4.1 Abstract 
Somatic cells can be reprogrammed to iPS cells, a process that suffers from low 
efficiency and whose molecular mechanisms remain poorly understood. We 
report an inhibitor screen identifying kinases that enhance or present a barrier to 
reprogramming. Overall, inhibitors of p38, IPTK and aurora kinases potently 
enhanced iPSCs generation. iPS cells derived from inhibitor-treated samples 
were capable of reaching a fully reprogrammed state. Knockdown of target 
kinases by siRNAs confirmed that these genes function as barriers. We show 
that Aurora A kinase, which functions in centrosome activity and spindle 
assembly, is highly induced during reprogramming and inhibits Akt-mediated 
inactivation of GSK3β, resulting in compromised reprogramming efficiency.  
Together, our results not only identify new compounds that enhance iPSC 
generation but provide heretofore unreported insight into the function of Aurora A 
kinase in the reprogramming process.  
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4.2 Introduction 
Since the discovery of techniques to create cells closely resembling embryonic 
stem cells, various types of mouse and human somatic cells have been 
reprogrammed to establish induced pluripotent stem cells (iPSCs) (Meissner et al, 
2007; Takahashi et al, 2007; Takahashi & Yamanaka, 2006; Wernig et al, 2007; 
Yu et al, 2007). These cells have acquired full capacity to differentiate into 
different lineages (Takahashi et al, 2007; Wernig et al, 2007; Yu et al, 2007). 
Resultant differentiated cells reportedly function in vitro and in vivo and serve to 
correct various diseases in mouse models (Hanna et al, 2007). Moreover, iPSCs 
have been generated from tissues of patients with different disease conditions 
and could be a valuable source to study those pathologies or for drug screening 
in vitro (Itzhaki et al, 2011; Lee et al, 2009; Liu et al, 2011; Marchetto et al, 2010). 
Nonetheless, the reprogramming process suffers from extreme low efficiency 
(Aoi et al, 2008; Meissner et al, 2007; Nakagawa et al, 2008; Takahashi & 
Yamanaka, 2006) . 
     Currently, there is a need to both better understand molecular 
mechanisms underlying reprogramming and develop more efficient methods to 
generate iPSCs. Elegant approaches have been applied to identify pathways 
regulating reprogramming. For example, mRNA profiling of somatic cells, iPSCs 
generated from those cells and intermediate populations that emerge during 
reprogramming indicates that cells can become ―trapped‖ in a partially 
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reprogrammed state and that treatment with DNA methyl transferase inhibitors 
enables them to become fully reprogrammed (Mikkelsen et al, 2008). Genome-
wide analysis of promoter binding of specific transcription factors supports the 
idea that DNA-binding and gene activation are altered in partially reprogrammed 
iPSCs (Sridharan et al, 2009). Moreover, several groups have shown that p53 
pathways, which are activated following overexpression of oncogenic 
reprogramming factors, act as a major reprogramming barrier (Hong et al, 2009; 
Kawamura et al, 2009; Li et al, 2009a; Utikal et al, 2009). Recent studies show 
that TGFβ signaling also inhibits reprogramming (Ichida et al, 2009; Maherali & 
Hochedlinger, 2009) and perturbs the mesenchymal-to-epithelial transition (MET) 
(Ashford et al, 2010; Garamszegi et al, 2010), a process that enhances 
reprogramming and is regulated by microRNAs (Li et al, 2011).   However, there 
remains little information about how terminally differentiated cells are 
reprogrammed to an ES-like state by four transcriptional factors.  
     Much effort has gone into identifying factors that enhance iPSC derivation. 
In addition to small molecules that can reportedly replace some reprogramming 
factors (Ichida et al, 2009; Lyssiotis et al, 2009; Shi et al, 2008a; Yuan et al, 
2011), some compounds are known to enhance overall reprogramming efficiency 
in the presence of the classic four factors (4F), namely, Tgfbr inhibitors, AZA, 
vitamin C and VPA (Esteban et al, 2010; Huangfu et al, 2008; Maherali & 
Hochedlinger, 2009; Mikkelsen et al, 2008). Although some investigators report 
that VPA treatment dramatically enhances iPSC generation, more recent reports 
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have reexamined the effects of the compound and found them to be modest 
(Anokye-Danso et al, 2011; Warren et al, 2010; Yusa et al, 2009). Therefore, 
currently only a limited number of compounds are available to enhance iPSC 
generation. 
     Kinases promote phosphorylation of targets by transferring phosphate 
groups from high-energy donors such as ATP. Kinases regulate many key 
processes such as cell cycle events and metabolic switching (Lens et al, 2010; 
Levine & Puzio-Kuter, 2010). However, few kinases have been shown to function 
in the reprogramming process (Feng et al, 2009). Given their critical function in 
numerous signaling pathways, we hypothesized that unidentified kinases may 
modulate the reprogramming process and that iPSC generation might be 
significantly enhanced by manipulating their activity.  
     Here we report an inhibitor screen to identify both barrier and essential 
kinases that function in reprogramming. We found that essential kinases were 
enriched within cell cycle and proliferation regulators, while three kinases, p38, 
ITPK and Aurora A kinase, were identified as new barrier genes. Inhibiting their 
function by small molecules significantly enhanced iPSC generation. iPSCs 
derived from inhibitor treatments reached a fully reprogrammed state and 
differentiated into different lineages in vitro and in vivo. The specificity of these 
factors was confirmed through analysis using other inhibitors and RNAi 
knockdown. Moreover, we found that Aurora A kinase functions to inhibit Akt-
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mediated GSKβ phosphorylation, which to our knowledge is the first report of a 
novel function for this kinase in addition to its characterized role in centrosome 
formation and spindle assembly. GSK3β inhibition has been reported to enhance 
somatic cell reprogramming efficiency (Silva et al, 2008). Overall, our data 
provide new insights into mechanisms underlying reprogramming and identify 
inhibitors that could significantly enhance iPSC generation.  
4.3 Results 
4.3.1 A kinase inhibitor library screen identifies small molecule activators 
or inhibitors of iPSC generation 
To define signaling mechanisms underlying reprogramming, we undertook a 
double-blind screen of 244 well-characterized cell-permeable protein kinase 
inhibitors to identify kinases that enhance or inhibit the process. Mouse 
embryonic fibroblasts from a transgenic line in which GFP expression is driven by 
the endogenous Oct4 promoter were chosen as the starting material. Fully 
reprogrammed cells switch on endogenous Oct4 expression, making resultant 
iPS colonies GFP-positive and enabling us to quantify reprogramming efficiency.  
To minimize well-to-well variation, MEFs were first transduced with 4F factors in 
bulk (Figure 4.1.) and then reseeded at 3000 cells/well into gelatin-coated 96-well 
plates before inhibitor treatment. Starting at day 3 post-transduction, inhibitors 
were added at a final concentration of 2µM and media were refreshed every 
other day with mES culture medium plus inhibitor. At day 13 post-transduction,  
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Figure 4.1. A kinase inhibitor library screen identifies essential and barrier 
kinases 
(A) Design of the screen. MEFs were transduced with the four mouse 
reprogramming factors (4F) for two days and reseeded into 96-well plates. Drugs 
were added at a final concentration of 2µM on day 3. Medium was changed 
every other day until day 13, and cells were then harvested for colony counting 
and AP staining. (B) Representative plate showing quantification of Oct4-GFP+ 
colonies.  GFP+ colonies were counted directly under a fluorescence microscope, 
and data was compared with DMSO-treated controls. * indicates identified hits.  
Columns 1 and 12 indicate control (DMSO) wells. Potential candidates were 
determined by both GFP+ colony number, morphology, and AP-positivity. (C) 
Representative barrier kinase hits. Oct4-GFP+ colony numbers were dramatically 
increased following some drug treatments. GFP+ colonies were quantified and 
images were taken at day 14 post 4F transduction. (d) Representative hits of 
essential kinases. Essential hits were identified by loss of AP staining and lack of 
signs of cell death   
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plates were fixed in 4% paraformaldehyde and GFP-positive colonies were 
directly quantified microscopically.      
     Two columns of wells from each plate (columns 1 and 12) were treated 
with DMSO (vehicle) only and served as controls. On average, we observed 2-3 
GFP positive colonies per well in control samples, which was around 0.07% 
overall reprogramming efficiency and comparable to other reports (Aoi et al, 2008; 
Meissner et al, 2007; Nakagawa et al, 2008; Takahashi & Yamanaka, 2006). To 
identify inhibitors that significantly enhance reprogramming efficiency, we set a 
minimum of a 2.5-fold increase in GFP-positive colony number as a filter. Using 
these criteria, we identified eleven inhibitors as potential activators of 
reprogramming or ―barrier hits‖ (Figure 4.1.B, C, Table 4.1). Since kinases may 
also be required for iPSC generation, we undertook alkaline phosphatase 
staining in order to identify potential ―essential hits‖. Since genes encoding 
targets of essential hits could function at various reprogramming stages, and 
most cells did not attain a fully reprogrammed state, we used an extremely 
stringent criterion: only wells devoid of any AP staining and with no obvious 
decrease in cell number were scored as essential hits (Figure 4.1.D). Based on 
these standards, nine kinase inhibitors were identified as essential hits, and 
further analysis revealed that among them (Table 4.2.) were four direct inhibitors 
of cell cycle dependent kinases (Cdks), indicating that cell cycle control is critical 
for reprogramming.  We tested four of the remaining essential hits (Figure 4.S1.A) 
and found that three inhibited MEF proliferation to various extents with or without 
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four-factor transduction (Figure 4.S1. B,C) and that reprogramming efficiency 
was positively correlated with the extent of that inhibition (Figure 4.S1.D). Overall, 
these findings suggest that compromised reprogramming efficiencies seen 
following inhibition of essential kinases are correlated with inhibition of 
proliferation. 
4.3.2 Inhibitors of TGFβ, IP3K, P38 and Aurora kinase significantly enhance 
reprogramming 
To confirm that the 11 compounds (Figure 4.2.A, Table 4.1.) identified in the 
primary screen targeting potential barrier genes enhance iPSC generation, we 
undertook a secondary screen using larger wells and two different drug 
concentrations (1µM and 2µM). For the eleven barrier candidates (Figure 4.2.A), 
these analyses confirmed that inhibitors B4, B8 and B10 consistently and 
significantly enhanced reprogramming (Figure 4.2.B) and were even more potent 
at the lower 1µM concentration in a secondary screen (Figure 4.2.B). Additionally, 
B8 and B10 enhanced iPSC generation even in non-permissive conditions in 
which 4F expression was too low to reprogram vehicle-treated MEFs (Figure 
4.S2.A). Two other groups recently identified the inhibitor B4 as enhancing 
reprogramming and/or capable of replacing Sox2 in the 4F cocktail (Ichida et al, 
2009; Maherali & Hochedlinger, 2009). Interestingly, inhibitor B6 enhanced 
reprogramming more robustly at 1µM than at 2µM. Dose/response analyses 
confirmed that B6, B8 and B10 act as potent enhancers at 0.5µM (Figure 4.S2.B).  
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Figure 4.2. Inhibitors of TGFβ, p38, IP3K and Aurora Kinase greatly 
enhance iPSC generation 
(a) Candidate hits for secondary screening conducted in 12-well plates of 11 
barrier (B) hits. (b) Compounds B4, B6, B8 and B10 significantly enhanced 
reprogramming. Drugs were added at day3 at a concentration of 2µM and 1µM 
and Oct4-GFP+ colonies were quantified at day13 after transduction. Notably, B6 
compound showed enhancement only at lower dose (1µM). Data represents 
three independent experiments. * p < 0.05. ** p<0.01 (Student t-test).  (c) 
Chemical structures of identified inhibitors.  
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Moreover, treatment of both uninfected and 4F-transduced MEFs with these 
three inhibitors did not significantly promote proliferation (Figure 4.S3.A, B). 
Combining B6, B8 and B10 at 1µM each resulted in a synergistic rather than an 
additive effect of the three compounds (Figure 4.S4.). Since p53 has been 
identified as a major barrier to reprogramming (Banito et al, 2009; Hong et al, 
2009; Kawamura et al, 2009; Li et al, 2009a; Utikal et al, 2009), we asked 
whether B6, B8 or B10 inhibitors enhanced reprogramming when p53 was down-
regulated by shRNA. As expected, p53 knockdown in 4F-transduced MEFs 
greatly enhanced iPSC generation, but that enhancement was equivalent in 
inhibitor-treated and -untreated conditions (Figure 4.S5.).  
Since B6, B8 and B10 could target multiple kinases at a given 
concentration, we validated drug specificity by RNAi experiments. To do so, 
MEFs and mES cells were transfected with siRNAs targeting potential targets of 
each kinase and knockdown efficiencies were evaluated by RT-qPCR. Indeed, all 
siRNAs tested efficiently knocked down target genes in MEFs (Figure 4.3.A,B) 
and in mES cells (Figure 4.3B and data not shown). We next transfected MEFs 
with these siRNAs and then transduced cells with 4F virus 3 hours post 
transfection. GFP+ colonies were counted at approximately day 12. Indeed, we 
found that Mapk11 (p38beta) (a target of inhibitor B10), ItpkA (a target of inhibitor 
B8), and Stk6 and Syk (targets of inhibitor B6) act as barrier genes: knockdown 
of any one of these genes during reprogramming resulted in significant increases  
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Figure 4.3. Inhibitor-targeted kinases are confirmed as barrier genes 
(A,B) siRNA knockdown of potential target mRNAs. Potential targets of B6, B8 
and B10 inhibitors were knocked down by siRNAs in MEFs or mES (ItpkA only). 
50nM siRNAs were transfected and total RNAs was harvested at day2 for RT-
qPCR analysis. Data represents analysis of duplicate wells. (C) Knockdown of 
B6 inhibitor targets enhances reprogramming. Potential targets of B6 were 
knocked down by siRNAs, and reprogramming efficiency was quantified by 
counting Oct4-GFP+ colonies. Data from three independent experiments were 
normalized to siControl-transfected samples. * p < 0.01. (D) Knockdown of B8 
and B10 targets enhances reprogramming. Data from two independent 
experiments were normalized to siControl-transfected cells.  
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in iPSC generation (Figure 4.3.C, D). Interestingly, knockdown of some B6 
targets, such as Bmx, Igf1R and Lck, compromised reprogramming, which may 
explain in part why B6 both inhibits and enhances reprogramming, depending on 
concentration. Together, these data confirm that inhibitors B4, B6, B8 and B10 
(Figure 4.2.D) are potent enhancers of iPSC generation and that effects of 
inhibitor treatment are target-specific.  
4.3.3 Inhibitor-treated iPSCs reach a fully reprogrammed state 
Although B6, B8 and B10 promote reprogramming, it is possible that treatment 
with these inhibitors turns on endogenous Oct4 expression but cells do not reach 
a fully reprogrammed state. To exclude this possibility, iPSCs derived from cells 
treated with respective inhibitors were analyzed for ES cell marker expression 
and pluripotency. All GFP+ clones (Figure 4.4.A) also stained positively with 
alkaline phosphatase (Figure 4.4.A). Immunostaining for other mES self-renewal 
markers confirmed that these cells expressed Nanog and the mES-specific 
surface protein SSEA1 (Figure 4.4.B). Moreover, genome-wide mRNA 
expression profiles verified that these cells showed a gene expression pattern 
highly similar to mES cells, one that differed significantly from starting MEFs 
(Figure 4.4.C). To determine whether inhibitor-treated cells acquire the full 
capacity to differentiate into different lineages, we used in vitro embryoid body 
formation assay to assess pluripotency. Clones tested readily differentiated into  
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Figure 4.4. Inhibitor-treated iPSCs reach a fully reprogrammed state 
(a) Inhibitor-treated iPS cells can be successfully derived. iPS clones from 
inhibitor-treated samples were picked and expanded. Cells show endogenous 
Oct4 expression (upper panels) and alkaline phosphatase positivity (lower 
panels). (B) Inhibitor-treated iPSCs are Nanog- and SSEA1-positive.  iPSCs 
were seeded on irMEF plates and cultured for 3 days, fixed in 4% 
paraformaldehyde and stained for Nanog and SSEA1 expression (see 
Supplemental Methods). (C) Genome wide mRNA expression profile of derived 
iPSCs. Kinase inhibitor-treated iPS clones show an expression profile resembling 
that of control mouse ES (CCE) cells (R2>0.95). (D) Inhibitor-treated iPSCs form 
teratomas in nude mice. iPS clones from each treatment were injected into 
athymic nude mice and tumors harvested after ~3 weeks. (E) Inhibitor-treated 
iPSCs can contribute to chimeric mice. Arrow refers to the representative 
contribution of injected iPSCs to the chimera mice.  
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three major lineages, including beating cardiomyocytes (Supplemental videos), 
and stained positively for AFP (endoderm), tubulin III (ectoderm) or cardiac actin 
(mesoderm) (Figure 4.S6.).  As a more stringent test of pluripotency, we injected 
these iPSCs into athymic nude mice and found that all tested clones generated 
heterogeneous teratomas within 3-4 weeks (Figure 4.4.D). When iPSCs were 
injected into the cavity of recipient blastocysts, they successfully integrated with 
cells of the inner cell mass the next day (Figure 4.7.A,B) and contributed to living 
chimeric mice (Figure 4.4.E). Cells also contributed to the germline of E13.5 
embryos, suggesting that these cells were germline-competent (Figure 4.S7.C). 
Together, these data strongly suggest that iPSCs derived from inhibitor-treated 
cells are fully reprogrammed and can differentiate into all lineages in vitro and in 
vivo.  
4.3.4 AurkA inhibition by B6 enhances Akt-mediated GSK3β inactivation 
To identify the mechanism underlying enhanced reprogramming mediated by a 
kinase inhibitor, the activity of a target of inhibitor B6, Aurora A Kinase (AurkA), 
was further analyzed due to its well known function in cell cycle progression, 
spindle formation and tumor development (Lens et al, 2010).  We first determined 
whether treatment with inhibitor B6 altered levels of AurkA protein. B6 treatment 
of both wild type MEFs and 4F-infected MEFs resulted in increased AurkA 
protein levels relative to untreated cells (Figure 4.5.A). In addition, a significant 
increase in AurkA protein levels was seen in untreated 4F-infected cells relative  
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Figure 4.5. Aurora A kinase inhibition by B6 promotes Akt mediated 
inactivation of GSK3β 
(A) B6 treatment increases aurora A kinase protein levels. Both 4F-infected 
(day3) and mock MEFs were treated with 1µM B6 for 2 days and cells were 
harvested for western blotting of Aurora A kinase. Actin served as loading control. 
(B) Aurora A kinase mRNA levels are signficantly increased by 4F expression 
during reprogramming. MEFs were infected with 4F for 3 days and treated under 
mock conditions or with DMSO or 1µM B6 for 2 days prior to RT-qPCR analysis 
of total RNA. B6 treatment did not alter induction of Aurora A kinase by 4F. (C) 
Inhibition of Aurora A kinase promotes increased phosphorylation of GSK3β 
kinase. 4F-infected MEFs were treated with different doses of B6 inhibitor 
starting at day 3 post-infection for 48 hrs before being harvested for western 
blotting analysis. (D) Inhibition of Aurora A kinase by MLN8237 promotes GSK3β 
phosphorylation dose-dependently.  The experiment was the same as (C). Actin 
served as the loading control. (E) Expression of a dominant negative form of 
Aurora A kinase promotes GSK3β phosphorylation (Ser9). MEFs were infected 
with 4F and expression vectors for RFP, wild-type (wt) Aurora A kinase or the 
D274A kinase-dead mutant of human Aurora A kinase. Expression of wt AurkA 
inhibited GSK3β phosphorylation (Ser9), while overexpression of the mutant 
promoted the process. Exposure time was almost doubled for 4F-infected 
samples. (F) Phosphorylation of GSK3β (Ser9) is mediated by Akt. 4F-infected 
MEFs were treated with 1µM each of Akt inhibitor (Akt X) and B6. GSK3β 
phosphorylation (Ser9) (Ser9) was diminished likely due to Akt inhibition. (G) 
Inhibition of AurkA by B6 induces Akt phosphorylation (Ser473). MEFs were 
infected with 4F for 3 days and then treated with 1µM B6 compound for 2 more 
days before harvesting for western blotting analysis. (H)Akt X treatment 
compromises reprogramming. Akt X inhibitor was added at a final concentration 
of 1μM. Error bar represents standard deviation of results derived from triplicate 
wells. *p <0.05. (I) AurkA inhibition by MLN8237 enhances reprogramming. 4F-
infected MEFs at day 3 were treated with 10nM MLN8237 for 10 days and GFP+ 
colonies counted to determine reprogramming efficiency. MLN8237 enhanced 
iPSC generation similarly to effects seen with 1µM B6. Data is derived from two 
experiments using triplicate wells. * p<0.05 
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Figure 4.5. Aurora A kinase inhibition by B6 promotes Akt mediated 
inactivation of GSK3β 
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to untreated MEFs. Further experiments suggested that this increase could be 
due to enhanced transcription, since AurkA mRNAs were induced by 3~4 fold in 
mock 4F-infected cells relative to mock MEFs (Figure 4.5.B), and mRNA levels 
were not significantly altered by B6 treatment (Figure 4.5.B). These results agree 
with previous expression profiling studies of MEFs expressed in mES or iPSCs 
compared with MEFs. During reprogramming with 4F we also observed 
decreased levels of phosphorylation of GSK3β (data not shown), indicating that 
GSK3β is activated. Interestingly, recent studies indicate that GSK3β inhibition 
by small molecules enhances iPSC generation from neural stem cells (Silva et al, 
2008). Therefore, we asked whether AurkA inhibition by B6 altered GSK3β 
phosphorylation. Indeed, we detected a significant increase in phospho-GSK3β 
in B6-treated cells (Figure 4.5.C), while GSK3β total protein levels were 
unchanged. As a test of specificity, we assessed reprogramming in the presence 
of a different AurkA inhibitor MLN8237, which has a potent inhibitory effect and 
has been tested in myeloma cell lines (Gorgun et al, 2010). AurkA inhibition by 
MLN8237 promoted a dose-dependent increase of phospho-GSK3β, while total 
GSK3β levels remained unchanged (Figure 4.5.D). Increased AurkA protein 
levels were also detected (Figure 4.S8.). Overall, these results indicate that 
AurkA inhibition promotes phosphorylation and subsequent inactivation of 
GSK3β, an effect that likely enhances reprogramming.  
     AurkA reportedly has a kinase-independent function (Otto et al, 2009). We 
therefore asked whether potential inactivation of GSK3β by AurkA proteins 
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requires AurkA kinase activity. To answer this question, we overexpressed AurkA 
in 4F-infected MEFs using two retroviral constructs: one encoding wild-type 
mouse AurkA and the other encoding a human AurkA kinase dead mutant 
D274A (Otto et al, 2009) (Figure 4.S9., as AurkA is highly conserved between 
humans and mouse (Figure 4.S10.)). If GSK3β inactivation seen following B6 
treatment is AurkA kinase-independent, overexpression of either construct 
should decrease GSK3β phosphorylation. If that effect is kinase-dependent, 
overexpression of the kinase-dead mutant should have a dominant-negative 
effect, similar to effects seen following AurkA inhibition by small molecules. 
Indeed, a significant increase in levels of phospho-GSK3β was detected in both 
4F- infected and untreated MEFs following expression of the kinase-dead mutant 
(Figure 4.5.E). Moreover, overexpression of wild-type AurkA promoted a 
decrease in phospho-GSK3β without altering total protein levels (Figure 4.5.E). 
Furthermore, AurkA knockdown by siRNAs in MEFs enhanced GSK3β 
phosphorylation (Figure 4.S11.). Meanwhile, overexpression of GSK3β in MEFs 
largely abolished the enhancing effect of B6 (Figure 4.S12.). Collectively, these 
findings suggest that inhibition of AurkA kinase activity promotes GSK3β 
inactivation.  
     Next, we asked which kinase potentially functions in GSK3β 
phosphorylation following B6 treatment. Since Akt kinases are well-characterized 
mediators of GSK3β phosphorylation, we asked whether Akt inhibitors abolished 
B6‘s effect on phospho-GSK3β induction. Indeed, treatment of 4F-infected MEFs 
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by small molecule Akt inhibitor decreased the effect of B6 on GSK3β 
phosphorylation (Figure 4.5.F) and inhibited reprogramming (Figure 4.5.H). 
Moreover, an increase of phosphorylated Akt (Ser473) was also detected in B6 
treated cells (Figure 4.5.G), suggesting that increased GSK3β phosphorylation 
seen following AurkA inhibition is mediated by Akt.  We also tested expression 
levels of several genes reportedly upstream of Akt such as Pdk1, Src, Pten and 
p85α but did not observe significant changes when MEFs were first transduced 
with 4F for three days and then treated with DMSO or B6 (Figure 4.S13.), 
indicating that B6 treatment does not alter transcription of Akt regulators.  
     As a test of specificity, we also determined whether MLN8237 enhanced 
iPSC generation. Treatment of MEF cells with MLN8237 at the low concentration 
of 10nM enhanced reprogramming approximately 4-fold, and the effect was 
dose-dependent (Figure 4.5.I, Figure 4.S14.A). Gene expression analysis of 
MLN8237-treated samples also confirmed increases in mES-specific gene 
expression (Figure 4.S14.B) 
     Since AurkA functions in control of spindle formation and the cell cycle 
(Lens et al, 2010), we determined whether the cell cycle of 4F-infected MEFs 
was significantly altered by treatment with AurkA inhibitors. Treatment with 
various concentrations of either B6 or MLN8237 promoted little change in cell 
cycle progression (Figure 4.S15.). However, at a higher concentration of 100nM, 
MLN8237 treatment increased the number of cells in G2. However, a significant 
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increase in the number of GFP+ colonies accompanied by induction of an mES-
specific gene expression profile was still detected at this concentration of 
MLN8237 (Figure 4.S14.A,B), and the size of resultant colonies resembled that 
of DMSO-treated cells (data not shown), indicating that iPSC formation was not 
affected by MLN8237 at this dose, in contrast to fibroblast cells which would have 
undergone G2-arrest under such dose.  
AurkA is highly expressed in mES and iPS cells compared with MEFs 
(Sridharan et al, 2009), suggesting that it functions to maintain mES self-renewal 
or pluripotency. To determine whether inhibition of AurkA altered mES self-
renewal or differentiation, we treated mES cells with B6 at both 0.5µM and 1µM 
and cultured cells in LIF+ and LIF- conditions for 4 days. LIF withdrawal in both 
B6-treated and DMSO control cells promoted mES cell differentiation, as 
indicated by loss of colonies, based on morphology and AP staining (Figure 
4.S16.A). RT-qPCR of self-renewal markers confirmed that differentiation was 
occurring, as those markers were down-regulated in LIF-minus cells (Figure 
4.S16.B). However, we did not see a significant effect on either mES self-renewal 
(in the presence of LIF) or differentiation (following LIF withdrawal), other than a 
very small increase in Oct4 expression in mES cells, suggesting that B6 
treatment has little effect on iPS cells once they have reached the fully 
reprogrammed state.  
4.4 Discussion 
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Since the discovery of reprogramming of fibroblasts to iPS cells, much effort has 
been put into overcoming the extreme low efficiency of the process. A few small 
molecules have been shown to replace some 4F reprogramming factors in large-
scale random screens (Feng et al, 2009), while only a handful—most of which 
are chromatin remodeling reagents—have been shown to enhance iPSC 
generation in 4F-infected cells. To date, TGFβ receptor inhibitors are the only 
kinase inhibitors shown to be capable of directly enhancing reprogramming and 
replacing Sox2 and cMyc by inducing Nanog expression (Ichida et al, 2009), an 
observation that led to the discovery that the MET is a key event during early 
reprogramming stages (Ashford et al, 2010; Garamszegi et al, 2010). Thus, 
identifying kinases functioning in the course of reprogramming could provide not 
only targets that could be modulated but also provide novel insight into how 
reprogramming works.  
     Here we report a kinase inhibitor library screen aimed at identifying 
additional kinases important for reprogramming. We found that inhibition of P38, 
IP3K and AurkA significantly enhanced reprogramming efficiency, indicating that 
these kinases could function as barriers to the process. Modulation of activities of 
these kinases possibly in combination with other currently available methods 
could substantially increase reprogramming efficiency. Interestingly, knock-down 
of p53 seemed to override the enhancing effects of these kinase inhibitors 
(Figure 4.S5.B). One potential reason could be that establishment of fast ES-like 
cell cycle could be most fundamental requirement to reach fully reprogrammed 
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state. Kinase inhibitor treatments may all lead to enhanced cell cycle progression 
among small percentage of the cells, which could not be easily detected in mixed 
population. Meanwhile, knockdown of p53 leads to a major release of cell cycle 
arrest caused by oncogene overexpression, which then largely tampered the 
enhancing effects of these inhibitors.    
     Our experiments also identified novel functional aspects of AurkA, whose 
kinase activity may inhibit Akt-mediated phosphorylation of GSK3β, which needs 
to be inactivated to promote iPSC generation (Silva et al, 2008). AurkA kinase is 
well characterized for its role in modulating centrosome function and spindle 
assembly(Lens et al, 2010). Aberrant expression of AurkA, either overexpressed 
or reduced, also reportedly leads to tumor development (Lens et al, 2010). We 
show that during reprogramming of MEFs to iPS cells, AurkA is highly induced 
even at an early stage (~day 5 post transduction) (Figure 4.5.B), an event 
correlated with reduction of phospho-GSK3β in these cells (Figure 4.5.E). 
Modulating AurkA kinase activity could thus affect GSK3β activity and alter 
reprogramming efficiency. Meanwhile, treatment with AurkA inhibitors could 
increase levels of AurkA protein. Recent studies indicate that AurkA may have a 
kinase-independent function, such as stabilizing N-MYC protein by direct binding 
to block MYC ubiquitination (Otto et al, 2009). N-MYC is also specifically 
expressed in mES or iPS cells, and recent work confirms that levels of 
endogenous N-MYC increase in reprogramming (Sridharan et al, 2009). 
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Interestingly, N-MYC degradation also requires sequential phosphorylation by 
cyclin B/Cdk1 and GSK3 (Otto et al, 2009). 
     Our screen also identified p38 and IP3K as barrier kinases. p38 reportedly 
regulates diverse processes, including the stress response, chromosome 
remodeling and the cell cycle (Wagner & Nebreda, 2009). Interestingly, p38 has 
been shown to have tumor suppressor function, and one target regulated by p38 
is p53 (Wagner & Nebreda, 2009). This observation could explain why p53 
knockdown abolished the enhancing effect of a p38 inhibitor (Figure 4.S5.). 
Meanwhile, p38 could also negatively regulate cell cycle progression (Wagner & 
Nebreda, 2009). Although we did not detect growth effects following inhibitor 
treatment of 4F-infected cells, we cannot rule out the possibility that a small 
percentage of cells gain a proliferative advantage following inhibition of p38, 
since very few cells reach a fully reprogrammed state.  By contrast, IP3K is the 
least studied protein identified here as a barrier kinase. Gene expression profiles 
indicate that MEFs express low levels of IP3K and its expression is induced in 
partially reprogrammed iPS cells and iPS/mES cells (Sridharan et al, 2009). IP3K 
functions primarily in calcium-dependent signal transduction (Xia & Yang, 2005) 
and its relationship to reprogramming requires further investigation. 
     We also identified kinases functioning as potential enhancers of 
reprogramming. Specifically, we found that knockdown of the insulin like growth 
factor (IGF) receptor Igf1r compromised reprogramming (Figure 3c). Interestingly, 
160 
 
 
IGF signaling reportedly activates the PI3K pathway, which could also activate 
Akt function (Zoncu et al, 2011). We have also found that knockdown of negative 
regulators of IGF signaling enhances reprogramming (data not shown). These 
findings suggest an important role for Akt function in iPSC generation. Although 
we found that the kinase inhibitors could enhance iPSCs generation and the 
reprogrammed cells reached fully pluripotent state, but the exact nature of cells 
population to increase iPSCs was not obvious.  For example, expression of four 
factors (OSKM) can lead a cell population to the path of pluripotency but not all of 
them reach fully iPSC state because a large number of unstable or partially 
reprogrammed cells never go over the barrier to fully reprogrammed state. Do 
the kinase inhibitors accelerate the process where unstable cells become fully 
reprogrammed or increase the starting pool of initiator cells for iPSC generation? 
We do not know the answers to these questions at this stage and future work 
would reveal these aspects of reprogramming stages.   
     Overall, our findings provide new insights into how somatic cells are 
reprogrammed into iPS cells and have identified new barrier genes that could 
serve as targets to design specific chemical inhibitors. Our study encourages 
further efforts to screen for small molecules that could prove useful in iPS cell-
based therapies.  
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Materials and Methods 
Cell culture, vectors and virus transduction 
Oct4-GFP MEFs were derived from mice carrying an IRES-EGFP fusion cassette 
downstream of the stop codon of pou5f1 (Jackson lab, Stock#008214) at E13.5.  
MEFs were cultured in DMEM (Invitrogen, 11995-065) with 10% FBS (Invitrogen) 
plus glutamine and NEAA. Only MEFs at passage of 0 to 4 were used for 
reprogramming.  pMX-Oct4, Sox2, Klf4 and cMyc were purchased from Addgene. 
Mouse AurkA was cloned into pMX. The human AurkA D274A mutant retroviral 
vector was purchased from Addgene. To generate retrovirus, PLAT-E cells were 
seeded in 10cm plates, and 9ug of each factor were transfected the next day 
using Lipofectamine (Invitrogen, 18324-012) with PLUS (Invitrogen, 11514-015). 
Viruses were harvested and combined 2 days later. For reprogramming, MEFs 
were seeded in 12-well plates and transduced with 4F virus the next day with 
4ug/ml Polybrene. One day later, the medium was changed to fresh MEF 
medium, and 3 days later it was changed to mES culture medium supplemented 
with LIF (Millipore, ESG1107). GFP+ colonies were picked at day 14 post-
transduction, and expanded clones were cultured in DMEM with 15% FBS 
(Hyclone) plus LIF, thioglycerol, glutamine and NEAA. Irradiated CF1 MEFs 
served as feeder layers to culture mES cells and derived iPS clones.  
 
Kinase library screening 
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A kinase library of 244 compounds was obtained from the chemical screening 
facility at the Sanford-Burnham Institute. The library was purchased from 
Calbiochem (Library 1: 80 compounds. Cat# 539744-1EA; Library 2: 80 
compounds. Cat# 539745-1EA; Library 3: 84 compounds. Cat# 539746-1EA). All 
compounds are well-characterized protein kinase inhibitors. 
Compounds were diluted to 2mM in 96-well plates. 4F-transduced cells were 
seeded into gelatin coated plates (4000 cells/well). Inhibitors were added every 
other day until day 13. Cells were then fixed with 4% paraformaldehyde for 20 
min at room temperature and number of Oct4-GFP+ colonies was directly 
counted under a microscope. Cells were then stained with Vector red alkaline 
phosphatase substrate kit I (Vector laboratories, SK5100).  
 
siRNA transfection of MEFs  
siRNAs were purchased from Dharmacon and diluted in Opti-MEM (Invitrogen, 
11058-021) to the desired final concentration. Lipofectamine 2000 (Invitrogen, 
11668-019) was added to the mix at 2ul/well in 12-well plates, which were 
incubated 20 min at RT. For 12-well transfections, 80ul of the siRNA/lipid mixture 
was added to each well with 320ul Opti-MEM. Three hours later, 0.8ml of the 
virus mixture (for iPS) or fresh medium was added to each well and the medium 
was changed to fresh MEF medium the next day. siRNAs were transfected twice 
during reprogramming (at days 0 and 5 post-4F infection).  
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Western blotting 
Total cell lysates were prepared by incubating cells in MPER buffer (PIERCE, 
78503) on ice for 20 min, and then cleared by centrifugation at 13,000 rpm for 10 
min. An equal volume of lysates was loaded onto 10%SDS-PAGE gels, and 
proteins were transferred to PVDF membranes (Bio-Rad, 1620177) using the 
semi-dry system (Bio-Rad). Membranes were blocked with 5% milk in TBST for 
at least 1hr at room temp or overnight at 4°C.  Antibodies used include: anti-
mNanog (R&D, AF2729), anti-h/mSSEA1 (R&D, MAB2156), anti-Actin (Thermo, 
MS1295P0), anti-AFP (Abcam, ab7751), anti-Beta III tubulin (R&D systems, 
MAB1368), and anti-alpha actinin (Sigma, A7811), anti-mAurkA (Bethyl lab, 
A300-072A), anti-hAurkA (Bethyl lab, A300-071A), total-GSK3β (Cell signaling 
technology, 9315S), phospho-GSK3β (Ser9) (Cell Signaling Technology, 9323S), 
total Akt (Cell signaling technology, 9272S), phosphor-Akt (Ser473) (Cell 
signaling technology, 9271S). 
 
mRNA quantitative PCR 
Total RNAs were extracted using Trizol (Invitrogen). After extraction, 1ug total 
RNA was used for RT using Superscript II (Invitrogen). Quantitative PCR was 
performed using a Roche LightCycler480 II and the Sybr green mixture from 
Abgene (Ab-4166). Gene primers are listed in Supplementary Table 3. Other 
primers were previously described (Takahashi & Yamanaka, 2006).  
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Immunostaining 
Cells were washed twice with PBS and fixed with 4% paraformaldehyde at room 
temperature for 20min. Fixed cells were permeabilized with 0.1% Triton X-100 for 
5min. Cells were then blocked in 5% BSA in PBS containing 0.1% Triton X-100 
for 1hr at room temperature. Primary antibodies were diluted from 1:100 to 1:400 
in 2.5% BSA PBS containing 0.1% Triton X-100, according to the manufacturer‘s 
suggestion. Cells were stained with primary antibody for 1hr and then washed 
three times with PBS. Secondary antibodies were diluted 1:400 and cells were 
stained for 45min at room temperature.  
 
EB formation and differentiation assay 
iPS cells were trypsinized into a single cell suspension and the hanging drop 
method was used to generate embryoid bodies (EB). For each drop, 4000 iPS 
cells in 20ul EB differentiation medium were used. EBs were cultured in hanging 
drops for 3 days before being reseeded onto gelatin-coated plates. After 
reseeding, cells were further cultured until day 14, when beating areas could be 
identified.  
 
Teratoma formation and chimera generation 
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iPS cells were trypsinized and resuspended at 1x107 cells/ml. Athymic nude mice 
were anesthetized with Avertin, and then approximately 150 ul of the cell 
suspension was injected into each mouse. Mice were checked for tumors every 
week for 3 to 4 weeks. Tumors were harvested and fixed in zinc formalin solution 
for 24hrs at room temp before paraffin embedding and H&E staining. To test the 
capacity of derived iPSC clones to contribute to chimeras, iPS cells were injected 
into C57BL/6J-Tyr(C-2J)/J (albino) blastocysts. Generally, each blastocyst received 
12-18 iPS cells. ICR recipient females were used for embryo transfer. Donor 
iPSCs confer agouti or black coat color.   
 
mRNA microarray analysis 
Total RNAs from derived iPSCs were harvested and extracted by Trizol method. 
mRNA microarray analysis was carried out by the microarray facility at the 
Sanford-Burnham Institute. A scatter plot was used to compare genome wide 
mRNA expression profiles between iPSCs, MEFs and mES cells. 
 
Cell proliferation assay 
3000 MEFs were seeded in each well in 96-well plates and transduced with 4F 
virus for three days. Cells were then treated with inhibitors at 0.5µM and 
harvested every other day.  Cells were incubated with mES medium containing 
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Celltiter 96 Aqueous one solution (Promega, G3580) for 1hr in tissue culture 
incubator. Absorbance at 490nm was then measured for each well using a plate 
reader, and data was used to generate relative proliferation curves using the 
signal from day 3 post-transduction as a reference. 
 
Cell cycle analysis 
MEFs or 4F-infected MEFs were treated with inhibitors for two days and then 
harvested and trypsinized before fixing in 75% ethanol overnight. Cells were 
centrifuged at 1000 rpm for 5min, washed once with PBS, and treated with PI 
staining solution for at least 30min at room temperature before flow cytometry 
analysis. ~20000 events per sample were collected per analysis and cell cycle 
data was modeled using ModFit.  
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Figure 4.S1. Essential hits can block the reprogramming process 
(A) List of essential hits that are not Cdk inhibitors. (B) Proliferation of wild-type 
MEFs is altered by inhibitor treatment.  MEFs were treated with drugs at 2µM and 
proliferation was assayed by using the Celltiter96 aqueous method (Promega). 
Y-axis represents the absorbance at 490nm to detect formazan, which is 
converted from MTS tetrazolium by living cells. A higher reading indicates 
increased cell number. (C) Proliferation of 4F-transduced MEFs was also altered 
by drug treatment. (D) Reprogramming efficiency was decreased by drug 
treatment. Oct4-GFP+ colonies were quantified at day13. *p<0.05. **p<0.01 
(Student t-test). 
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Figure 4.S2. Dose/response analysis of kinase inhibitor hits 
(A) Inhibitor B8 and B10 enhanced iPSC generation in non-permissive conditions 
in which 4F expression was too low to reprogram vehicle-treated MEFs. Cells 
were infected with 4F and drugs were added at days 3 post-infection. GFP+ 
colonies were counted at day 12-13. Non permissive condition refers to 
occasions where 4F expression level does not reach to the threshold for 
successful reprogramming thus no GFP+ colonies could be detected. Data 
represents experiments using duplicate wells for each treatment. (B) 4F-
transduced MEFs were treated with indicated concentrations of kinase inhibitors 
B6, B8 or B10 or with DMSO control starting at day3 post 4F transduction, and 
Oct4-GFP+ colonies were counted at day 13 after transduction. Data represents 
three independent wells.  
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Figure 4.S3. Identified barrier hits do not alter proliferation of 4F-infected 
MEFs 
(A) 4F-infected MEFs were seeded in 96-well plates and 0.5µM of three inhibitors 
was added at day 3 after transduction (Day 0 in dataset). Proliferation of cells 
was analyzed every other day using the Celltiter96 aqueous method (Promega). 
(B) Proliferation of uninfected MEFs is not altered by inhibitor treatment. The 
experimental procedure is the same as in (A).  
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Figure 4.S4. A combination of three inhibitors enhances iPSC generation 
A combination of B6, B8 and B10 (Combined) enhances reprogramming. The 
three inhibitors were used at 1μM each. Data is derived from experiments using 
triplicate wells. A GSK3β inhibitor (CHIR99021) was also included to evaluate its 
effect on reprogramming. Error bar represents two experiments with three 
independent wells. **p <0.01. *p<0.05 (Student t-test). 
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Figure 4.S5. Kinase inhibitors’ effect on iPSC generation when p53 is 
silenced by RNAi 
(A) p53 was efficiently knocked down by shRNA. MEFs were transduced by 
pLKO-shp53 and nontargeting control and harvested for RT-qPCR analysis at 
day4 post transduction. Error bar represents experiment with duplicate wells. (B) 
Enhancements of inhibitors in reprogramming were largely abolished in p53-
knocked down samples. MEFs were infected with 4F plus either non-targeting or 
p53 shRNA. Inhibitor treatments were started at day 3 post-infection. Media were 
changed every other day, and GFP+ colonies were counted at day 12 post-
infection.  
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Figure 4.S6. Inhibitor-treated iPSCs can differentiate into tissues 
representing all three germ layers 
iPS clones were picked and expanded from inhibitor-treated cells and used for 
embryoid body (EB) formation. EBs were formed by the hanging drop method 
with ~2000 cells/20ul drop. After three days, EBs were transferred to gelatin-
coated plates and cultured until day 13, when beating areas were apparent (see 
Supplemental Videos). Cells were fixed with paraformaldehyde and stained with 
indicated antibodies. AFP, tubulin III and cardiac actin mark endoderm, ectoderm, 
and mesoderm, respectively. 
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Figure 4.S7. Inhibitor-treated iPSCs contribute to the germline of chimeric 
embryos 
(A) B10-treated iPSCs were injected into the cavity of recipient blastocysts at day 
0. Image showed GFP+ iPSCs right after injection into the recipient embryo. (B) 
iPSCs integrated into inner cell mass of recipient blastocysts by day 1. Arrows 
refer to GFP+ iPSCs. (C) iPSCs contribute to the germline of chimeric embryos. 
Injected embryos were harvested at E13.5 and genital ridge tissues were 
dissected and analyzed for GFP-positivity.  
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Figure 4.S8. MLN8237 increases levels of AurkA protein 
4F-infected MEFs were treated with MLN8237 at various concentrations at day 3 
post 4F infection. Cells were harvested 48 hrs after drug treatment for western 
blotting analysis of AurkA protein. Actin serves as loading control.  
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Figure 4.S9. Overexpression of wt and kinase-dead AurkA in MEFs  
MEFs or 4F-infected MEFs were infected with either wild-type (wt) mouse AurkA 
virus or virus expressing a kinase-dead mutant human AurkA D274A virus at day 
0. Cells were harvested at day 5 post-infection for analysis of AurkA proteins.  
mAURKA refers to wild type mouse AurkA protein and hAURKA refers to kinase-
dead mutant of human AurkA protein. Specific antibodies to each protein were 
used to detect overexpressed proteins.  
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Figure 4.S10. Conservation of mouse and human AurkA 
Amino acid alignment of mouse and human proteins shows ~84% identity in 
amino acid sequence.  
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Figure 4.S11. AurkA knockdown promotes GSK3β inactivation 
MEFs were transfected with AurkA and control siRNAs at a final concentration of 
50nM for two days. Cells were then harvested for western blotting analysis of 
AurkA, total and phosphorylated GSK3β (Ser9), and actin, as a loading control.  
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Figure 4.S12. Overexpression of Gsk3β largely blocks B6’s effect on 
reprogramming 
(A) Gsk3β was overexpressed in MEFs by pMXs retroviral vector. MEFs were 
infected with pMX-Gsk3β virus for four days before harvesting for RT-qPCR 
analysis. pMX-RFP was used as control. Error bar represents experiment with 
duplicate wells. (B) Overxpression of Gsk3β blocked B6‘s effect on 
reprogramming. Mouse Gsk3β was cloned into pMX retroviral vector and 
transduced into MEFs together with OSKM. Compound treatment (1µM) was 
started at day3 post transduction. GFP+ colonies were quantified at day12 post 
transduction. Error bar represents experiment with three independent wells. * 
p<0.05  (Student t-test).  
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Figure 4.S13. B6 treatment does not alter expression of genes upstream of 
Akt  
MEFs were first transduced with 4F for three days and then treated for another 
two days with DMSO or 1μM B6. Total RNAs were harvested and analyzed for 
indicated factors, which reportedly function upstream of Akt.  
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Figure 4.S14. MLN8237 dose-dependently enhances reprogramming 
(A) The number of Oct4-GFP+ colonies was significantly increased upon 
MLN8237 treatment. Data is derived from analysis of three independent wells. (B) 
MLN8237 treatment induces mES-specific gene expression in 4F-transduced 
MEFs. Cells were harvested at day14 post 4F transduction. Nanog, Tet1 and 
Eras expression was analyzed in cells treated with DMSO or MLN8237. Shown 
are data derived from three independent wells.  
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Figure 4.S15. Low concentrations of AurkA inhibitors do not alter the cell 
cycle 
(A) 4F-infected MEFs were treated with different concentrations of B6 at day 3 
post-infection. Cells were harvested after 48 hr of drug treatment, subjected to PI 
staining and analyzed for DNA content by flow cytometry. (B) MLN8237 
treatment at 10 nM did not alter the cell cycle of 4F-infected MEFs. The 
experimental procedure was as in (A). 
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Figure 4.S16. AurkA inhibitor treatment does not inhibit mES cell 
differentiation 
(A) Treatment with inhibitor B6 does not block changes in mES cell morphology 
following LIF withdrawal. mES cells were cultured both in LIF+ or LIF- medium for 
4 days and harvested for AP staining. Differentiating cells become AP-negative 
and show a more scattered morphology. (B) Inhibitor B6 does not alter silencing 
of self-renewal genes following LIF withdrawal.  The experimental procedure was 
as in (A). Cells were harvested for RNA extraction and RT-qPCR of indicated 
mES self-renewal genes. N.S.: Not significant. 
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Table 4.1. List of barrier hits and potential targets 
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Table 4.2. List of essential hits and potential targets 
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CHAPTER V: FINAL SUMMARY AND PERSPECTIVES 
In this dissertation, we have utilized both microRNAs and small molecules to 
understand a part of the molecular mechanism on how somatic cells could be 
reprogrammed to become pluripotent stem cells. Our findings revealed that 
microRNAs could play important functional roles in somatic cell reprogramming 
such as promoting mesenchymal-to-epithelial transition, modulating p53-p21 and 
TGFβ pathways and kinase functions. The finding that microRNAs could target 
the expression of signature ECM genes has also indicated that besides the 
common intracellular signaling regulation, extracellular networks are also 
regulated by microRNAs, which could result in profound effect on the fate and 
proper function of the target cells. Meanwhile, kinase inhibitor screen has 
discovered several new lines in understanding somatic cell reprogramming. The 
identification of p38, IP3K and Aurora A kinases as the new barrier genes as well 
as the discovery that essential kinases are enriched with cell cycle regulators has 
provided the proof of principle that studying kinases in genome wide scale could 
yield in depth mechanistic and functional insights of both reprogramming process 
and the target kinases themselves. In addition, we have identified that inhibition 
of Aurora A kinase, a gene that is involved in spindle formation and can act both 
as an oncogene and tumor suppressor could enhance the inactivation 
/phosphorylation of GSK3β in an Akt-dependent manner, a function that has not 
been reported before. 
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 Meanwhile, our discoveries have also revealed new insights on the barrier 
pathways that inhibit reprogramming. Since the discovery that somatic cells could 
be reprogrammed to an ES-like state, it has long been proposed that certain 
barrier pathways may be the main inhibitor that prevents cells from becoming 
reprogrammed. With the mounting evidence of years‘ efforts, it has become 
much clearer that intracellular gene networks indeed have a primary role in 
inhibiting somatic cell reprogramming. In general, terminal differentiated cells are 
restricted or locked in their specific cell types due to the existence of two main 
regulatory networks: one is the cellular network that define or maintain their 
current identities. This network usually provides all the necessary regulations to 
maintain the cells in a healthy growing state and functioning properly. This 
network could be highly tissue specific due to the fact that different cell types 
from various tissues should have very different signature gene expressions and 
regulations to maintain their normal function. Once this network is compromised, 
the cells will lose their identities and could not function properly, which would 
trigger a series of events that may finally lead them to the senescence and 
apoptosis. The other network is the cell defense/safety mechanisms that prevent 
the cells from transformation or tumor initiation and usually consists of tumor 
suppressing and cell death related signaling pathways. These signaling 
pathways shall be the common mechanisms that exist in most of the cell types, 
as they all need to have such system to prevent the cells from becoming tumor 
cells. Once the cells become transformed, their normal function and growth 
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regulation will be lost, affecting the function of the whole tissue/organ. Activation 
of these defense/safety pathways could help the system to eliminate the cells 
that have accumulate enough genetic mutations and DNA damages to initiate 
tumors, without the risk of compromising the whole tissue/organ. Finally, the two 
regulatory networks will not act independently. They do not have clearer 
boundaries and function together to regulate the normal life of a particular cell. 
 Therefore, during the reprogramming process, once the four factors are 
introduced and overexpressed in the target cells, they would need to overcome 
both of the two regulatory networks in order to reprogramme the cells 
successfully.  In our experiments, we have identified that one of the mechanisms 
that four factors utilized is through microRNA mediated regulatory machinery. We 
have found that miR-93 family microRNAs could target to p53-p21 and TGFβ 
signaling pathways, which are the common cell defense/safety mechanisms, and 
miR-135b could target to Wisp1-mediated extracellular matrix signaling pathway, 
which is a tissue-specific network required for maintaining MEFs‘ identity. These 
findings have provided the first evidence that both of these two regulatory 
networks could be regulated by microRNAs which are induced by 4F during the 
reprogramming process. Loss of microRNA biogenesis machinery thus could 
have huge impact on the repgoramming efficiency as the level of microRNAs 
available in the cells will be very limited and could not silence the targeted 
pathways to promote reprogramming. 
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 Moreover, in our studies, the discovery that Wisp1-mediated ECM 
formation could affect the efficiency of somatic cell reprogramming has raised an 
interesting question: how is the reprogramming process regulated by 
extracellular signaling networks? Previous findings have all focused on the 
intracellular gene networks that could modulate reprogramming process. The 
effect of extracellular matrix and establishment of proper niche for iPSCs 
undergoing reprogramming has long been overlooked. In fact, certain evidences 
have clearly implied an important role of extracellular matrix networks in 
regulating reprogramming efficiency. For example, if cultured alone and long 
enough, most of the somatic cells (>80%) could become fully reprogrammed 
(Hanna et al, 2009). However, in reality, when a bulk of cells is being 
reprogrammed, only 0.01-0.2% cells could reach the fully reprogrammed state 
(Aoi et al, 2008; Meissner et al, 2007; Nakagawa et al, 2008; Takahashi & 
Yamanaka, 2006). Even with prolonged culture time, the total number of iPSCs 
colonies would maintain the same (Sridharan et al, 2009). These data clearly 
suggest that intracellular gene regulation is not the only force to affect the overall 
reprogramming efficiency and some other factors could contribute to the process 
as well. One such example is ECM mediated niche formation.  
 Mouse ES cells and iPSCs have distinct morphology from embryonic 
fibroblasts (MEFs). While MEFs could usually grow separately in a dish and are 
in general independent on cell-to-cell contacts, mESCs and iPSCs usually grow 
in colonies. These cells have tight junctions with nearby cells and form their own 
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niches when cultured in the feeder plates. It has been previously reported that 
establishing their own niches is required for ES cells to have robust and healthy 
growth and maintain self renewal state (Bendall et al, 2007). Therefore, ideally, in 
order to grow in such a state, reprogramming cells would also need to establish 
such niches to support their growth. Interrupting the process therefore will result 
in a decreased reprogramming efficiency. In addition to that, reprogramming cells 
also face some complicated situations. For example, since these cells are not 
growing in a stable state, the gene regulatory networks for mES/iPSCs self 
renewal are not established yet by four factors. At the same time, they still 
express a significant portion of MEFs specific genes and retain some of MEFs‘ 
original signaling networks. When these cells are in culture, they are surrounded 
by many feeder cells which constantly secret fibroblasts factors, such as WISP1, 
TGFBI, NOV and DKK2, as well as necessary nutrients that support iPSC/mES 
growth. For mES cells or iPSCs, since they do not have any MEF specific 
signaling network, they will not be affected by those fibroblasts factors. However, 
for reprogramming cells, they could be stimulated by them, which could make 
those target cells confused due to the existence of two networks, and thus 
resistant to reach fully reprogrammed state. Therefore, it is possible to modulate 
these processes and pathways in order to enhance the reprogramming efficiency. 
In this dissertation, we found that miR-135b mediated regulation of Wisp1-related 
ECM formation indeed could strongly affect the reprogramming efficiency and by 
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manipulating the expression of ECM components, we were able to push the 
balance toward full reprogrammed state. 
 Another aspect that modulates somatic reprogramming is cell cycle. In the 
kinase inhibitor screen, we have found that essential hits identified were enriched 
with cell cycle inhibitors. Recent reports from other colleagues also have 
indicated that cell cycle control could be one of the key events that affect the 
overall reprogramming efficiency (Ruiz et al, 2011). Why is cell cycle so 
important? Here comes another striking difference between mESC/iPSCs and 
MEFs. For fibroblast cells, their overall proliferation rate is quite low compared 
with mESCs/iPSCs. In addition, since the telomerases are active in 
mESCs/iPSCs, these cells could divide unlimitedly, while MEFs do not have such 
advantage due to lack of telomerase activity. Therefore, it is not surprising that 
MEFs will have a quite different cell cycle regulation from mESCs/iPSCs and 
when they are being reprogrammed, it is required that a suitable cell cycle control 
is established by overexpression of reprogramming factors. Furthermore, as 
mentioned previously, cell defense/safety mechanisms are one of the main 
barriers to inhibit reprogramming process. In fact, many of such mechanisms, for 
example, p53-p21 pathways and DNA damage responses, are closely 
associated with cell cycle control. Overexpression of some of the reprogramming 
factors could result in activation of such mechanisms that leads to DNA damages 
accumulation and cell cycle arrest. Therefore, it may be beneficial to eliminate 
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the cell cycle inhibitors and increase the overall proliferation for the 
reprogramming cells.  
 However, increasing the speed of proliferation could also have negative 
impact on the reprogramming efficiency. One such concern is the amount of 
reprogramming factors accumulated in the nucleus. Given the general speed of 
expression of reprogramming factors remains the same, increased the cell 
division will reduce the amount of proteins accumulated. It has been long known 
that reprogramming factors need to reach certain amounts or overall dose in 
order to initiate efficient reprogramming process (Sridharan et al, 2009). Reduced 
amount of transcription factors in the nucleus could lead to insufficient 
suppression of MEF specific gene networks and insufficient activation of 
mESC/iPSC signaling pathways and thus result in the overall reprogramming 
efficiency. In fact, according to our observations, 4F transduced population with 
large percentage of fast growing transformed cells usually generate much less 
full reprogrammed iPSC colonies, to which partial reason may be due to the low 
amount of accumulated reprogramming factors. Therefore, modest increase of 
cell proliferation may be more beneficial for the somatic cells to become 
efficiently reprogrammed. 
 In addition, when MEFs are reprogrammed to iPSCs, they need to change 
from slow proliferating cells to acquire a state with fast growing and short cell 
cycle. All these changes would require sufficient supply of nucleotides and other 
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nutrients so that DNA synthesis and replication could be coordinated.  Therefore, 
it is expected that reprogramming cells would also undergo significant rewiring of 
their metabolic pathways. Recent report has also indicated that such process is 
required for efficient reprogramming (Folmes et al, 2011; Panopoulos et al, 2012). 
Interestingly, some of mostly highly regulated genes identified from miR-135b 
experiments are key components of important metabolic pathways. For example, 
4EBP1 is one of the main downstream effector of mTOR pathway, an important 
metabolic regulatory pathway that is involved in many human diseases (Zoncu et 
al, 2011). 4EBP1 function through direct interaction with translation initiation 
factor 4E and inhibit the recruitment and formation of initiation complex in order 
to repress translation. It has been shown to have a central role in mTOR 
dependent oncogenic signaling pathway during tumorigenesis (Hsieh et al, 2010). 
In our experiments, we have found that 4EBP1 mRNA was strongly repressed 
upon miR-135b transfection, which could partially explain why miR-135b exhibits 
more specific enhancing effects on the reprogramming process than other miRs 
such as miR-93. Since miR-135b decreases the expression of 4EBP1, it may 
reduce the downstream effects of 4EBP1 and have inhibitory effects on other 
transformed tumor-like cells rather than real iPSCs due to the loss of oncogenic 
mTOR signaling. Therefore, we could have a specific increase of overall 
percentage of fully reprogrammed cells.  
Finally, in summary, the discovery that somatic cells could be 
reprogrammed back to an embryonic stem cell-like pluripotent state has 
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revolutionized the current concept and understanding of cell fate determination. 
Terminally differentiated cells are used to be recognized as the final state of cell 
differentiation, which was thought not to be reversed. It is realized now that 
somatic cells indeed can be reprogrammed back to pluripotent stem cells and 
this process will only need a few transcriptional factors.  This has led to a number 
of important questions: first, is there a signature set of transcriptional factors (TFs) 
for every kind of cells from various tissues? If so, by ectopic expression of these 
signature TFs, can we cross-differentiate cells of distinct origin? Indeed, recent 
progress has clearly proved that many kinds of cells could be trans-differentiated 
given the right set of transcriptional factors and culture conditions were provided, 
including cardiomyocytes, neurons and pancreatic cells (Ambasudhan et al, 2011; 
Ieda et al, 2010; Zhou et al, 2008). Therefore, it may be true that the cells from 
various tissues maintain their identities through the expression of tissue specific 
transcription factors, which are the main force to drive downstream tissue specific 
gene expressions and maintain the normal function of these cells. In order to 
change the fate or identity of terminal differentiated cells, one would just need to 
express a few new transcription factors as well as silencing the original gene 
networks in those target cells.   
However, despite its great impact on understanding the fundamental 
biology of cell fate and pluripotency, somatic cell reprogramming still face a few 
challenges. In order to develop the therapeutic use of iPSCs, two main issues 
still need to be solved. One is the use of oncogenes as reprogramming factors 
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such as Klf4 and Myc. Overexpression of these genes could result in high 
tumorigenesis potential in derived iPSCs. In addition, overexpression of these 
could lead to accumulation of DNA damages which may significantly increase the 
risk of introducing additional mutations that could not be identified easily. These 
challenges will require further work in order to develop a more sophisticated 
method for deriving safe iPSC lines. Besides that, another challenge is the 
differentiation of iPSCs into pure downstream lineages. One of the main 
purposes of deriving iPSCs for personal medicine is to provide unlimited source 
for deriving important differentiated populations. However, there are only a few 
cell types for which a successfully method has been established to efficiently 
differentiate ES cells or iPSCs to the target population. Some of the key 
functional cells that iPSCs hold the most interest in, such as HSCs, are still 
difficult to get in an in vitro system.  Therefore, it may be too early to see the 
therapeutic use of iPSCs. However, it could become a powerful tool to address 
some key issues of human diseases, such as the pathogenesis of ALS or other 
neural diseases. By using patient specific iPSCs, it is possible to model certain 
human diseases and understand their molecular mechanism, which could be 
extremely valuable for developing life-saving treatments and therapeutics. 
Alternatively, trans-differentiation could serve as a potential way for generating 
large number of target cell population both in vitro and in vivo, within a relatively 
shorter period of time. Since the signature transcriptional factors usually do not 
contain oncogenes, these cells could be safer to iPSCs and thus might be 
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suitable for developing novel treatments. Overall, it is remarkable to witness that 
the discovery of somatic cell reprogramming makes such an impact on both the 
basic knowledge of cell biology and development of new therapeutics. In years to 
come, more insightful studies are expected on the molecular mechanism of 
reprogramming process, which will benefits us all and let us understand how 
different cells are programmed by nature and how their functions are properly 
maintained.  
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